United States Patent	12391980
Kind Code	B2
Date of Patent	August 19, 2025
Inventor(s)	Chee; Mark S.

Spatially encoded biological assays

Abstract

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Inventors: **Chee; Mark S. (San Diego, CA)**

Applicant: **Prognosys Biosciences, Inc.** (San Diego, CA)

Family ID: **1000008766362**

Assignee: **Prognosys Biosciences, Inc. (San Diego, CA)**

Appl. No.: **19/074001**

Filed: **March 07, 2025**

Prior Publication Data

Document Identifier	Publication Date
US 20250207183 A1	Jun. 26, 2025

Related U.S. Application Data

continuation parent-doc US 18972148 20241206 US 12297488 child-doc US 19074001
continuation parent-doc US 18793359 20240802 US 12234505 20250225 child-doc US 18972148
continuation parent-doc US 18100127 20230123 PENDING child-doc US 18793359
continuation parent-doc US 17878519 20220801 US 11560587 20230124 child-doc US 18100127
continuation parent-doc US 17556588 20211220 US 11401545 20220808 child-doc US 17878519
continuation parent-doc US 17223669 20210406 US 11208684 20211228 child-doc US 17556588
continuation parent-doc US 17030230 20200923 US 11384386 20220712 child-doc US 17223669
continuation parent-doc US 16988284 20200807 US 10961566 20210330 child-doc US 17030230
continuation parent-doc US 16414213 20190516 US 10787701 20200929 child-doc US 16988284
continuation parent-doc US 16402098 20190502 US 10472669 20191112 child-doc US 16414213
continuation parent-doc US 16276235 20190214 US 10480022 20191119 child-doc US 16402098
continuation parent-doc US 15187661 20160620 US 10308982 20190604 child-doc US 16276235
continuation parent-doc US 13080616 20110405 US 9371598 20160621 child-doc US 15187661
us-provisional-application US 61321124 20100405

Publication Classification

Int. Cl.: **C12Q1/6837** (20180101); **B01L3/00** (20060101); **C12Q1/68** (20180101); **C12Q1/6804** (20180101); **C12Q1/6809** (20180101); **C12Q1/6834** (20180101); **C12Q1/6841** (20180101); **C12Q1/6869** (20180101); **C12Q1/6874** (20180101); **C12Q1/6876** (20180101); **C40B30/04** (20060101); **C40B60/04** (20060101); **G01N33/53** (20060101); **G01N33/543** (20060101); **G01N33/68** (20060101); C12Q1/6858 (20180101)

U.S. Cl.:

CPC **C12Q1/6837** (20130101); **B01L3/502715** (20130101); **C12Q1/68** (20130101); **C12Q1/6804** (20130101); **C12Q1/6809** (20130101); **C12Q1/6834** (20130101); **C12Q1/6841** (20130101); **C12Q1/6869** (20130101); **C12Q1/6874** (20130101); **C12Q1/6876** (20130101); **C40B30/04** (20130101); **C40B60/04** (20130101); **G01N33/5308** (20130101); **G01N33/543** (20130101); **G01N33/54366** (20130101); **G01N33/6845** (20130101); **G01N33/6848** (20130101); C12Q1/6858 (20130101); C12Q2600/156 (20130101); C12Q2600/158 (20130101); G01N2458/10 (20130101); G01N2458/40 (20130101)

Field of Classification Search

CPC: C12Q (1/6837); C12Q (1/68); C12Q (1/6804); C12Q (1/6809); C12Q (1/6834); C12Q (1/6841); C12Q (1/6869); C12Q (1/6874); C12Q (1/6876); C12Q (1/6858); C12Q (2600/156); C12Q (2600/158); B01L (3/502715); C40B (30/04); C40B (60/04); G01N (33/5308); G01N (33/543); G01N (33/54366); G01N (33/6845); G01N (33/6848); G01N (2458/10); G01N (2458/40)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
4514388	12/1984	Psaledakis	N/A	N/A
4557903	12/1984	McCormick	N/A	N/A
4574729	12/1985	Wells	N/A	N/A
4683195	12/1986	Mullis	N/A	N/A
4683202	12/1986	Mullis	N/A	N/A
4731335	12/1987	Brigati	N/A	N/A
4800159	12/1988	Mullis	N/A	N/A
4829012	12/1988	Cambiaso et al.	N/A	N/A
4883867	12/1988	Lee	N/A	N/A
4965188	12/1989	Mullis	N/A	N/A
4968601	12/1989	Jacobson et al.	N/A	N/A
4988617	12/1990	Landegren et al.	N/A	N/A
5002882	12/1990	Lunnen	N/A	N/A
5061049	12/1990	Hornbeck	N/A	N/A
5130238	12/1991	Malek	N/A	N/A
5183053	12/1992	Yeh et al.	N/A	N/A
5308751	12/1993	Ohkawa	N/A	N/A
5321130	12/1993	Yue	N/A	N/A
5410030	12/1994	Yue	N/A	N/A
5436129	12/1994	Stapleton	N/A	N/A
5436134	12/1994	Haugland	N/A	N/A
5455166	12/1994	Walker	N/A	N/A
5472881	12/1994	Beebe et al.	N/A	N/A
5487972	12/1995	Gelfand et al.	N/A	N/A
5494810	12/1995	Barany et al.	N/A	N/A
5496518	12/1995	Arai et al.	N/A	N/A
5503980	12/1995	Cantor	N/A	N/A
5512439	12/1995	Hornes	N/A	N/A
5512462	12/1995	Cheng	N/A	N/A
5512478	12/1995	Orser et al.	N/A	N/A
5559032	12/1995	Porneroy	N/A	N/A
5582977	12/1995	Yue	N/A	N/A
5589173	12/1995	O'Brien	N/A	N/A
5599675	12/1996	Brenner	N/A	N/A
5610287	12/1996	Nikiforov et al.	N/A	N/A
5641658	12/1996	Adams	N/A	N/A
5648245	12/1996	Fire et al.	N/A	N/A
5658751	12/1996	Yue	N/A	N/A
5667976	12/1996	Van Ness et al.	N/A	N/A
5672344	12/1996	Kelley et al.	N/A	N/A
5695940	12/1996	Drmanac et al.	N/A	N/A
5716825	12/1997	Hancock et al.	N/A	N/A
5750341	12/1997	Macevicz	N/A	N/A
5752982	12/1997	Lang et al.	N/A	N/A
5763175	12/1997	Brenner	N/A	N/A
5807522	12/1997	Brown et al.	N/A	N/A
5817783	12/1997	Calabretta et al.	N/A	N/A
5830711	12/1997	Barany et al.	N/A	N/A
5837832	12/1997	Chee et al.	N/A	N/A
5837860	12/1997	Anderson et al.	N/A	N/A
5854033	12/1997	Lizardi	N/A	N/A
5863753	12/1998	Haugland	N/A	N/A
5866377	12/1998	Kim et al.	N/A	N/A
5871921	12/1998	Landegren et al.	N/A	N/A
5875258	12/1998	Ortyn et al.	N/A	N/A
5912148	12/1998	Eggerding	N/A	N/A
5919626	12/1998	Shi et al.	N/A	N/A
5925545	12/1998	Reznikoff et al.	N/A	N/A
5928906	12/1998	Koester et al.	N/A	N/A
5958775	12/1998	Wickstrom et al.	N/A	N/A
5962271	12/1998	Chenchik et al.	N/A	N/A
5962272	12/1998	Chenchik et al.	N/A	N/A
5965443	12/1998	Reznikoff et al.	N/A	N/A
5994136	12/1998	Naldini et al.	N/A	N/A
6013440	12/1999	Lipshutz	N/A	N/A
6013516	12/1999	Verma et al.	N/A	N/A

6027889	12/1999	Barany et al.	N/A	N/A
6054274	12/1999	Sampson et al.	N/A	N/A
6060240	12/1999	Kamb et al.	N/A	N/A
6083761	12/1999	Kedar et al.	N/A	N/A
6130073	12/1999	Eggerding	N/A	N/A
6133436	12/1999	Koester et al.	N/A	N/A
6136592	12/1999	Leighton	N/A	N/A
6143496	12/1999	Brown	N/A	N/A
6153389	12/1999	Haarer	N/A	N/A
6153408	12/1999	Abastado et al.	N/A	N/A
6157432	12/1999	Helbing	N/A	N/A
6159736	12/1999	Reznikoff et al.	N/A	N/A
6165714	12/1999	Lane et al.	N/A	N/A
6172218	12/2000	Brenner	N/A	N/A
6210891	12/2000	Nyren	N/A	N/A
6210894	12/2000	Brennan	N/A	N/A
6214587	12/2000	Dattagupta	N/A	N/A
6221591	12/2000	Aerts	N/A	N/A
6221654	12/2000	Quake	N/A	N/A
6251639	12/2000	Kurn	N/A	N/A
6258558	12/2000	Szostak	N/A	N/A
6258568	12/2000	Nyren	N/A	N/A
6261804	12/2000	Szostak	N/A	N/A
6265552	12/2000	Schatz	N/A	N/A
6266459	12/2000	Walt	N/A	N/A
6268148	12/2000	Barany et al.	N/A	N/A
6274320	12/2000	Rothberg	N/A	N/A
6281804	12/2000	Haller	N/A	N/A
6291180	12/2000	Chu	N/A	N/A
6291187	12/2000	Kingsmore et al.	N/A	N/A
6300063	12/2000	Lipshutz et al.	N/A	N/A
6300093	12/2000	Kindsvogel et al.	N/A	N/A
6306597	12/2000	Macevicz	N/A	N/A
6309824	12/2000	Drmanac	N/A	N/A
6323009	12/2000	Lasken et al.	N/A	N/A
6337472	12/2001	Garner et al.	N/A	N/A
6344316	12/2001	Lockhart	N/A	N/A
6344329	12/2001	Lizardi et al.	N/A	N/A
6348990	12/2001	Igasaki et al.	N/A	N/A
6355431	12/2001	Chee	N/A	N/A
6358508	12/2001	Ni et al.	N/A	N/A
6368801	12/2001	Faruqi	N/A	N/A
6391937	12/2001	Beuhler et al.	N/A	N/A
6401267	12/2001	Drmanac	N/A	N/A
6404907	12/2001	Gilchrist	N/A	N/A
6416950	12/2001	Lohse	N/A	N/A
6426215	12/2001	Sandell	N/A	N/A
6432360	12/2001	Church et al.	N/A	N/A
6444661	12/2001	Barton et al.	N/A	N/A
6485982	12/2001	Charlton	N/A	N/A
6503713	12/2002	Rana	N/A	N/A
6506561	12/2002	Cheval et al.	N/A	N/A
6518018	12/2002	Szostak	N/A	N/A
6534266	12/2002	Singer	N/A	N/A
6544732	12/2002	Chee	N/A	N/A
6544790	12/2002	Sabatini	N/A	N/A
6565727	12/2002	Shenderov	N/A	N/A
6573043	12/2002	Cohen et al.	N/A	N/A
6579695	12/2002	Lambalot	N/A	N/A
6620584	12/2002	Chee	435/7.1	C12Q 1/6837
6632641	12/2002	Brennan	N/A	N/A
6673620	12/2003	Loeffler	N/A	N/A
6677160	12/2003	Stockman et al.	N/A	N/A
6699710	12/2003	Kononen	N/A	N/A
6737236	12/2003	Pieken et al.	N/A	N/A
6770441	12/2003	Dickinson	N/A	N/A
6773566	12/2003	Shenderov	N/A	N/A
6773886	12/2003	Kaufman	N/A	N/A
6787308	12/2003	Balasubramanian	N/A	N/A
6797470	12/2003	Barany et al.	N/A	N/A
6800453	12/2003	Labaer	N/A	N/A
6812005	12/2003	Fan et al.	N/A	N/A
6828100	12/2003	Ronaghi	N/A	N/A
6833246	12/2003	Balasubramanian	N/A	N/A
6852487	12/2004	Barany et al.	N/A	N/A

6859570	12/2004	Walt	N/A	N/A
6864052	12/2004	Drmanac	N/A	N/A
6867028	12/2004	Janulaitis	N/A	N/A
6872816	12/2004	Hall et al.	N/A	N/A
6875572	12/2004	Prudent et al.	N/A	N/A
6878515	12/2004	Landegren	N/A	N/A
6890741	12/2004	Fan et al.	N/A	N/A
6897023	12/2004	Fu	N/A	N/A
6911132	12/2004	Pamula	N/A	N/A
6911345	12/2004	Quake	N/A	N/A
6913881	12/2004	Aizenstein et al.	N/A	N/A
6913921	12/2004	Fischer	N/A	N/A
6942968	12/2004	Dickinson et al.	N/A	N/A
6969488	12/2004	Bridgham	N/A	N/A
6969589	12/2004	Patil	N/A	N/A
6977033	12/2004	Becker	N/A	N/A
7001792	12/2005	Sauer et al.	N/A	N/A
7011944	12/2005	Prudent et al.	N/A	N/A
7052244	12/2005	Fouillet	N/A	N/A
7057026	12/2005	Barnes	N/A	N/A
7060431	12/2005	Chee et al.	N/A	N/A
7083980	12/2005	Reznikoff et al.	N/A	N/A
7098041	12/2005	Kaylor et al.	N/A	N/A
7115400	12/2005	Adessi	N/A	N/A
7118883	12/2005	Inoue	N/A	N/A
7128893	12/2005	Leamon et al.	N/A	N/A
7163612	12/2006	Sterling	N/A	N/A
7166431	12/2006	Chee et al.	N/A	N/A
7192735	12/2006	Lambalot	N/A	N/A
7211414	12/2006	Hardin	N/A	N/A
7223371	12/2006	Hayenga et al.	N/A	N/A
7229769	12/2006	Kozlov	N/A	N/A
7244559	12/2006	Rothberg	N/A	N/A
7255994	12/2006	Lao	N/A	N/A
7258976	12/2006	Mitsuhashi	N/A	N/A
7259258	12/2006	Kozlov et al.	N/A	N/A
7264929	12/2006	Rothberg	N/A	N/A
7270950	12/2006	Szostak	N/A	N/A
7282328	12/2006	Kong et al.	N/A	N/A
7297518	12/2006	Quake	N/A	N/A
7315019	12/2007	Turner	N/A	N/A
7328979	12/2007	Decre	N/A	N/A
7329492	12/2007	Hardin	N/A	N/A
7358047	12/2007	Hafner et al.	N/A	N/A
7361488	12/2007	Fan et al.	N/A	N/A
7375234	12/2007	Sharpless et al.	N/A	N/A
7378242	12/2007	Hurt	N/A	N/A
7393665	12/2007	Brenner	N/A	N/A
7405281	12/2007	Xu	N/A	N/A
7407757	12/2007	Brenner	N/A	N/A
7427678	12/2007	Pieken et al.	N/A	N/A
7456012	12/2007	Ryttsen et al.	N/A	N/A
7462449	12/2007	Quake	N/A	N/A
7473767	12/2008	Dimitrov	N/A	N/A
7499806	12/2008	Kermani et al.	N/A	N/A
7500637	12/2008	Marimon et al.	N/A	N/A
7501245	12/2008	Quake	N/A	N/A
7510637	12/2008	Barlow et al.	N/A	N/A
7534991	12/2008	Miller et al.	N/A	N/A
7537897	12/2008	Brenner	N/A	N/A
7544473	12/2008	Brennan	N/A	N/A
7547380	12/2008	Velev	N/A	N/A
7555155	12/2008	Levenson et al.	N/A	N/A
7561336	12/2008	Osaka et al.	N/A	N/A
7563576	12/2008	Chee	N/A	N/A
7579153	12/2008	Brenner	N/A	N/A
7582420	12/2008	Oliphant et al.	N/A	N/A
7595883	12/2008	El Gamal	N/A	N/A
7601492	12/2008	Fu et al.	N/A	N/A
7601498	12/2008	Mao	N/A	N/A
7608434	12/2008	Reznikoff et al.	N/A	N/A
7611869	12/2008	Fan	N/A	N/A
7635566	12/2008	Brenner	N/A	N/A
7641779	12/2009	Becker	N/A	N/A
7655898	12/2009	Miller	N/A	N/A

7666612	12/2009	Johnsson	N/A	N/A
7674589	12/2009	Cohen et al.	N/A	N/A
7674752	12/2009	He	N/A	N/A
7700286	12/2009	Stroun et al.	N/A	N/A
7709198	12/2009	Luo et al.	N/A	N/A
7741106	12/2009	Moyle et al.	N/A	N/A
7754429	12/2009	Rigatti	N/A	N/A
7776547	12/2009	Roth	N/A	N/A
7776567	12/2009	Mao	N/A	N/A
7785869	12/2009	Belgrader et al.	N/A	N/A
7803943	12/2009	Mao	N/A	N/A
7844940	12/2009	Shin et al.	N/A	N/A
7848553	12/2009	Hertel et al.	N/A	N/A
7858321	12/2009	Glezer	N/A	N/A
7888009	12/2010	Barany et al.	N/A	N/A
7892747	12/2010	Barany et al.	N/A	N/A
7910304	12/2010	Drmanac	N/A	N/A
7914981	12/2010	Barany et al.	N/A	N/A
7941279	12/2010	Hwang et al.	N/A	N/A
7955794	12/2010	Shen et al.	N/A	N/A
7960119	12/2010	Chee	N/A	N/A
7960120	12/2010	Rigatti	N/A	N/A
7985565	12/2010	Mayer et al.	N/A	N/A
8003354	12/2010	Shen et al.	N/A	N/A
8030466	12/2010	Shin et al.	N/A	N/A
8030477	12/2010	Cerrina et al.	N/A	N/A
8046043	12/2010	Asano et al.	N/A	N/A
8076063	12/2010	Fan	N/A	N/A
8092784	12/2011	Mao	N/A	N/A
8124751	12/2011	Pierce et al.	N/A	N/A
8131476	12/2011	Cline et al.	N/A	N/A
8148068	12/2011	Brenner	N/A	N/A
8148518	12/2011	Buchanan	N/A	N/A
8198028	12/2011	Rigatti et al.	N/A	N/A
8199999	12/2011	Hoyt et al.	N/A	N/A
8206917	12/2011	Chee	N/A	N/A
8207093	12/2011	Szostak	N/A	N/A
8268554	12/2011	Schallmeiner	N/A	N/A
8278034	12/2011	Muraca	N/A	N/A
8288103	12/2011	Oliphant	N/A	N/A
8288122	12/2011	O'Leary et al.	N/A	N/A
8330087	12/2011	Domenicali	N/A	N/A
8337851	12/2011	Aukerman	N/A	N/A
8343500	12/2012	Wraith	N/A	N/A
8383338	12/2012	Kitzman	N/A	N/A
8415102	12/2012	Geiss et al.	N/A	N/A
8431691	12/2012	McKernan et al.	N/A	N/A
8460865	12/2012	Chee	N/A	N/A
8462981	12/2012	Determan et al.	N/A	N/A
8481257	12/2012	Van Eijk	N/A	N/A
8481258	12/2012	Church et al.	N/A	N/A
8481292	12/2012	Casbor	N/A	N/A
8481698	12/2012	Lieberman et al.	N/A	N/A
8486625	12/2012	Gunderson	N/A	N/A
8507204	12/2012	Pierce et al.	N/A	N/A
8519115	12/2012	Webster et al.	N/A	N/A
8551710	12/2012	Bernitz et al.	N/A	N/A
8568979	12/2012	Stuelpnagel et al.	N/A	N/A
RE44596	12/2012	Stroun et al.	N/A	N/A
8586310	12/2012	Mitra	N/A	N/A
8597891	12/2012	Barany et al.	N/A	N/A
8603743	12/2012	Liu et al.	N/A	N/A
8604182	12/2012	Luo et al.	N/A	N/A
8614073	12/2012	Van Eijk	N/A	N/A
8624016	12/2013	Barany et al.	N/A	N/A
8637242	12/2013	Shen	N/A	N/A
8658361	12/2013	Wu et al.	N/A	N/A
8685889	12/2013	Van Eijk	N/A	N/A
8741564	12/2013	Seligmann	N/A	N/A
8741606	12/2013	Casbon	N/A	N/A
8748103	12/2013	Faham et al.	N/A	N/A
8771950	12/2013	Church et al.	N/A	N/A
8778849	12/2013	Bowen	N/A	N/A
8785353	12/2013	Van Eijk	N/A	N/A
8790873	12/2013	Namsaraev et al.	N/A	N/A

8809238	12/2013	Livak et al.	N/A	N/A
8815512	12/2013	Van Eijk	N/A	N/A
8835358	12/2013	Fodor	N/A	N/A
8865410	12/2013	Shendure	N/A	N/A
8906626	12/2013	Oliphant et al.	N/A	N/A
8911945	12/2013	Van Eijk	N/A	N/A
8936912	12/2014	Mitra	N/A	N/A
8951726	12/2014	Luo et al.	N/A	N/A
8951728	12/2014	Rasmussen	N/A	N/A
8951781	12/2014	Reed	N/A	N/A
8986926	12/2014	Ferree et al.	N/A	N/A
9005891	12/2014	Sinicropi et al.	N/A	N/A
9005935	12/2014	Belyaev	N/A	N/A
9023768	12/2014	Van Eijk	N/A	N/A
9062348	12/2014	Van Eijk	N/A	N/A
9080210	12/2014	Van Eijk	N/A	N/A
9085798	12/2014	Chee	N/A	N/A
9121069	12/2014	Lo	N/A	N/A
9163283	12/2014	Chee et al.	N/A	N/A
9194001	12/2014	Brenner	N/A	N/A
9201063	12/2014	Sood et al.	N/A	N/A
9217176	12/2014	Faham et al.	N/A	N/A
9290808	12/2015	Fodor	N/A	N/A
9290809	12/2015	Fodor	N/A	N/A
9309556	12/2015	Myllykangas et al.	N/A	N/A
9328383	12/2015	Van Eijk	N/A	N/A
9334536	12/2015	Van Eijk	N/A	N/A
9340830	12/2015	Lipson	N/A	N/A
9371563	12/2015	Geiss et al.	N/A	N/A
9371598	12/2015	Chee	N/A	N/A
9376716	12/2015	Van Eijk	N/A	N/A
9376717	12/2015	Gao et al.	N/A	N/A
9376719	12/2015	Van Eijk	N/A	N/A
9404156	12/2015	Hicks	N/A	N/A
9416409	12/2015	Hayden	N/A	N/A
9447459	12/2015	Van Eijk	N/A	N/A
9453256	12/2015	Van Eijk	N/A	N/A
9493820	12/2015	Van Eijk	N/A	N/A
9494588	12/2015	Springer	N/A	N/A
9506061	12/2015	Brown	N/A	N/A
9512487	12/2015	Faham et al.	N/A	N/A
9541504	12/2016	Hoyt	N/A	N/A
9557330	12/2016	Siciliano et al.	N/A	N/A
9574230	12/2016	Van Eijk	N/A	N/A
9593365	12/2016	Frisen et al.	N/A	N/A
9598728	12/2016	Barany et al.	N/A	N/A
9624538	12/2016	Church et al.	N/A	N/A
9657335	12/2016	Van Eijk	N/A	N/A
9670542	12/2016	Van Eijk	N/A	N/A
9671344	12/2016	Staker	N/A	N/A
9694361	12/2016	Bharadwaj	N/A	N/A
9702004	12/2016	Van Eijk	N/A	N/A
9714446	12/2016	Webster et al.	N/A	N/A
9714937	12/2016	Dunaway	N/A	N/A
9745627	12/2016	Van Eijk	N/A	N/A
9777324	12/2016	Van Eijk	N/A	N/A
9816134	12/2016	Namsaraev	N/A	N/A
9850536	12/2016	Oliphant et al.	N/A	N/A
9868979	12/2017	Chee et al.	N/A	N/A
9879313	12/2017	Chee et al.	N/A	N/A
9889422	12/2017	Smith et al.	N/A	N/A
9896721	12/2017	Van Eijk	N/A	N/A
9898576	12/2017	Van Eijk	N/A	N/A
9898577	12/2017	Van Eijk	N/A	N/A
9902950	12/2017	Church et al.	N/A	N/A
9902991	12/2017	Sinicropi et al.	N/A	N/A
9958454	12/2017	Kozlov et al.	N/A	N/A
10023907	12/2017	Van Eijk	N/A	N/A
10030261	12/2017	Frisen et al.	N/A	N/A
10072104	12/2017	Winnik et al.	N/A	N/A
10077478	12/2017	Faham et al.	N/A	N/A
10095832	12/2017	Van Eijk	N/A	N/A
10144966	12/2017	Cantor	N/A	N/A
10196691	12/2018	Harkin et al.	N/A	N/A
10227639	12/2018	Levner et al.	N/A	N/A

10246752	12/2018	Faham et al.	N/A	N/A
10266876	12/2018	Cai et al.	N/A	N/A
10267808	12/2018	Cai	N/A	N/A
10357771	12/2018	Bharadwaj	N/A	N/A
10391467	12/2018	Zhou et al.	N/A	N/A
10428326	12/2018	Belhocine et al.	N/A	N/A
10465235	12/2018	Gullberg et al.	N/A	N/A
10501791	12/2018	Church et al.	N/A	N/A
10633648	12/2019	Seelig et al.	N/A	N/A
10669569	12/2019	Gullberg et al.	N/A	N/A
10685210	12/2019	Wimberger-Friedl et al.	N/A	N/A
10697013	12/2019	Brenner et al.	N/A	N/A
10725027	12/2019	Bell	N/A	N/A
10767223	12/2019	Brenner et al.	N/A	N/A
10774372	12/2019	Chee et al.	N/A	N/A
10774374	12/2019	Frisen et al.	N/A	N/A
10829803	12/2019	Terbrueggen et al.	N/A	N/A
10858702	12/2019	Lucero et al.	N/A	N/A
10927403	12/2020	Chee et al.	N/A	N/A
10995362	12/2020	Dallett et al.	N/A	N/A
11046996	12/2020	Chee et al.	N/A	N/A
11162132	12/2020	Frisen et al.	N/A	N/A
11214796	12/2021	Shirai et al.	N/A	N/A
11286515	12/2021	Chee et al.	N/A	N/A
11299774	12/2021	Frisen et al.	N/A	N/A
11332790	12/2021	Chell et al.	N/A	N/A
11352659	12/2021	Frisen et al.	N/A	N/A
11359228	12/2021	Chee et al.	N/A	N/A
11390912	12/2021	Frisen et al.	N/A	N/A
11407992	12/2021	Dadhwal	N/A	N/A
11408029	12/2021	Katiraee et al.	N/A	N/A
11434524	12/2021	Ramachandran Iyer et al.	N/A	N/A
11459607	12/2021	Terry et al.	N/A	N/A
11479809	12/2021	Frisen et al.	N/A	N/A
11492612	12/2021	Dadhwal	N/A	N/A
11501440	12/2021	Weisenfeld et al.	N/A	N/A
11505828	12/2021	Chell et al.	N/A	N/A
11512308	12/2021	Gallant et al.	N/A	N/A
11519033	12/2021	Schnall-Levin et al.	N/A	N/A
11535887	12/2021	Gallant et al.	N/A	N/A
11560592	12/2022	Chew et al.	N/A	N/A
11560593	12/2022	Chell et al.	N/A	N/A
11592447	12/2022	Uytingco et al.	N/A	N/A
11608498	12/2022	Gallant et al.	N/A	N/A
11608520	12/2022	Galonska et al.	N/A	N/A
11613773	12/2022	Frisen et al.	N/A	N/A
11618897	12/2022	Kim et al.	N/A	N/A
11618918	12/2022	Chee et al.	N/A	N/A
11624063	12/2022	Dadhwal	N/A	N/A
11624086	12/2022	Uytingco et al.	N/A	N/A
11649485	12/2022	Yin et al.	N/A	N/A
11661626	12/2022	Katiraee et al.	N/A	N/A
11680260	12/2022	Kim et al.	N/A	N/A
11692218	12/2022	Engblom et al.	N/A	N/A
11702693	12/2022	Bharadwaj	N/A	N/A
11702698	12/2022	Stoeckius	N/A	N/A
11732299	12/2022	Ramachandran Iyer	N/A	N/A
11732300	12/2022	Bava	N/A	N/A
11739372	12/2022	Frisen et al.	N/A	N/A
11739381	12/2022	Chew et al.	N/A	N/A
11753673	12/2022	Chew et al.	N/A	N/A
11753674	12/2022	Chee et al.	N/A	N/A
11753675	12/2022	Ramachandran Iyer	N/A	N/A
11761038	12/2022	Stoeckius	N/A	N/A
11768175	12/2022	Kim et al.	N/A	N/A
11773433	12/2022	Gallant et al.	N/A	N/A
11781130	12/2022	Dadhwal	N/A	N/A
11788122	12/2022	Frisen et al.	N/A	N/A
11795498	12/2022	Frisen et al.	N/A	N/A
11795507	12/2022	Chell et al.	N/A	N/A
11808769	12/2022	Uytingco et al.	N/A	N/A
11821024	12/2022	Chee et al.	N/A	N/A
11821035	12/2022	Bent et al.	N/A	N/A
11827935	12/2022	Ramachandran Iyer et al.	N/A	N/A
11835462	12/2022	Bava	N/A	N/A

11840687	12/2022	Gallant et al.	N/A	N/A
11840724	12/2022	Chew et al.	N/A	N/A
11845979	12/2022	Engblom et al.	N/A	N/A
11859178	12/2023	Gallant et al.	N/A	N/A
11866767	12/2023	Uytingco et al.	N/A	N/A
11873482	12/2023	Kim et al.	N/A	N/A
11891654	12/2023	Alvarado Martinez et al.	N/A	N/A
11898205	12/2023	Bava	N/A	N/A
11926822	12/2023	Gohil et al.	N/A	N/A
11926863	12/2023	Boutet	N/A	N/A
11926867	12/2023	Yin et al.	N/A	N/A
11933957	12/2023	Tentori et al.	N/A	N/A
11952627	12/2023	Stoeckius	N/A	N/A
11959076	12/2023	Kim et al.	N/A	N/A
11959130	12/2023	Galonska et al.	N/A	N/A
11965213	12/2023	Williams	N/A	N/A
11970739	12/2023	Chew et al.	N/A	N/A
11981958	12/2023	Galonska	N/A	N/A
11981960	12/2023	Lin et al.	N/A	N/A
11981965	12/2023	Chell et al.	N/A	N/A
RE50065	12/2023	Frisen et al.	N/A	N/A
12024741	12/2023	Tentori et al.	N/A	N/A
12031177	12/2023	Tentori et al.	N/A	N/A
12060604	12/2023	Katiraee et al.	N/A	N/A
12071655	12/2023	Sukovich et al.	N/A	N/A
12076701	12/2023	Bava	N/A	N/A
12098417	12/2023	Engblom et al.	N/A	N/A
12098985	12/2023	Cox et al.	N/A	N/A
12110541	12/2023	Bava	N/A	N/A
12117439	12/2023	Delaney et al.	N/A	N/A
12128403	12/2023	Kim et al.	N/A	N/A
12129516	12/2023	Tentori et al.	N/A	N/A
12157124	12/2023	Cox et al.	N/A	N/A
12180543	12/2023	Uytingco et al.	N/A	N/A
12195790	12/2024	Sukovich et al.	N/A	N/A
12203134	12/2024	Nagendran et al.	N/A	N/A
12209280	12/2024	Mignardi et al.	N/A	N/A
D1064308	12/2024	Alimsijah et al.	N/A	N/A
12223751	12/2024	Li et al.	N/A	N/A
12228544	12/2024	Kim et al.	N/A	N/A
12241060	12/2024	Kim et al.	N/A	N/A
12241890	12/2024	Delaney et al.	N/A	N/A
12249085	12/2024	Tentori et al.	N/A	N/A
12265079	12/2024	Bent	N/A	N/A
12270077	12/2024	Schnall-Levin et al.	N/A	N/A
12275988	12/2024	Galonska et al.	N/A	N/A
12281357	12/2024	Tentori et al.	N/A	N/A
12286673	12/2024	Bava	N/A	N/A
12287264	12/2024	Cox et al.	N/A	N/A
12297486	12/2024	Patterson et al.	N/A	N/A
12344892	12/2024	Schnall-Levin et al.	N/A	N/A
2001/0029017	12/2000	Yasuda et al.	N/A	N/A
2001/0039029	12/2000	Nemori et al.	N/A	N/A
2001/0053519	12/2000	Fodor et al.	N/A	N/A
2001/0055764	12/2000	Empendocles et al.	N/A	N/A
2002/0006477	12/2001	Shishido et al.	N/A	N/A
2002/0022261	12/2001	Anderson et al.	N/A	N/A
2002/0040275	12/2001	Cravatt	N/A	N/A
2002/0045169	12/2001	Shoemaker et al.	N/A	N/A
2002/0045272	12/2001	McDevitt et al.	N/A	N/A
2002/0048766	12/2001	Doyle et al.	N/A	N/A
2002/0051986	12/2001	Baez et al.	N/A	N/A
2002/0055100	12/2001	Kawashima	N/A	N/A
2002/0058250	12/2001	Firth	N/A	N/A
2002/0064779	12/2001	Landegren	N/A	N/A
2002/0086441	12/2001	Baranov et al.	N/A	N/A
2002/0132246	12/2001	Kallioniemi et al.	N/A	N/A
2002/0137031	12/2001	Wolber	N/A	N/A
2002/0150909	12/2001	Stuelpnagel	N/A	N/A
2002/0164611	12/2001	Bamdad	N/A	N/A
2002/0168645	12/2001	Taylor	N/A	N/A
2003/0017451	12/2002	Wang et al.	N/A	N/A
2003/0022207	12/2002	Balasubramanian	N/A	N/A
2003/0027342	12/2002	Sheridan et al.	N/A	N/A
2003/0040035	12/2002	Slamon	N/A	N/A

2003/0064398	12/2002	Barnes	N/A	N/A
2003/0073086	12/2002	Guire et al.	N/A	N/A
2003/0087232	12/2002	Christians	N/A	N/A
2003/0092624	12/2002	Wang et al.	N/A	N/A
2003/0096323	12/2002	James	N/A	N/A
2003/0108726	12/2002	Schembri et al.	N/A	N/A
2003/0113713	12/2002	Glezer	N/A	N/A
2003/0124595	12/2002	Lizardi	N/A	N/A
2003/0134279	12/2002	Isola et al.	N/A	N/A
2003/0138879	12/2002	Lambalot	N/A	N/A
2003/0148335	12/2002	Shen et al.	N/A	N/A
2003/0152927	12/2002	Jakobsen et al.	N/A	N/A
2003/0153850	12/2002	Davis et al.	N/A	N/A
2003/0162216	12/2002	Gold	N/A	N/A
2003/0165948	12/2002	Alsmadi et al.	N/A	N/A
2003/0170637	12/2002	Pirrung et al.	N/A	N/A
2003/0175947	12/2002	Liu et al.	N/A	N/A
2003/0190744	12/2002	McGarry et al.	N/A	N/A
2003/0205632	12/2002	Kim et al.	N/A	N/A
2003/0211489	12/2002	Shen et al.	N/A	N/A
2003/0215936	12/2002	Kallioniemi et al.	N/A	N/A
2003/0224419	12/2002	Corcoran	N/A	N/A
2003/0232348	12/2002	Jones et al.	N/A	N/A
2003/0232382	12/2002	Brennan	N/A	N/A
2003/0235535	12/2002	Zhou	N/A	N/A
2003/0235852	12/2002	Roberts	N/A	N/A
2003/0235854	12/2002	Chan et al.	N/A	N/A
2004/0002090	12/2003	Mayer et al.	N/A	N/A
2004/0019005	12/2003	Van Ness	N/A	N/A
2004/0023320	12/2003	Steiner et al.	N/A	N/A
2004/0033499	12/2003	Ilsley et al.	N/A	N/A
2004/0050699	12/2003	Goncalves	N/A	N/A
2004/0067492	12/2003	Peng et al.	N/A	N/A
2004/0067493	12/2003	Matsuzaki	N/A	N/A
2004/0082058	12/2003	Schleifer et al.	N/A	N/A
2004/0082059	12/2003	Webb	N/A	N/A
2004/0096853	12/2003	Mayer	N/A	N/A
2004/0106110	12/2003	Balasubramanian	N/A	N/A
2004/0112442	12/2003	Maerkl	N/A	N/A
2004/0121456	12/2003	Fischer	N/A	N/A
2004/0175822	12/2003	Timperman et al.	N/A	N/A
2004/0219588	12/2003	Furuta	N/A	N/A
2004/0224326	12/2003	Kim et al.	N/A	N/A
2004/0235103	12/2003	Reznikoff et al.	N/A	N/A
2004/0241660	12/2003	Wojtowicz et al.	N/A	N/A
2004/0248287	12/2003	Hu et al.	N/A	N/A
2004/0248325	12/2003	Bukusoglu et al.	N/A	N/A
2004/0259105	12/2003	Fan et al.	N/A	N/A
2005/0003431	12/2004	Wucherpfennig	N/A	N/A
2005/0014203	12/2004	Darfler et al.	N/A	N/A
2005/0019776	12/2004	Callow et al.	N/A	N/A
2005/0019842	12/2004	Prober et al.	N/A	N/A
2005/0026188	12/2004	Van Kessel	N/A	N/A
2005/0037362	12/2004	Remacle et al.	N/A	N/A
2005/0037393	12/2004	Gunderson et al.	N/A	N/A
2005/0042695	12/2004	Meares et al.	N/A	N/A
2005/0048535	12/2004	Santin	N/A	N/A
2005/0048580	12/2004	Labaer	N/A	N/A
2005/0064432	12/2004	Huang et al.	N/A	N/A
2005/0064460	12/2004	Holliger et al.	N/A	N/A
2005/0079518	12/2004	Baker et al.	N/A	N/A
2005/0079520	12/2004	Wu	N/A	N/A
2005/0095627	12/2004	Kolman et al.	N/A	N/A
2005/0100900	12/2004	Kawashima et al.	N/A	N/A
2005/0106617	12/2004	Besemer et al.	N/A	N/A
2005/0118602	12/2004	Li et al.	N/A	N/A
2005/0130173	12/2004	Leamon et al.	N/A	N/A
2005/0130188	12/2004	Walt	N/A	N/A
2005/0136414	12/2004	Gunderson et al.	N/A	N/A
2005/0147537	12/2004	Sangha	N/A	N/A
2005/0164292	12/2004	Farooqui	N/A	N/A
2005/0170373	12/2004	Monforte	N/A	N/A
2005/0179746	12/2004	Roux et al.	N/A	N/A
2005/0191656	12/2004	Drmanac et al.	N/A	N/A
2005/0191698	12/2004	Chee et al.	N/A	N/A

2005/0196786	12/2004	Levy	N/A	N/A
2005/0202433	12/2004	Van Beuningen	N/A	N/A
2005/0226780	12/2004	Sandell et al.	N/A	N/A
2005/0227271	12/2004	Kwon	N/A	N/A
2005/0239119	12/2004	Tsukada et al.	N/A	N/A
2005/0239192	12/2004	Nasarabadi et al.	N/A	N/A
2005/0244850	12/2004	Huang	N/A	N/A
2005/0255548	12/2004	Lipovsek et al.	N/A	N/A
2005/0257284	12/2004	Nakajima et al.	N/A	N/A
2005/0260653	12/2004	LaBaer	N/A	N/A
2005/0266417	12/2004	Barany et al.	N/A	N/A
2006/0003394	12/2005	Song	N/A	N/A
2006/0039823	12/2005	Yamakawa et al.	N/A	N/A
2006/0041384	12/2005	Kermani et al.	N/A	N/A
2006/0041385	12/2005	Bauer et al.	N/A	N/A
2006/0046313	12/2005	Roth	N/A	N/A
2006/0063160	12/2005	West et al.	N/A	N/A
2006/0073506	12/2005	Christians et al.	N/A	N/A
2006/0079453	12/2005	Sidney et al.	N/A	N/A
2006/0084078	12/2005	Zhao	N/A	N/A
2006/0105352	12/2005	Qiao et al.	N/A	N/A
2006/0110739	12/2005	Heyduk	N/A	N/A
2006/0127946	12/2005	Montagu et al.	N/A	N/A
2006/0134669	12/2005	Casasanta	N/A	N/A
2006/0154286	12/2005	Kong et al.	N/A	N/A
2006/0164490	12/2005	Kim et al.	N/A	N/A
2006/0180489	12/2005	Guiney et al.	N/A	N/A
2006/0183150	12/2005	Cohen et al.	N/A	N/A
2006/0188875	12/2005	Cox et al.	N/A	N/A
2006/0188901	12/2005	Barnes et al.	N/A	N/A
2006/0188906	12/2005	Kim et al.	N/A	N/A
2006/0194331	12/2005	Pamula et al.	N/A	N/A
2006/0199183	12/2005	Valat et al.	N/A	N/A
2006/0199207	12/2005	Matysiak	N/A	N/A
2006/0211001	12/2005	Yu et al.	N/A	N/A
2006/0216721	12/2005	Kozlov et al.	N/A	N/A
2006/0216775	12/2005	Burkart et al.	N/A	N/A
2006/0228758	12/2005	Muchhal et al.	N/A	N/A
2006/0240439	12/2005	Smith et al.	N/A	N/A
2006/0246475	12/2005	Peterson et al.	N/A	N/A
2006/0263789	12/2005	Kincaid	N/A	N/A
2006/0275782	12/2005	Gunderson et al.	N/A	N/A
2006/0275799	12/2005	Banerjee et al.	N/A	N/A
2006/0281109	12/2005	Barr Ost et al.	N/A	N/A
2006/0292559	12/2005	Reddy et al.	N/A	N/A
2007/0003954	12/2006	Kodadek et al.	N/A	N/A
2007/0014810	12/2006	Baker et al.	N/A	N/A
2007/0020625	12/2006	Duchaud et al.	N/A	N/A
2007/0020640	12/2006	McCloskey et al.	N/A	N/A
2007/0020669	12/2006	Ericsson	N/A	N/A
2007/0023292	12/2006	Kim et al.	N/A	N/A
2007/0026430	12/2006	Andersen et al.	N/A	N/A
2007/0036511	12/2006	Lundquist et al.	N/A	N/A
2007/0048812	12/2006	Moravec et al.	N/A	N/A
2007/0054288	12/2006	Su et al.	N/A	N/A
2007/0087360	12/2006	Boyd	N/A	N/A
2007/0099208	12/2006	Drmanac et al.	N/A	N/A
2007/0116612	12/2006	Williamson	N/A	N/A
2007/0128071	12/2006	Shea et al.	N/A	N/A
2007/0128624	12/2006	Gormley et al.	N/A	N/A
2007/0128656	12/2006	Agrawal	N/A	N/A
2007/0134723	12/2006	Kozlov et al.	N/A	N/A
2007/0141718	12/2006	Bui et al.	N/A	N/A
2007/0161020	12/2006	Luo et al.	N/A	N/A
2007/0161029	12/2006	Li et al.	N/A	N/A
2007/0166705	12/2006	Milton et al.	N/A	N/A
2007/0166725	12/2006	McBride et al.	N/A	N/A
2007/0172873	12/2006	Brenner et al.	N/A	N/A
2007/0178503	12/2006	Jiang	N/A	N/A
2007/0184456	12/2006	Chee et al.	N/A	N/A
2007/0207482	12/2006	Church et al.	N/A	N/A
2007/0215466	12/2006	Okada	N/A	N/A
2007/0231823	12/2006	McKernan	N/A	N/A
2007/0231824	12/2006	Chee et al.	N/A	N/A
2007/0243634	12/2006	Pamula et al.	N/A	N/A

2007/0251824	12/2006	Patton	N/A	N/A
2007/0254305	12/2006	Paik et al.	N/A	N/A
2007/0264656	12/2006	Kawamura	N/A	N/A
2007/0269805	12/2006	Hogers	N/A	N/A
2007/0280517	12/2006	De La Torre-Bueno et al.	N/A	N/A
2008/0003586	12/2007	Hyde et al.	N/A	N/A
2008/0009071	12/2007	Sogard	N/A	N/A
2008/0009420	12/2007	Schroth et al.	N/A	N/A
2008/0032301	12/2007	Rank et al.	N/A	N/A
2008/0032310	12/2007	Shannon et al.	N/A	N/A
2008/0033159	12/2007	Kadushin et al.	N/A	N/A
2008/0038734	12/2007	Sorge et al.	N/A	N/A
2008/0043235	12/2007	Oldham et al.	N/A	N/A
2008/0047835	12/2007	MacConnell	N/A	N/A
2008/0071071	12/2007	LaBaer et al.	N/A	N/A
2008/0108082	12/2007	Rank et al.	N/A	N/A
2008/0108804	12/2007	Hayashizaki et al.	N/A	N/A
2008/0124252	12/2007	Marchand et al.	N/A	N/A
2008/0124810	12/2007	Terbrueggen et al.	N/A	N/A
2008/0128627	12/2007	Lundquist et al.	N/A	N/A
2008/0132429	12/2007	Perov et al.	N/A	N/A
2008/0145378	12/2007	Ovaa et al.	N/A	N/A
2008/0145616	12/2007	Gharib et al.	N/A	N/A
2008/0153086	12/2007	Wong	N/A	N/A
2008/0160580	12/2007	Adessi et al.	N/A	N/A
2008/0199929	12/2007	Yeung et al.	N/A	N/A
2008/0218838	12/2007	Rey-Mermet	N/A	N/A
2008/0220434	12/2007	Thomas	N/A	N/A
2008/0220981	12/2007	McGregor	N/A	N/A
2008/0261204	12/2007	Lexow	N/A	N/A
2008/0280773	12/2007	Fedurco et al.	N/A	N/A
2008/0286795	12/2007	Kawashima et al.	N/A	N/A
2008/0293046	12/2007	Allawi et al.	N/A	N/A
2008/0293591	12/2007	Taussig et al.	N/A	N/A
2008/0312103	12/2007	Nemoto et al.	N/A	N/A
2009/0005252	12/2008	Drmanac et al.	N/A	N/A
2009/0006002	12/2008	Honisch et al.	N/A	N/A
2009/0011943	12/2008	Drmanac et al.	N/A	N/A
2009/0018024	12/2008	Church et al.	N/A	N/A
2009/0023148	12/2008	Moyle et al.	N/A	N/A
2009/0026082	12/2008	Rothberg et al.	N/A	N/A
2009/0036323	12/2008	van Eijk et al.	N/A	N/A
2009/0048510	12/2008	Miller et al.	N/A	N/A
2009/0060866	12/2008	Dousson et al.	N/A	N/A
2009/0062148	12/2008	Goldberg	N/A	N/A
2009/0068667	12/2008	Meisner et al.	N/A	N/A
2009/0082212	12/2008	Williams	N/A	N/A
2009/0099041	12/2008	Church et al.	N/A	N/A
2009/0105959	12/2008	Braverman et al.	N/A	N/A
2009/0117573	12/2008	Fu et al.	N/A	N/A
2009/0127589	12/2008	Rothberg et al.	N/A	N/A
2009/0152116	12/2008	Boles et al.	N/A	N/A
2009/0155781	12/2008	Drmanac et al.	N/A	N/A
2009/0169089	12/2008	Hunt et al.	N/A	N/A
2009/0170713	12/2008	van Eijk et al.	N/A	N/A
2009/0181375	12/2008	Peter et al.	N/A	N/A
2009/0192044	12/2008	Fouillet	N/A	N/A
2009/0197326	12/2008	El Gamal et al.	N/A	N/A
2009/0202998	12/2008	Schlumpberger et al.	N/A	N/A
2009/0215633	12/2008	van Eijk et al.	N/A	N/A
2009/0226911	12/2008	Mauk et al.	N/A	N/A
2009/0233802	12/2008	Bignell et al.	N/A	N/A
2009/0239232	12/2008	Kurn	N/A	N/A
2009/0253163	12/2008	Xie et al.	N/A	N/A
2009/0253581	12/2008	van Eijk et al.	N/A	N/A
2009/0253582	12/2008	Pena et al.	N/A	N/A
2009/0264299	12/2008	Drmanac et al.	N/A	N/A
2009/0270273	12/2008	Burns et al.	N/A	N/A
2009/0280487	12/2008	Hung et al.	N/A	N/A
2009/0283407	12/2008	Shah et al.	N/A	N/A
2009/0286249	12/2008	Becker et al.	N/A	N/A
2009/0289184	12/2008	Deininger	N/A	N/A
2009/0291854	12/2008	Weisinger-Mayr et al.	N/A	N/A
2009/0305237	12/2008	Cantor et al.	N/A	N/A
2009/0312193	12/2008	Kim et al.	N/A	N/A

2009/0321262	12/2008	Adachi et al.	N/A	N/A
2010/0009871	12/2009	Reed et al.	N/A	N/A
2010/0014537	12/2009	Jacquet et al.	N/A	N/A
2010/0031757	12/2009	Hoyer	N/A	N/A
2010/0035249	12/2009	Hayashizaki et al.	N/A	N/A
2010/0047790	12/2009	Southern et al.	N/A	N/A
2010/0055733	12/2009	Lutolf et al.	N/A	N/A
2010/0069263	12/2009	Shendure et al.	N/A	N/A
2010/0096266	12/2009	Kim et al.	N/A	N/A
2010/0099103	12/2009	Hsieh et al.	N/A	N/A
2010/0105052	12/2009	Drmanac et al.	N/A	N/A
2010/0105112	12/2009	Heltze et al.	N/A	N/A
2010/0108577	12/2009	Wang et al.	N/A	N/A
2010/0111768	12/2009	Banerjee et al.	N/A	N/A
2010/0113302	12/2009	Williams	N/A	N/A
2010/0120043	12/2009	Sood et al.	N/A	N/A
2010/0120097	12/2009	Matz et al.	N/A	N/A
2010/0120098	12/2009	Grunenwald et al.	N/A	N/A
2010/0126862	12/2009	Sabin et al.	N/A	N/A
2010/0129874	12/2009	Mitra et al.	N/A	N/A
2010/0137143	12/2009	Rothberg et al.	N/A	N/A
2010/0145037	12/2009	Makarov et al.	N/A	N/A
2010/0151447	12/2009	Ely	N/A	N/A
2010/0151464	12/2009	Stuelpnagel et al.	N/A	N/A
2010/0151511	12/2009	Gereenizer et al.	N/A	N/A
2010/0159446	12/2009	Haff et al.	N/A	N/A
2010/0173384	12/2009	Johnsson et al.	N/A	N/A
2010/0184614	12/2009	Ye et al.	N/A	N/A
2010/0184618	12/2009	Namsaraev et al.	N/A	N/A
2010/0201809	12/2009	Oyama et al.	N/A	N/A
2010/0210475	12/2009	Lee et al.	N/A	N/A
2010/0216137	12/2009	Bankaitis-Davis et al.	N/A	N/A
2010/0227329	12/2009	Cuppens	N/A	N/A
2010/0267590	12/2009	Grudzien et al.	N/A	N/A
2010/0273219	12/2009	May et al.	N/A	N/A
2010/0273679	12/2009	Cuppoletti et al.	N/A	N/A
2010/0282617	12/2009	Rothberg et al.	N/A	N/A
2010/0303722	12/2009	Jin et al.	N/A	N/A
2011/0015494	12/2010	Spaulding	N/A	N/A
2011/0024511	12/2010	Rietzler et al.	N/A	N/A
2011/0027772	12/2010	Ahn et al.	N/A	N/A
2011/0028685	12/2010	Purkayastha et al.	N/A	N/A
2011/0033854	12/2010	Drmanac et al.	N/A	N/A
2011/0045462	12/2010	Fu et al.	N/A	N/A
2011/0048951	12/2010	Wu	N/A	N/A
2011/0059436	12/2010	Hardin et al.	N/A	N/A
2011/0059865	12/2010	Smith et al.	N/A	N/A
2011/0086774	12/2010	Dunaway	N/A	N/A
2011/0090563	12/2010	Krasov	N/A	N/A
2011/0111409	12/2010	Sinicropi et al.	N/A	N/A
2011/0151451	12/2010	Lemaire et al.	N/A	N/A
2011/0152111	12/2010	Fan et al.	N/A	N/A
2011/0165178	12/2010	Wasylyk et al.	N/A	N/A
2011/0172115	12/2010	Thompson et al.	N/A	N/A
2011/0177518	12/2010	Kartalov et al.	N/A	N/A
2011/0201515	12/2010	Webster et al.	N/A	N/A
2011/0207134	12/2010	Faham et al.	N/A	N/A
2011/0223613	12/2010	Gut	N/A	N/A
2011/0237449	12/2010	McMaster et al.	N/A	N/A
2011/0244448	12/2010	Shirai et al.	N/A	N/A
2011/0245101	12/2010	Chee et al.	N/A	N/A
2011/0245111	12/2010	Chee	N/A	N/A
2011/0269155	12/2010	Reker-Hadrup et al.	N/A	N/A
2011/0269647	12/2010	Ule et al.	N/A	N/A
2011/0275077	12/2010	James	N/A	N/A
2011/0287435	12/2010	Grunenwald et al.	N/A	N/A
2012/0010091	12/2011	Linnarson	N/A	N/A
2012/0021930	12/2011	Schoen et al.	N/A	N/A
2012/0046175	12/2011	Rodesch et al.	N/A	N/A
2012/0046178	12/2011	Van Den Boom et al.	N/A	N/A
2012/0065081	12/2011	Chee	N/A	N/A
2012/0077693	12/2011	Cazalis et al.	N/A	N/A
2012/0129248	12/2011	Chee et al.	N/A	N/A
2012/0135871	12/2011	van Eijk et al.	N/A	N/A
2012/0142014	12/2011	Cai	N/A	N/A

2012/0157322	12/2011	Myllykangas	N/A	N/A
2012/0160683	12/2011	Ye et al.	N/A	N/A
2012/0177543	12/2011	Battrell	N/A	N/A
2012/0195810	12/2011	Cohen et al.	N/A	N/A
2012/0196297	12/2011	Yost et al.	N/A	N/A
2012/0202698	12/2011	van Eijk et al.	N/A	N/A
2012/0202704	12/2011	Fan et al.	N/A	N/A
2012/0220479	12/2011	Ericsson et al.	N/A	N/A
2012/0245053	12/2011	Shirai et al.	N/A	N/A
2012/0252702	12/2011	Muratani et al.	N/A	N/A
2012/0258871	12/2011	Kozlov et al.	N/A	N/A
2012/0270305	12/2011	Reed et al.	N/A	N/A
2012/0270748	12/2011	Chee et al.	N/A	N/A
2012/0279954	12/2011	Ceremony et al.	N/A	N/A
2012/0283106	12/2011	Wang et al.	N/A	N/A
2012/0289414	12/2011	Mitra et al.	N/A	N/A
2012/0301925	12/2011	Belyaev	N/A	N/A
2012/0308445	12/2011	Roper et al.	N/A	N/A
2012/0316086	12/2011	Lin et al.	N/A	N/A
2012/0322099	12/2011	Lapen et al.	N/A	N/A
2013/0005594	12/2012	Terbrueggen et al.	N/A	N/A
2013/0005600	12/2012	Olek	N/A	N/A
2013/0023433	12/2012	Luo et al.	N/A	N/A
2013/0035239	12/2012	Kong et al.	N/A	N/A
2013/0040842	12/2012	Lim et al.	N/A	N/A
2013/0052331	12/2012	Kram et al.	N/A	N/A
2013/0053273	12/2012	Juncker et al.	N/A	N/A
2013/0065768	12/2012	Zheng et al.	N/A	N/A
2013/0079232	12/2012	Kain et al.	N/A	N/A
2013/0096033	12/2012	Routenberg	N/A	N/A
2013/0109595	12/2012	Routenberg	N/A	N/A
2013/0122516	12/2012	Hong et al.	N/A	N/A
2013/0146459	12/2012	Bazant et al.	N/A	N/A
2013/0171621	12/2012	Luo et al.	N/A	N/A
2013/0195963	12/2012	Serda et al.	N/A	N/A
2013/0202718	12/2012	Pepin et al.	N/A	N/A
2013/0203100	12/2012	Otter et al.	N/A	N/A
2013/0211249	12/2012	Barnett et al.	N/A	N/A
2013/0244884	12/2012	Jacobson et al.	N/A	N/A
2013/0244895	12/2012	Voros et al.	N/A	N/A
2013/0252847	12/2012	McKenna et al.	N/A	N/A
2013/0260372	12/2012	Buermann et al.	N/A	N/A
2013/0261019	12/2012	Lin et al.	N/A	N/A
2013/0302801	12/2012	Asbury et al.	N/A	N/A
2014/0011289	12/2013	Smith et al.	N/A	N/A
2014/0011707	12/2013	Ye et al.	N/A	N/A
2014/0065609	12/2013	Hicks et al.	N/A	N/A
2014/0066318	12/2013	Frisen et al.	N/A	N/A
2014/0121118	12/2013	Warner	N/A	N/A
2014/0155274	12/2013	Xie et al.	N/A	N/A
2014/0155297	12/2013	Heinz	N/A	N/A
2014/0162293	12/2013	Springer et al.	N/A	N/A
2014/0227705	12/2013	Vogelstein et al.	N/A	N/A
2014/0342921	12/2013	Weiner	N/A	N/A
2014/0378350	12/2013	Hindson et al.	N/A	N/A
2015/0010860	12/2014	Kataoka et al.	N/A	N/A
2015/0051085	12/2014	Vogelstein et al.	N/A	N/A
2015/0065371	12/2014	Seppo et al.	N/A	N/A
2015/0072867	12/2014	Soldatov	N/A	N/A
2015/0087027	12/2014	Makarov et al.	N/A	N/A
2015/0344942	12/2014	Frisen et al.	N/A	N/A
2016/0003812	12/2015	Porreca et al.	N/A	N/A
2016/0024576	12/2015	Chee	N/A	N/A
2016/0138091	12/2015	Chee et al.	N/A	N/A
2016/0145677	12/2015	Chee et al.	N/A	N/A
2016/0201125	12/2015	Samuels et al.	N/A	N/A
2016/0291006	12/2015	Trau et al.	N/A	N/A
2016/0298180	12/2015	Chee	N/A	N/A
2016/0304952	12/2015	Boyden et al.	N/A	N/A
2016/0333403	12/2015	Chee	N/A	N/A
2017/0058339	12/2016	Chee	N/A	N/A
2017/0058340	12/2016	Chee	N/A	N/A
2017/0058345	12/2016	Chee	N/A	N/A
2017/0088881	12/2016	Chee	N/A	N/A
2017/0166962	12/2016	van Eijk et al.	N/A	N/A

2017/0266667	12/2016	Mortillaro et al.	N/A	N/A
2018/0094316	12/2017	Scott et al.	N/A	N/A
2018/0105808	12/2017	Mikkelsen et al.	N/A	N/A
2018/0112209	12/2017	Eshoo	N/A	N/A
2018/0179590	12/2017	Belgrader et al.	N/A	N/A
2018/0201980	12/2017	Chee et al.	N/A	N/A
2018/0216162	12/2017	Belhocine et al.	N/A	N/A
2018/0247017	12/2017	van Eijk et al.	N/A	N/A
2018/0291439	12/2017	van Eijk et al.	N/A	N/A
2018/0334670	12/2017	Bharadwaj et al.	N/A	N/A
2019/0002971	12/2018	Koslover et al.	N/A	N/A
2019/0017106	12/2018	Frisen et al.	N/A	N/A
2019/0024153	12/2018	Frisen et al.	N/A	N/A
2019/0024154	12/2018	Frisen et al.	N/A	N/A
2019/0064173	12/2018	Bharadwaj et al.	N/A	N/A
2019/0177800	12/2018	Boutet et al.	N/A	N/A
2019/0203275	12/2018	Friesen et al.	N/A	N/A
2019/0264268	12/2018	Frisen et al.	N/A	N/A
2019/0360034	12/2018	Zhou et al.	N/A	N/A
2019/0367982	12/2018	Belhocine et al.	N/A	N/A
2019/0367997	12/2018	Bent et al.	N/A	N/A
2020/0109443	12/2019	Chee	N/A	N/A
2020/0277663	12/2019	Ramachandran Iyer et al.	N/A	N/A
2020/0277664	12/2019	Frenz	N/A	N/A
2020/0283852	12/2019	Oliphant et al.	N/A	N/A
2020/0354774	12/2019	Church et al.	N/A	N/A
2020/0399687	12/2019	Frisen et al.	N/A	N/A
2020/0407781	12/2019	Schnall-Levin et al.	N/A	N/A
2021/0010068	12/2020	Chee et al.	N/A	N/A
2021/0010070	12/2020	Schnall-Levin et al.	N/A	N/A
2021/0017583	12/2020	Chee et al.	N/A	N/A
2021/0140982	12/2020	Uytingco	N/A	N/A
2021/0172007	12/2020	Chee et al.	N/A	N/A
2021/0189475	12/2020	Tentori et al.	N/A	N/A
2021/0190770	12/2020	Delaney et al.	N/A	N/A
2021/0198741	12/2020	Williams	N/A	N/A
2021/0199660	12/2020	Williams et al.	N/A	N/A
2021/0214785	12/2020	Stoeckius	N/A	N/A
2021/0222241	12/2020	Bharadwaj	N/A	N/A
2021/0222242	12/2020	Ramachandran Iyer	N/A	N/A
2021/0222253	12/2020	Uytingco	N/A	N/A
2021/0223227	12/2020	Stoeckius	N/A	N/A
2021/0230681	12/2020	Patterson et al.	N/A	N/A
2021/0230692	12/2020	Daugharthy et al.	N/A	N/A
2021/0237022	12/2020	Bava	N/A	N/A
2021/0238581	12/2020	Mikkelsen et al.	N/A	N/A
2021/0238664	12/2020	Bava	N/A	N/A
2021/0238675	12/2020	Bava	N/A	N/A
2021/0238680	12/2020	Bava	N/A	N/A
2021/0247316	12/2020	Bava	N/A	N/A
2021/0262019	12/2020	Alvarado Martinez et al.	N/A	N/A
2021/0277460	12/2020	Bava	N/A	N/A
2021/0285036	12/2020	Yin et al.	N/A	N/A
2021/0285046	12/2020	Chell et al.	N/A	N/A
2021/0292748	12/2020	Frisen et al.	N/A	N/A
2021/0292822	12/2020	Frisen et al.	N/A	N/A
2021/0317510	12/2020	Chee et al.	N/A	N/A
2021/0317524	12/2020	Lucero et al.	N/A	N/A
2021/0324457	12/2020	Ramachandran Iyer et al.	N/A	N/A
2021/0332424	12/2020	Schnall-Levin	N/A	N/A
2021/0332425	12/2020	Pfeiffer et al.	N/A	N/A
2021/0348221	12/2020	Chell et al.	N/A	N/A
2022/0002791	12/2021	Frisen et al.	N/A	N/A
2022/0010367	12/2021	Ramachandran Iyer et al.	N/A	N/A
2022/0017951	12/2021	Ramachandran Iyer et al.	N/A	N/A
2022/0025446	12/2021	Shah	N/A	N/A
2022/0025447	12/2021	Tentori et al.	N/A	N/A
2022/0033888	12/2021	Schnall-Levin et al.	N/A	N/A
2022/0049293	12/2021	Frenz et al.	N/A	N/A
2022/0049294	12/2021	Uytingco et al.	N/A	N/A
2022/0064630	12/2021	Bent et al.	N/A	N/A
2022/0081728	12/2021	Williams	N/A	N/A
2022/0088561	12/2021	Brenan et al.	N/A	N/A
2022/0090058	12/2021	Frisen et al.	N/A	N/A
2022/0090175	12/2021	Uytingco et al.	N/A	N/A

2022/0090181	12/2021	Gallant et al.	N/A	N/A
2022/0098576	12/2021	Dadhwal	N/A	N/A
2022/0098661	12/2021	Chew et al.	N/A	N/A
2022/0106632	12/2021	Galonska et al.	N/A	N/A
2022/0106633	12/2021	Engblom et al.	N/A	N/A
2022/0112486	12/2021	Ramachandran Iyer et al.	N/A	N/A
2022/0119869	12/2021	Ramachandran Iyer et al.	N/A	N/A
2022/0127659	12/2021	Frisen et al.	N/A	N/A
2022/0127666	12/2021	Katiraee et al.	N/A	N/A
2022/0127672	12/2021	Stoeckius	N/A	N/A
2022/0145361	12/2021	Frenz et al.	N/A	N/A
2022/0154255	12/2021	Chee et al.	N/A	N/A
2022/0170083	12/2021	Khaled et al.	N/A	N/A
2022/0195422	12/2021	Gallant et al.	N/A	N/A
2022/0195505	12/2021	Frisen et al.	N/A	N/A
2022/0213526	12/2021	Frisen et al.	N/A	N/A
2022/0241780	12/2021	Tentori et al.	N/A	N/A
2022/0267844	12/2021	Ramachandran Iyer et al.	N/A	N/A
2022/0275444	12/2021	Salmanzadeh	N/A	N/A
2022/0282329	12/2021	Chell et al.	N/A	N/A
2022/0290217	12/2021	Frenz et al.	N/A	N/A
2022/0298560	12/2021	Frisen et al.	N/A	N/A
2022/0325325	12/2021	Chee et al.	N/A	N/A
2022/0326251	12/2021	Uytingco et al.	N/A	N/A
2022/0333191	12/2021	Mikkelsen et al.	N/A	N/A
2022/0333192	12/2021	Uytingco	N/A	N/A
2022/0333195	12/2021	Schnall-Levin et al.	N/A	N/A
2022/0334031	12/2021	Delaney et al.	N/A	N/A
2022/0348905	12/2021	Dadhwal	N/A	N/A
2022/0348992	12/2021	Stoeckius et al.	N/A	N/A
2022/0356464	12/2021	Kim et al.	N/A	N/A
2022/0364163	12/2021	Stahl et al.	N/A	N/A
2022/0389503	12/2021	Mikkelsen et al.	N/A	N/A
2022/0389504	12/2021	Chew et al.	N/A	N/A
2022/0403455	12/2021	Ramachandran Iyer et al.	N/A	N/A
2022/0404245	12/2021	Chell et al.	N/A	N/A
2023/0002812	12/2022	Stoeckius et al.	N/A	N/A
2023/0014008	12/2022	Shastry	N/A	N/A
2023/0017773	12/2022	Kim et al.	N/A	N/A
2023/0031305	12/2022	Hernandez Neuta et al.	N/A	N/A
2023/0033960	12/2022	Gallant et al.	N/A	N/A
2023/0034039	12/2022	Shahjamali	N/A	N/A
2023/0034216	12/2022	Bava	N/A	N/A
2023/0042817	12/2022	Mignardi	N/A	N/A
2023/0047782	12/2022	Tentori et al.	N/A	N/A
2023/0056549	12/2022	Dadhwal	N/A	N/A
2023/0064372	12/2022	Chell et al.	N/A	N/A
2023/0069046	12/2022	Chew et al.	N/A	N/A
2023/0077364	12/2022	Patterson et al.	N/A	N/A
2023/0080543	12/2022	Katiraee et al.	N/A	N/A
2023/0081381	12/2022	Chew et al.	N/A	N/A
2023/0100497	12/2022	Frisen et al.	N/A	N/A
2023/0111225	12/2022	Chew et al.	N/A	N/A
2023/0113230	12/2022	Kim et al.	N/A	N/A
2023/0126825	12/2022	Nagendran et al.	N/A	N/A
2023/0129552	12/2022	Ramachandran Iyer	N/A	N/A
2023/0135010	12/2022	Tentori et al.	N/A	N/A
2023/0143569	12/2022	Iyer et al.	N/A	N/A
2023/0145575	12/2022	Gallant et al.	N/A	N/A
2023/0147726	12/2022	Hadrup et al.	N/A	N/A
2023/0159995	12/2022	Iyer et al.	N/A	N/A
2023/0160008	12/2022	Chell et al.	N/A	N/A
2023/0175045	12/2022	Katsori et al.	N/A	N/A
2023/0183684	12/2022	Gallant et al.	N/A	N/A
2023/0183785	12/2022	Frisen et al.	N/A	N/A
2023/0194469	12/2022	Tentori et al.	N/A	N/A
2023/0194470	12/2022	Kim et al.	N/A	N/A
2023/0203478	12/2022	Kim et al.	N/A	N/A
2023/0212650	12/2022	Chew et al.	N/A	N/A
2023/0220368	12/2022	Kim	N/A	N/A
2023/0220454	12/2022	Bent et al.	N/A	N/A
2023/0220455	12/2022	Galonska et al.	N/A	N/A
2023/0227811	12/2022	Dadhwal	N/A	N/A
2023/0228762	12/2022	Uytingco et al.	N/A	N/A
2023/0242973	12/2022	Frisen et al.	N/A	N/A

2023/0242976	12/2022	Tentori et al.	N/A	N/A
2023/0265488	12/2022	Gohil et al.	N/A	N/A
2023/0265489	12/2022	Uytingco et al.	N/A	N/A
2023/0265491	12/2022	Tentori et al.	N/A	N/A
2023/0267625	12/2022	Tentori et al.	N/A	N/A
2023/0279474	12/2022	Katiraee	N/A	N/A
2023/0279477	12/2022	Kvastad et al.	N/A	N/A
2023/0279481	12/2022	Marrache et al.	N/A	N/A
2023/0287399	12/2022	Gallant et al.	N/A	N/A
2023/0287475	12/2022	Chell et al.	N/A	N/A
2023/0287481	12/2022	Katsori et al.	N/A	N/A
2023/0295699	12/2022	Sukovich et al.	N/A	N/A
2023/0295722	12/2022	Bharadwaj	N/A	N/A
2023/0304072	12/2022	Gohil et al.	N/A	N/A
2023/0304074	12/2022	Chee et al.	N/A	N/A
2023/0304078	12/2022	Frisen et al.	N/A	N/A
2023/0313279	12/2022	Giacomello et al.	N/A	N/A
2023/0323340	12/2022	Dadhwal	N/A	N/A
2023/0323434	12/2022	Yin et al.	N/A	N/A
2023/0323447	12/2022	Schnall-Levin et al.	N/A	N/A
2023/0323453	12/2022	Stoeckius	N/A	N/A
2023/0332138	12/2022	Kim et al.	N/A	N/A
2023/0332212	12/2022	Chew et al.	N/A	N/A
2023/0332227	12/2022	Ramachandran Iyer	N/A	N/A
2023/0332247	12/2022	Singh et al.	N/A	N/A
2023/0351619	12/2022	Tentori et al.	N/A	N/A
2023/0358733	12/2022	Chee	N/A	N/A
2023/0366008	12/2022	Chew et al.	N/A	N/A
2023/0383285	12/2022	Kim et al.	N/A	N/A
2023/0383344	12/2022	Stoeckius	N/A	N/A
2023/0392204	12/2022	Chell et al.	N/A	N/A
2023/0393071	12/2022	Bava	N/A	N/A
2023/0407404	12/2022	Baumgartner et al.	N/A	N/A
2023/0416808	12/2022	Sukovich et al.	N/A	N/A
2023/0416850	12/2022	Singh et al.	N/A	N/A
2024/0002931	12/2023	Bava	N/A	N/A
2024/0011090	12/2023	Chew et al.	N/A	N/A
2024/0018572	12/2023	Mignardi	N/A	N/A
2024/0018575	12/2023	Gallant et al.	N/A	N/A
2024/0018589	12/2023	Schnall-Levin et al.	N/A	N/A
2024/0026445	12/2023	Ramachandran Iyer et al.	N/A	N/A
2024/0033743	12/2023	Tentori et al.	N/A	N/A
2024/0035937	12/2023	Cox et al.	N/A	N/A
2024/0043908	12/2023	Chew et al.	N/A	N/A
2024/0043925	12/2023	Bent et al.	N/A	N/A
2024/0052343	12/2023	Gallant et al.	N/A	N/A
2024/0053351	12/2023	Uytingco et al.	N/A	N/A
2024/0060115	12/2023	Chee et al.	N/A	N/A
2024/0067953	12/2023	Mikkelsen et al.	N/A	N/A
2024/0068016	12/2023	Frisen et al.	N/A	N/A
2024/0068017	12/2023	Lundeberg et al.	N/A	N/A
2024/0076723	12/2023	Mignardi	N/A	N/A
2024/0080346	12/2023	Engblom et al.	N/A	N/A
2024/0084365	12/2023	Frisen et al.	N/A	N/A
2024/0084366	12/2023	Chee	N/A	N/A
2024/0084383	12/2023	Ramachandran Iyer et al.	N/A	N/A
2024/0093274	12/2023	Frisen et al.	N/A	N/A
2024/0093290	12/2023	Stahl et al.	N/A	N/A
2024/0110228	12/2023	Uytingco et al.	N/A	N/A
2024/0124933	12/2023	Chell et al.	N/A	N/A
2024/0125772	12/2023	Delaney et al.	N/A	N/A
2024/0141327	12/2023	Kim et al.	N/A	N/A
2024/0158838	12/2023	Alvarado Martinez et al.	N/A	N/A
2024/0175080	12/2023	Galonska et al.	N/A	N/A
2024/0182968	12/2023	Bava	N/A	N/A
2024/0191286	12/2023	Boutet et al.	N/A	N/A
2024/0200121	12/2023	Boutet	N/A	N/A
2024/0209425	12/2023	Yin et al.	N/A	N/A
2024/0218427	12/2023	Sukovich et al.	N/A	N/A
2024/0218432	12/2023	Mielinis	N/A	N/A
2024/0219701	12/2023	Tentori et al.	N/A	N/A
2024/0253036	12/2023	Kim et al.	N/A	N/A
2024/0263218	12/2023	Katiraee et al.	N/A	N/A
2024/0271190	12/2023	Stoeckius et al.	N/A	N/A
2024/0271195	12/2023	Mikhaiel et al.	N/A	N/A

2024/0279747	12/2023	Williams	N/A	N/A
2024/0287600	12/2023	Iyer et al.	N/A	N/A
2024/0294971	12/2023	Galonska	N/A	N/A
2024/0294974	12/2023	Galonska et al.	N/A	N/A
2024/0294975	12/2023	Lin et al.	N/A	N/A
2024/0301488	12/2023	Stoeckius	N/A	N/A
2024/0301489	12/2023	Chew et al.	N/A	N/A
2024/0360494	12/2023	Costa et al.	N/A	N/A
2024/0368711	12/2023	Giacomello et al.	N/A	N/A
2024/0377297	12/2023	Cox et al.	N/A	N/A
2024/0385088	12/2023	Kim et al.	N/A	N/A
2024/0392349	12/2023	Frisen et al.	N/A	N/A
2024/0392352	12/2023	Stahl et al.	N/A	N/A
2024/0392353	12/2023	Engblom et al.	N/A	N/A
2024/0401109	12/2023	Kim et al.	N/A	N/A
2024/0401117	12/2023	Bava	N/A	N/A
2024/0401118	12/2023	Tentori et al.	N/A	N/A
2024/0404301	12/2023	Li et al.	N/A	N/A
2024/0408593	12/2023	Kim et al.	N/A	N/A
2024/0416315	12/2023	Bava	N/A	N/A
2024/0417783	12/2023	Chew et al.	N/A	N/A
2024/0417784	12/2023	Sukovich et al.	N/A	N/A
2025/0002980	12/2024	Tentori et al.	N/A	N/A
2025/0002982	12/2024	Stoeckius et al.	N/A	N/A
2025/0003956	12/2024	Delaney et al.	N/A	N/A
2025/0019689	12/2024	Galonska et al.	N/A	N/A
2025/0019749	12/2024	Katiraee et al.	N/A	N/A
2025/0066762	12/2024	Man et al.	N/A	N/A
2025/0066770	12/2024	Costa	N/A	N/A
2025/0073719	12/2024	Cox et al.	N/A	N/A
2025/0075261	12/2024	Kim	N/A	N/A
2025/0101504	12/2024	Nagendran et al.	N/A	N/A
2025/0122564	12/2024	Mignardi et al.	N/A	N/A
2025/0122565	12/2024	Schnall-Levin et al.	N/A	N/A
2025/0129412	12/2024	Uytingco et al.	N/A	N/A
2025/0129421	12/2024	Schnall-Levin et al.	N/A	N/A
2025/0137043	12/2024	Tentori	N/A	N/A
2025/0145984	12/2024	Ma et al.	N/A	N/A
2025/0146057	12/2024	Schnall-Levin et al.	N/A	N/A
2025/0146058	12/2024	Tentori	N/A	N/A
2025/0146071	12/2024	Schnall-Levin et al.	N/A	N/A
2025/0146072	12/2024	Schnall-Levin et al.	N/A	N/A
2025/0154568	12/2024	Frisen et al.	N/A	N/A
2025/0154569	12/2024	Stoeckius et al.	N/A	N/A
2025/0154571	12/2024	Ramachandran Iyer et al.	N/A	N/A
2025/0154588	12/2024	Ramachandran Iyer et al.	N/A	N/A
2025/0155446	12/2024	Uytingco et al.	N/A	N/A
2025/0163501	12/2024	Singh et al.	N/A	N/A
2025/0163509	12/2024	Daugharthy et al.	N/A	N/A
2025/0171833	12/2024	Frisen et al.	N/A	N/A
2025/0171848	12/2024	Chell et al.	N/A	N/A
2025/0179475	12/2024	Borgstrom et al.	N/A	N/A
2025/0182305	12/2024	Tentori et al.	N/A	N/A
2025/0182503	12/2024	Li et al.	N/A	N/A
2025/0188526	12/2024	Sukovich et al.	N/A	N/A
2025/0189483	12/2024	Kim et al.	N/A	N/A
2025/0197847	12/2024	Kim et al.	N/A	N/A
2025/0197938	12/2024	Bjorninen	N/A	N/A
2025/0207125	12/2024	Gupta et al.	N/A	N/A
2025/0207195	12/2024	Chell et al.	N/A	N/A
2025/0208115	12/2024	Bent	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2003200718	12/2005	AU	N/A
2169928	12/2006	CA	N/A
1273609	12/1999	CN	N/A
1425133	12/2002	CN	N/A
1537953	12/2003	CN	N/A
1680604	12/2004	CN	N/A
1749752	12/2005	CN	N/A
1813059	12/2005	CN	N/A
1898398	12/2006	CN	N/A
1934452	12/2006	CN	N/A
1981188	12/2006	CN	N/A

101142325	12/2007	CN	N/A
101205560	12/2007	CN	N/A
101221182	12/2007	CN	N/A
101405400	12/2008	CN	N/A
101460633	12/2008	CN	N/A
101522915	12/2008	CN	N/A
202548048	12/2011	CN	N/A
102851369	12/2012	CN	N/A
102947330	12/2012	CN	N/A
105441549	12/2015	CN	N/A
0901631	12/1998	EP	N/A
0961110	12/1998	EP	N/A
1782737	12/2006	EP	N/A
1878502	12/2007	EP	N/A
1923471	12/2007	EP	N/A
1929039	12/2007	EP	N/A
1966393	12/2007	EP	N/A
2002017	12/2007	EP	N/A
2130913	12/2008	EP	N/A
2161336	12/2009	EP	N/A
1910562	12/2009	EP	N/A
2292788	12/2010	EP	N/A
2302070	12/2010	EP	N/A
2350648	12/2010	EP	N/A
2363504	12/2010	EP	N/A
2580351	12/2012	EP	N/A
2789696	12/2013	EP	N/A
2963127	12/2015	EP	N/A
3045544	12/2015	EP	N/A
3239304	12/2016	EP	N/A
1846164	12/2017	EP	N/A
2007-014297	12/2006	JP	N/A
2007-074967	12/2006	JP	N/A
2009-036694	12/2008	JP	N/A
2011-182702	12/2010	JP	N/A
2013-544498	12/2012	JP	N/A
2014-217381	12/2013	JP	N/A
10-2009-0000812	12/2008	KR	N/A
10-2009-0081260	12/2008	KR	N/A
2145635	12/1999	RU	N/A
2270254	12/2005	RU	N/A
2410439	12/2010	RU	N/A
WO 1989/010977	12/1988	WO	N/A
WO 1991/006678	12/1990	WO	N/A
WO 1993/004199	12/1992	WO	N/A
WO 1995/023875	12/1994	WO	N/A
WO 1995/025116	12/1994	WO	N/A
WO 1995/035505	12/1994	WO	N/A
WO 1996/007669	12/1995	WO	N/A
WO 1997/031256	12/1996	WO	N/A
WO 1997/047640	12/1996	WO	N/A
WO 1998/010277	12/1997	WO	N/A
WO 1998/044151	12/1997	WO	N/A
WO 1999/032654	12/1998	WO	N/A
WO 1999/044062	12/1998	WO	N/A
WO 1999/044063	12/1998	WO	N/A
WO 1999/049082	12/1998	WO	N/A
WO 1999/063385	12/1998	WO	N/A
WO 1999/067641	12/1998	WO	N/A
WO 2000/017390	12/1999	WO	N/A
WO 2000/018957	12/1999	WO	N/A
WO 2000/024940	12/1999	WO	N/A
WO 2000/075373	12/1999	WO	N/A
WO 2001/006012	12/2000	WO	N/A
WO 2001/007915	12/2000	WO	N/A
WO 2001/009363	12/2000	WO	N/A
WO 2001/012862	12/2000	WO	N/A
WO 2001/042796	12/2000	WO	N/A
WO 2001/046402	12/2000	WO	N/A
WO 2001/059161	12/2000	WO	N/A
WO 2001/090415	12/2000	WO	N/A
WO 2001/096608	12/2000	WO	N/A
WO 2002/024952	12/2001	WO	N/A
WO 2002/040874	12/2001	WO	N/A
WO 2002/059355	12/2001	WO	N/A

WO 2002/059364	12/2001	WO	N/A
WO 2002/077283	12/2001	WO	N/A
WO 2002/088396	12/2001	WO	N/A
WO 2003/002979	12/2002	WO	N/A
WO 2003/003810	12/2002	WO	N/A
WO 2003/008538	12/2002	WO	N/A
WO 2003/010176	12/2002	WO	N/A
WO 2003/020261	12/2002	WO	N/A
WO 2003/077851	12/2002	WO	N/A
WO 2003/102233	12/2002	WO	N/A
WO 2003/106973	12/2002	WO	N/A
WO 2004/015080	12/2003	WO	N/A
WO 2004/028955	12/2003	WO	N/A
WO 2004/055159	12/2003	WO	N/A
WO 2004/067759	12/2003	WO	N/A
WO 2004/081225	12/2003	WO	N/A
WO 2004/108268	12/2003	WO	N/A
WO 2005/007814	12/2004	WO	N/A
WO 2005/010145	12/2004	WO	N/A
WO 2005/026387	12/2004	WO	N/A
WO 2005/042759	12/2004	WO	N/A
WO 2005/067648	12/2004	WO	N/A
WO 2005/084367	12/2004	WO	N/A
WO 2005/113804	12/2004	WO	N/A
WO 2006/020515	12/2005	WO	N/A
WO 2006/056861	12/2005	WO	N/A
WO 2006/064199	12/2005	WO	N/A
WO 2006/065597	12/2005	WO	N/A
WO 2006/074351	12/2005	WO	N/A
WO 2006/081021	12/2005	WO	N/A
WO 2006/081222	12/2005	WO	N/A
WO 2006/084130	12/2005	WO	N/A
WO 2006/117541	12/2005	WO	N/A
WO 2006/124771	12/2005	WO	N/A
WO 2006/137733	12/2005	WO	N/A
WO 2007/000669	12/2006	WO	N/A
WO 2007/010251	12/2006	WO	N/A
WO 2007/030373	12/2006	WO	N/A
WO 2007/037678	12/2006	WO	N/A
WO 2007/041689	12/2006	WO	N/A
WO 2007/053719	12/2006	WO	N/A
WO 2007/060599	12/2006	WO	N/A
WO 2007/073165	12/2006	WO	N/A
WO 2007/073171	12/2006	WO	N/A
WO 2007/073271	12/2006	WO	N/A
WO 2007/076128	12/2006	WO	N/A
WO 2007/076726	12/2006	WO	N/A
WO 2007/114693	12/2006	WO	N/A
WO 2007/120241	12/2006	WO	N/A
WO 2007/139766	12/2006	WO	N/A
WO 2007/145612	12/2006	WO	N/A
WO 2008/005673	12/2007	WO	N/A
WO 2008/022332	12/2007	WO	N/A
WO 2008/069906	12/2007	WO	N/A
WO 2008/075086	12/2007	WO	N/A
WO-2008075086	12/2007	WO	G01N 33/554
WO 2008/157801	12/2007	WO	N/A
WO 2009/032167	12/2008	WO	N/A
WO 2009/036525	12/2008	WO	N/A
WO 2009/086487	12/2008	WO	N/A
WO 2009/137521	12/2008	WO	N/A
WO 2009/152928	12/2008	WO	N/A
WO 2009/156725	12/2008	WO	N/A
WO 2010/019826	12/2009	WO	N/A
WO 2010/027870	12/2009	WO	N/A
WO 2010/053587	12/2009	WO	N/A
WO 2010/060439	12/2009	WO	N/A
WO 2010/088517	12/2009	WO	N/A
WO 2010/100265	12/2009	WO	N/A
WO 2010/110929	12/2009	WO	N/A
WO 2010/126614	12/2009	WO	N/A
WO 2010/127186	12/2009	WO	N/A
WO 2011/008502	12/2010	WO	N/A
WO 2011/014879	12/2010	WO	N/A
WO 2011/019964	12/2010	WO	N/A

WO 2011/062933	12/2010	WO	N/A
WO 2011/071943	12/2010	WO	N/A
WO 2011/102903	12/2010	WO	N/A
WO 2011/127006	12/2010	WO	N/A
WO 2011/127099	12/2010	WO	N/A
WO 2011/143583	12/2010	WO	N/A
WO 2011/155833	12/2010	WO	N/A
WO 2012/022975	12/2011	WO	N/A
WO 2012/049316	12/2011	WO	N/A
WO 2012/058096	12/2011	WO	N/A
WO 2012/061832	12/2011	WO	N/A
WO 2012/071428	12/2011	WO	N/A
WO 2012/083225	12/2011	WO	N/A
WO 2012/129242	12/2011	WO	N/A
WO 2012/139110	12/2011	WO	N/A
WO 2012/140224	12/2011	WO	N/A
WO 2012/142213	12/2011	WO	N/A
WO 2012/148477	12/2011	WO	N/A
WO 2012/148497	12/2011	WO	N/A
WO 2012/159089	12/2011	WO	N/A
WO 2012/168003	12/2011	WO	N/A
WO 2013/022807	12/2012	WO	N/A
WO 2013/033271	12/2012	WO	N/A
WO 2013/040257	12/2012	WO	N/A
WO 2013/090390	12/2012	WO	N/A
WO 2013/123442	12/2012	WO	N/A
WO 2013/131962	12/2012	WO	N/A
WO 2013/138510	12/2012	WO	N/A
WO 2013/142389	12/2012	WO	N/A
WO 2013/150083	12/2012	WO	N/A
WO 2013/025952	12/2012	WO	N/A
WO 2014/060483	12/2013	WO	N/A
WO 2014/210223	12/2013	WO	N/A
WO 2014/210225	12/2013	WO	N/A
WO 2014/210353	12/2013	WO	N/A
WO 2017/013170	12/2016	WO	N/A
WO 2020/076979	12/2019	WO	N/A
WO 2020/123305	12/2019	WO	N/A
WO 2020/123309	12/2019	WO	N/A
WO 2020/123311	12/2019	WO	N/A
WO 2020/123316	12/2019	WO	N/A
WO 2020/123317	12/2019	WO	N/A
WO 2020/123318	12/2019	WO	N/A
WO 2020/123319	12/2019	WO	N/A
WO 2020/167862	12/2019	WO	N/A
WO 2020/176882	12/2019	WO	N/A
WO 2020/190509	12/2019	WO	N/A
WO 2020/198071	12/2019	WO	N/A
WO 2020/219901	12/2019	WO	N/A
WO 2021/091611	12/2020	WO	N/A
WO 2021/092433	12/2020	WO	N/A
WO 2021/097255	12/2020	WO	N/A
WO 2021/133842	12/2020	WO	N/A
WO 2021/133849	12/2020	WO	N/A
WO 2021/142233	12/2020	WO	N/A
WO 2021/168261	12/2020	WO	N/A
WO 2021/168278	12/2020	WO	N/A
WO 2021/207610	12/2020	WO	N/A
WO 2021/216708	12/2020	WO	N/A
WO 2021/225900	12/2020	WO	N/A
WO 2021/236625	12/2020	WO	N/A
WO 2021/236929	12/2020	WO	N/A
WO 2021/237056	12/2020	WO	N/A
WO 2021/237087	12/2020	WO	N/A
WO 2021/242834	12/2020	WO	N/A
WO 2021/247543	12/2020	WO	N/A
WO 2021/247568	12/2020	WO	N/A
WO 2021/252499	12/2020	WO	N/A
WO 2021/252576	12/2020	WO	N/A
WO 2021/252591	12/2020	WO	N/A
WO 2021/263111	12/2020	WO	N/A
WO 2022/025965	12/2021	WO	N/A
WO 2022/060798	12/2021	WO	N/A
WO 2022/060953	12/2021	WO	N/A
WO 2022/061150	12/2021	WO	N/A

WO 2022/087273	12/2021	WO	N/A
WO 2022/098810	12/2021	WO	N/A
WO 2022/099037	12/2021	WO	N/A
WO 2022/103712	12/2021	WO	N/A
WO 2022/109181	12/2021	WO	N/A
WO 2022/140028	12/2021	WO	N/A
WO 2022/147005	12/2021	WO	N/A
WO 2022/147296	12/2021	WO	N/A
WO 2022/164615	12/2021	WO	N/A
WO 2022/178267	12/2021	WO	N/A
WO 2022/198068	12/2021	WO	N/A
WO 2022/221425	12/2021	WO	N/A
WO 2022/226057	12/2021	WO	N/A
WO 2022/236054	12/2021	WO	N/A
WO 2022/256503	12/2021	WO	N/A
WO 2022/271820	12/2021	WO	N/A
WO 2023/018799	12/2022	WO	N/A
WO 2023/034489	12/2022	WO	N/A
WO 2023/076345	12/2022	WO	N/A
WO 2023/086880	12/2022	WO	N/A
WO 2023/102118	12/2022	WO	N/A
WO 2023/122033	12/2022	WO	N/A
WO 2023/287765	12/2022	WO	N/A
WO 2023/150098	12/2022	WO	N/A
WO 2023/150163	12/2022	WO	N/A
WO 2023/150171	12/2022	WO	N/A
WO 2023/215552	12/2022	WO	N/A
WO 2023/225519	12/2022	WO	N/A
WO 2023/229988	12/2022	WO	N/A
WO 2023/250077	12/2022	WO	N/A
WO 2024/015578	12/2023	WO	N/A
WO 2024/035844	12/2023	WO	N/A
WO 2024/081212	12/2023	WO	N/A
WO 2024/086167	12/2023	WO	N/A
WO 2024/086776	12/2023	WO	N/A
WO 2024/102809	12/2023	WO	N/A
WO 2024/137826	12/2023	WO	N/A
WO 2024/145224	12/2023	WO	N/A
WO 2024/145441	12/2023	WO	N/A
WO 2024/145445	12/2023	WO	N/A
WO 2024/145491	12/2023	WO	N/A
WO 2024/206603	12/2023	WO	N/A
WO 2024/220882	12/2023	WO	N/A
WO 2024/238900	12/2023	WO	N/A
WO 2024/254316	12/2023	WO	N/A
WO 2025/029605	12/2024	WO	N/A
WO 2025/029627	12/2024	WO	N/A
WO 2025/043076	12/2024	WO	N/A
WO 2025/072119	12/2024	WO	N/A
WO 2025/090912	12/2024	WO	N/A
WO 2025/096581	12/2024	WO	N/A
WO 2025/101864	12/2024	WO	N/A

OTHER PUBLICATIONS

U.S. Appl. No. 16/353,937, filed Mar. 14, 2019, Frisen et al. cited by applicant
U.S. Appl. No. 17/707,189, filed Mar. 29, 2022, Chell et al. cited by applicant
[No Author Listed], “HuSNP Mapping Assay User's Manual,” Affymetrix Part No. 90094 (Affymetrix, Santa Clara, Calif.), GeneChip, 2000, 104 pages. cited
[No Author Listed], “Microarray technologies have excellent possibilities in genomics-related researches,” Science Tools From Amersham Pharmacia Biotech
Translation). cited by applicant
Adessi et al., “Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms,” Nucl. Acids Res., Oct. 2000, 28(20):E8
Affymetrix, “GeneChip Human Genome U133 Set,” retrieved from the Internet: on the World Wide Web at affymetrix.com/support/technical/datasheets/hgu1
2003. cited by applicant
Affymetrix, “Human Genome U95Av2,” Internet Citation, retrieved from the internet: on the World Wide Web affymetrix.com, retrieved on Oct. 2, 2002. cite
Agbavwe et al., “Efficiency, error and yield in light-directed maskless synthesis of DNA microarrays,” Journal of Nanobiotechnology, Dec. 2011, 9:57, 17 pag
Ahern et al., “Biochemical, Reagents Kits Offer Scientists Good Return On Investment,” The Scientist, 1995, 9(15):20, 7 pages. cited by applicant
Ahlfen et al., “Determinants of RNA quality from FFPE samples,” PLoS One, Dec. 2007, 2(12):e1261, 7 pages. cited by applicant
AJCC, “25 Lungs and 26 Pleural Mesothelioma,” AJCC Cancer Staging Manual 7th Ed., Springer, 2010, pp. 253-278, 38 pages. cited by applicant
Akatsuka et al., “Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: Application for assessment of clonal composition,” Tissue A
cited by applicant
Akatsuka et al., “T cell receptor clonal diversity following allogeneic marrow grafting,” Human Immunology, Jun.-Jul. 1996, 48:125-134. cited by applicant
Akeroyd, “Click chemistry for the preparation of advanced macromolecular architectures,” Stellenbosch University, PhD Dissertation, Mar. 2010, 138 pages.
Albretsen et al., “Applications of magnetic beads with covalently attached oligonucleotides in hybridization: Isolation and detection of specific measles virus
Biochem. 189: 40-50, 1990. cited by applicant
Albretsen et al., “Optimal conditions for hybridization with oligonucleotides: a study with myc-oncogene DNA probes,” Anal Biochem., Apr. 1988, 170(1):19
Allawi et al., “Thermodynamics and NMR of Internal G.T Mismatches in DNA,” Biochemistry, 1996, 36(34):10581-10594. cited by applicant

Almog et al., “The crystal structures of the psychrophilic subtilisin S41 and the mesophilic subtilisin Sph reveal the same calcium-loaded state,” Proteins, Feb
applicant
Altaras et al., “Production and formulation of adenovirus vectors,” Adv Biochem Eng Biotechnol., Nov. 2005, 99:193-260. cited by applicant
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,” Science, Oct. 4, 1996, 274(5284):94-96. cited by applicant
Altschul et al., “Basic local alignment search tool,” J. Mol. Biol., Oct. 5, 1990, 215(3):403-410. cited by applicant
Anderson et al., “Microarrayed Compound Screening to Identify Activators and Inhibitors of AMP-Activated Protein Kinase,” J. of Biomolecular Screening, 2
Andersson et al., “Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics.,” J Histochem Cytochem., 4(12): 1413-1423, 2006
Andresen et al., “Deciphering the Antibodyome—Peptide Arrays for Serum Antibody Biomarker Diagnostics,” Current Proteomics, 6(1), 1-12, 2009. cited by
Andresen et al., “Helicase-dependent amplification: use in OnChip amplification and potential for point-of-care diagnostics,” Expert Rev Mol Diagn., Oct. 20
Angenendt et al., “Cell-free Protein expression and functional assay in a nanowell chip format,” Analytical Chemistry, 2004, 76(7):1844-49. cited by applican
Angenendt et al., “Generation of High Density Protein Microarrays by Cell-free in Situ Expression of Unpurified PCR Products,” Molecular and Cellular Prot
1666. cited by applicant
Appella, “Non-natural nucleic acids for synthetic biology,” Current Opinion in Chemical Biology, Dec. 2009, 13(5-6): 687-696. cited by applicant
Armani et al., “2D-PCR: a method of mapping DNA in tissue sections,” Lab on a Chip, 2009, 9(24):3526-34. cited by applicant
Atkinson, Overview of Translation: Lecture Manuscript, U of Texas (2000) DD. 6.1-6.8. cited by applicant
Azioune et al., “Simple and rapid process for single cell micro-patterning,” Lab Chip, Jun. 2009, 9(11):1640-1642. cited by applicant
Baerwald et al., “Discovery of genes implicated in whirling disease infection and resistance in rainbow trout using genome-wide expression profiling,” BMC
pages. cited by applicant
Bains et al, “A Novel Method for Nucleic Acid Sequence Determination”, Journal of Theoretical Biology, 1988, 135(3), 303-7. cited by applicant
Baird et al., “Rapid SNP Discovery and Genetic Mapping Using Sequenced RAD markers,” PLoS One, 2008, 3(10):e3376. cited by applicant
Bakker et al., “Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -All, and -B7,” Proc Nat
105(10):3825-3830. cited by applicant
Bandiera et al., “Nuclear Outsourcing of RNA Interference Components to Human Mitochondria,” PLoS One, Jun. 2011, 6(6):e20746, 1-16. cited by applican
Baner et al., “Signal amplification of padlock probes by rolling circle replication,” Nucleic Acids Res., 1998, 26(22):5073-5078. cited by applicant
Barbie et al., “Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1,” Nature, Nov. 2009, 462(7269):108-12. cited by appl
Barnes, “PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates.,” Proc. Natl. Acad. Sci USA, 91: 221
Bates et al., “Block copolymers-designer soft materials,” Phys Today, Feb. 2000, 52:32-8. cited by applicant
Baugh et al., “Quantitative analysis of mRNA amplification by in vitro transcription,” Nucleic Acids Res., 2001, 29:5:e29. cited by applicant
Beattie et al., “Advances in genosensor research,” Clin Chem., May 1995, 41(5):700-6. cited by applicant
Beier et al., “Versatile derivatisation of solid support media for covalent bonding on DNA-microchips,” Nucleic Acids Res., May 1999, 27(9):1970-7. cited by
Bell, “A Simple Way to Treat PCR Products Prior to Sequencing Using ExoSAP-IT,” Biotechniques, 2008, vol. 44, No. 6. cited by applicant
Bentley et al, “Accurate whole human genome sequencing using reversible terminator chemistry”, Nature, 2008, 456:53-59. cited by applicant
Berent et al., “Comparison of oligonucleotide and long DNA fragments as probes in DNA and RNA dot, Southern, Northern, colony and plaque hybridizations
(Abstract Only). cited by applicant
Berger et al., “Universal bases for hybridization, replication and chain termination,” Nucleic Acid Res., Aug. 2000, 28(15):2911-2914. cited by applicant
Bessmertnykh et al., “Efficient Palladium-Catalyzed Synthesis of Aminopyridyl Phosphonates from Bromopyridines and Diethyl Phosphite,” Synthesis, 2008,
Bibikova et al., “Quantitative gene expression profiling in formalin-fixed paraffin-embedded tissues using universal bead arrays,” The American Journal of Pa
1807. cited by applicant
Bielas et al., “Human cancers express a mutator phenotype,” Proc. Natl. Acad. Sci. USA, 2006, 103(48): 18238-18242. cited by applicant
Bielas et al., “Quantification of random genomic mutations,” Nat. Methods, 2005, 2(4):285-290. cited by applicant
Biol.wwu.edu [online], “Principles of Di-Base Sequencing and the Advantages of Color Space Analysis in the SOLiD System,” 2008, retrieved on Mar. 11, 20
URL<https://biol.wwu.edu//young/470/stuff/abi-solid.pdf>, 4 pages. cited by applicant
Birney, et al., “Identification and analysis of functional elements in 1% of the human genome by the Encode pilot project,” Nature, 2007, 447:799-816. cited b
Blair et al., “Microarray temperature optimization using hybridization kinetics,” Methods Mol Biol., 2009, 529:171-96. cited by applicant
Blanchard et al., “High-density oligonucleotide arrays,” Biosensors & Bioelectronics, 1996, 11(6-7):687-690. cited by applicant
Blanco et al., “A practical approach to FRET-based PNA fluorescence in situ hybridization,” Methods, Dec. 2010, 52(4):343-51. cited by applicant
Blandini et al., “Animal models of Parkinson's disease,” FEBS J., Apr. 2012, 279(7):1156-66. cited by applicant
Blokzijl et al., “Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine,” J Intern. Med., 2010, 268:232-245. cited
Blow, “Tissue Issues,” Nature, 448(23), 959-962, 2007. cited by applicant
Boeke et al., “Transcription and reverse transcription of retrotransposons,” Annu Rev Microbiol, 1989, 43:403-34. cited by applicant
Bonfield et al., “The application of numerical estimates of base calling accuracy to DNA sequencing projects,” Nucleic Acids Research, 1995, 23(8):1406-141
Bos et al., “In Vitro Evaluation of DNA-DNA Hybridization as a Two-Step Approach in Radioimmunotherapy of Cancer,” Cancer Res., Jul. 1, 1994, 54(13):3
Boulé et al., “Terminal deoxynucleotidyl transferase indiscriminately incorporates ribonucleotides and deoxyribonucleotides,” J Biol Chem., Aug. 2001, 276(3
Boutros et al., “The art and design of genetic screens: RNA interference,” Nat Rev Genet., Jul. 2008, 9(7):554-66. cited by applicant
Bowtell, “The genesis and evolution of high-grade serous ovarian cancer,” Nat. Rev. Cancer, 2010, (11):803-808 Abstract. cited by applicant
Brandon et al., “Mitochondrial mutations in cancer,” Oncogene, 2006, 25(34):4647-4662. cited by applicant
Brenner et al, “In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs,” Proc. Natl. Acad. Sci. U
applicant
Brenner et al., “Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays”, Nat. Biotech. 18: 630-634, 2000. cited by
Brockman et al., “Quality scores and SNP detection in sequencing-by-synthesis systems,” Methods, 2008, 18:763-770. cited by applicant
Brow, “35—The Cleavase I enzyme for mutation and polymorphism scanning,” PCR Applications Protocols for Functional Genomics, 1999, pp. 537-550. cite
Brown et al., “Multiplex Three-Dimensional Brain Gene Expression Mapping in a Mouse Model of Parkinson's Disease,” Genome Research, 2002, 12:868-88
Brown et al., “Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein,” Proc Natl Acad Sci USA, A
applicant
Bullard et al., “Direct comparison of nick-joining activity of the nucleic acid ligases from bacteriophage T4,” Biochem. J. 2006, 398:135-144. cited by applica
Burns et al., “Well-less, gel-permeation formats for ultra-HTS,” DDT, 2001, 6(12):S40-S47. cited by applicant
Cai et al., “Glutathione-mediated shedding of PEG layers based on disulfide-linked catiomers for DNA delivery,” J. Mater. Chem., Sep. 20, 2011, 21(38):1463
Calvert, “Materials science. Printing cells,” Science, Oct. 2007, 318(5848):208-209. cited by applicant
Cardona et al., “TrakEM2 0.9a User Manual,” Sep. 8, 2011, retrieved on Jul. 29, 2022, retrieved from URL <https://www.ini.uzh.ch/~acardona/trakem2_manu
Cardullo et al., “Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer,” PNAS, Dec. 1, 1988, 85:8790-8794. cited by
Carlson et al., “Function and Structure of a Prokaryotic Formylglycine-generating Enzyme,” J. of Biological Chemistry, 2008, 283(29):20117-125. cited by ap
Carter et al., “Stabilization of an optical microscope to 0.1 nm in three dimensions,” Applied Optics, 2007, 46:421-427. cited by applicant
Cerritelli et al., “Ribonuclease H: the enzymes in eukaryotes,” FEBS Journal, Mar. 2009, 276(6):1494-505. cited by applicant
Cerutti et al., “Generation of sequence-specific, high affinity anti-DNA antibodies,” Journal of Biological Chemistry, 2001, 276(16):12769-12773. cited by ap
Cha et al., “Specificity, Efficiency and Fidelity of PCR,” Genome Res., 1993, 3:518-29. cited by applicant

Chandra et al., “Cell-free synthesis-based protein microarrays and their applications,” Proteomics, 2009, 5(6):717-30. cited by applicant
Chapin et al., “Rapid microRNA Profiling on Encoded Gel Microparticles,” Angew Chem Int Ed Engl., 2011, 50(10):2289-2293. cited by applicant
Chatterjee et al., “Protein Microarray On-Demand: A Novel Protein Microarray System,” PLos One, 2008, 3(9):e3265. cited by applicant
Chatterjee, et al., “Mitochondrial DNA mutations in human cancer. Oncogene,” 2006, 25(34):4663-4674. cited by applicant
Chen et al., “A Homogeneous, Ligase-mediated DNA diagnostic test,” Genome research, 1998, 8(5):549-556. cited by applicant
Chen et al., “DNA hybridization detection in a microfluidic Channel using two fluorescently labelled nucleic acid probes,” Biosensors and Bioelectronics, 200
Chen et al., “Geometric control of cell life and death,” Science, May 1997, 276(5317):1425-1428. cited by applicant
Chen et al., “Gray-scale photolithography using microfluidic photomasks,” PNAS, Feb. 2003, 100(4):1499-1504. cited by applicant
Chen et al., “Parallel single nucleotide polymorphism genotyping by surface invasive cleavage with universal detection,” Anal Chem., Apr. 2005, 77(8):2400-
Cheng et al., “Sensitive Detection of Small Molecules by Competitive Immunomagnetic-Proximity Ligation Assay,” Anal Chem, 2012, 84:2129-2132. cited b
Cheng, “The Contrast Formation in Optical Microscopy,” Handbook Of Biological Confocal Microscopy, 2006, Chapter 8, pp. 162-206. cited by applicant
Chester et al., “Dimethyl sulfoxide-mediated primer Tm reduction: a method for analyzing the role of renaturation temperature in the polymerase chain reactio
209(2):284-90. cited by applicant
Chial, “DNA Sequencing Technologies Key to the Human Genome Project,” Nature Education, 2008, 1(1):219, 7 pages. cited by applicant
Chiang et al., “NFkappaB translocation in human microvessel endothelial cells using a four-compartment subcellular protein redistribution assay,” J Biochem
2):53-68. cited by applicant
Chrisey et al., “Covalent attachment of synthetic DNA to self-assembled monolayer films,” Nucleic Acids Res., Aug. 1996, 24(15):3031-9. cited by applicant
Chu et al., “SV40 DNA transfection of cells in suspension: analysis of the efficiency of transcription and translation of T-antigen,” Gene, Mar. 1981, 13(2):19
applicant
Chung et al., “Imaging single-cell signaling dynamics with a deterministic high-density single-cell trap array,” Anal Chem, Sep. 2011, 83(18):7044-7052. cite
Ciaccio et al., “Systems analysis of EGF receptor signaling dynamics with microwestern arrays,” Nat Methods, Feb. 2010, 7(2):148-55. cited by applicant
Cockroft et al., “A single-molecule nanopore device detects DNA polymerase activity with single-nucleotide resolution,” J Am Chem Soc., Jan. 2008, 130(3):
Colegio et al., “In vitro transposition system for efficient generation of random mutants of Campylobacter jejuni,” J Bacteriol., Apr. 2001, 183(7):2384-8. cite
Condina et al., “A sensitive magnetic bead method for the detection and identification of tyrosine phosphorylation in proteins by Maldi-TOF/TOF MS,” Prote
applicant
Constantine et al., “Use of genechip high-density oligonucleotide arrays for gene expression monitoring,” Life Sceience News, Amersham Life Science; 11-14
Cook et al., “The effects of secondary structure and O2 on the formation of direct strand breaks upon UV irradiation of 5-bromodeoxyuridine-containing oligo
6(7):451-9. cited by applicant
Copeland et al., “Mitochondrial DNA Alterations in Cancer,” Cancer Invest., 2002, 557-569. cited by applicant
Cornett et al., “Maldi imaging mass spectrometry: molecular snapshots of biochemical systems,” Nature Methods, 2007, 4(10):828-833. cited by applicant
Cox et al., “Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics,” Nat Protoc., 2006, 1(4):1872-8. cited by a
Craig, “Transposon Tn7,” Curr Top Microbiol Immunol., 1996, 204:27-48. cited by applicant
Craig, “V(D)J recombination and transposition: closer than expected,” Science, Mar. 1996, 271(5255):1512, 1 page. cited by applicant
Crisalli et al., “Multi-Path Quenchers: Efficient Quenching of Common Fluorophores,” Bioconjug Chem., Oct. 28, 2011, 22(11): 2345-2354. cited by applicar
Crisalli et al., “Water-soluble Organocatalysts for Hydrazone and Oxime Formation,” J Org Chem, Feb. 1, 2013, 78(3):1184-1189, 20 pages (Author Manuscri
Cujec et al. “Selection of v-abl tyrosine kinase substate sequences from randomized peptide and cellular proteomic libraries using mRNA display,” Chemistry
by applicant
Curtis et al., “Adhesion of cells to polystyrene surfaces,” J Cell Biol., Nov. 1983, 97(5):1500-1506. cited by applicant
Czarnik, “Encoding methods for combinatorial chemistry,” Curr Opin Chem Biol., Jun. 1997, 1(1):60-6. cited by applicant
Dahl et al., “Circle-to-circle amplification for precise and sensitive DNA analysis,” Proc. Natl. Acad. Sci., 2004, 101:4548-4553. cited by applicant
Dalma-Weiszhausz et al., “The affymetrix GeneChip platform: an overview,” Methods Enzymol., 2006, 410:3-28. cited by applicant
Darmanis, et al., “ProteinSeq: High-Performance Proteomic Analyses by Proximity, Ligation and Next Generation Sequencing,” PLos One, 2011, 6(9):e25583
Daubendiek et al., “Rolling-Circle RNA Synthesis: Circular Oligonucleotides as Efficient Substrates for T7 RNA Polymerase,” J. Am. Chem. Soc., 1995, 117:
Dawson et al., “Genetic animal models of Parkinson's disease,” Neuron, Jun. 2010, 66(5):646-661. cited by applicant
De Clercq, “A 40-year journey in search of selective antiviral chemotherapy,” Annu Rev Pharmacol Toxicol., 2011, 51:1-24. cited by applicant
Deamer et al., “Characterization of nucleic acids by nanopore analysis,” Acc Chem Res., Oct. 2002, 35(10):817-25. cited by applicant
Deamer et al., “Nanopores and nucleic acids: prospects for ultrarapid sequencing,” Trends Biotechnol., Apr. 2000, 18(4):147-51. cited by applicant
Dean et al., “Comprehensive human genome amplification using multiple displacement amplification,” Proc Natl. Acad. Sci. USA 99:5261-66, 2002. cited by
Dean et al., “Rapid Amplification Of Plasmid And Phage DNA Using Phi29 DNA Polymerase And Multiply-Primed Rolling Circle Amplification,” Genome F
cited by applicant
Dedeoglu et al., “On the Source of Asymmetry in Image Registration Problems,” Technical Report, 2005, retrieve from
URL<https://www.ri.cmu.edu/pub_files/pub4/dedeoglu_goksel_2005_1/dedeoglu_goksel_2005_1.pdf>, 18 pages. cited by applicant
Deibel et al., “Biochemical properties of purified human terminal deoxynucleotidyltransferase,” J Biol Chem., May 1980, 255(9):4206-12. cited by applicant
Deininger et al., “Allograft inflammatory factor-1 defines a distinct subset of infiltrating macrophages/microglial cells in rat and human gliomas,” Acta Neuro
cited by applicant
Deo et al., “Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides,” Dev Dyn., Sep. 2006, 235(9):2538-48. cited
Devereux et al., “A comprehensive set of sequence analysis programs for the VAX,” Nucleic Acids Res., 1984, 12:387-395. cited by applicant
Devine et al., “Efficient integration of artificial transposons into plasmid targets in vitro: a useful tool for DNA mapping, sequencing and genetic analysis,” Nu
22(18):3765-72. cited by applicant
Dhindsa et al., “Virtual Electrowetting Channels: Electronic Liquid Transport with Continuous Channel Functionality,” Lab Chip, 2010, 10:832-836. cited by
Diez-Roux et al., “A high-resolution anatomical atlas of the transcriptome in the mouse embryo,” PLoS Biol., Jan. 2011, 9(1):e1000582, 14 pages. cited by ap
Doddridge et al., “UV-induced strand break damage in single stranded bromodeoxyuridine-containing DNA oligonucleotides,” Chem Commun., 1998, p. 199
Dressman et al., “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations,” Proc. Natl. Ac
cited by applicant
Drmanac et al., “Accurate sequencing by hybridization for DNA diagnostics and individual genomics,” Nature Biotechnology, 16:54-58, 1998. cited by applic
Druley et al., “Quantification of rare allelic variants from pooled genomic DNA,” Nat. Methods 6: 263-65, 2009. cited by applicant
Duhr et al., “Why molecules move along a temperature gradient,” Proc Natl Acad Sci USA, Dec. 2006, 103(52):19678-19682. cited by applicant
Duncan et al., “Affinity chromatography of a sequence-specific DNA binding protein using teflon-linked oligonucleotides”, Anal. Biochem. 169: 104-108, 198
Eberwine et al., “Analysis of gene expression in single live neurons,” Proc. Natl. Acad. Sci., USA 89, 3010-3014, 1992. cited by applicant
Eberwine et al., “Complementary DNA Synthesis in Situ: Methods and Applications,” Methods in Enzymology, 1992, 216:80-100. cited by applicant
Eberwine, “Amplification of mRNA Populations Using aRNA Generated from Immobilized Oligo(dT)-T7 Primed cDNA,” BioTechniques 20 (4), 584, 1996.
Ebihara et al., “Molecular detection of dermatophytes and nondermatophytes in onychomycosis by nested polymerase chain reaction based on 28S ribosomal
Dermatol., Nov. 2009, 161(5):1038-44. cited by applicant
Eguiluz et al., “Multitissue array review: A chronological description of tissue array techniques, applications and procedures,” Pathology Research and Practic
applicant

Ekins et al., "Microarrays: their origins and applications," Trends in Biotechnology, Jun. 1999, 17(6):217-218. cited by applicant
Eldridge et al. "An in vitro selection strategy for conferring protease resistance to ligand binding peptides," Protein Eng Des Sel., 22(11): 691-698, 2009. cited
Ellington et al., "Antibody-based protein multiplex platforms: technical and operational challenges," Clin Chem 56(2): 186-193, 2010. cited by applicant
Emmert-Buck et al., "Laser capture microdissection," Science, Nov. 1996, 274(5289):998-1001. cited by applicant
Ergin et al., "Proteomic Analysis of PAXgene-Fixed Tissues," J Proteome Res., 2010, 9(10):5188-96. cited by applicant
Ertsey et al., "Coverslip Mounted-Immersion Cycled in Situ RT-PCR for the Localization of mRNA in Tissue Sections," Biotechniques, 1998, 24; pp. 92-100.
Escholarship.org [online], "Methods and devices for fabricating and assembling DNA and protein arrays for high-throughput analyses [electronic resource]," 2
retrieved from URL<https://escholarship.org/uc/item/6tf7p46s>, 155 pages. cited by applicant
Espina et al., "Laser-capture microdissection," Nat Protoc, 2006, 1(2):586-603. cited by applicant
Evers et al., "The effect of formaldehyde fixation on RNA: optimization of formaldehyde adduct removal," J Mol Diagn., May 2011, 13(3):282-8. cited by ap
Extended European Search Report in European Appln. No. 11766613.1, dated Jan. 15, 2014, 4 pages. cited by applicant
Fahy et al., "Design and synthesis of polyacrylamide-based oligonucleotide supports for use in nucleic acid diagnostics," Nucleic Acids Res., Apr. 1993, 21(8)
Falconnet et al., "Rapid, Sensitive and Real-Time Multiplexing Platform for the Analysis of Protein and Nucleic-Acid Biomarkers," Anal. Chem., Jan. 7, 2015
Falconnet et al., "Surface engineering approaches to micropattern surfaces for cell-based assays," Biomaterials, Jun. 2006, 27(16):3044-3063. cited by applica
Fan et al., "A versatile assay for high-throughput gene expression profiling on universal array matrices," Genome Research, May 1, 2004, 14(5):878-885. cite
Fan et al., "Highly parallel SNP genotyping," Cold Spring Symp. Quant. Biol., 68: 69-78, 2003. cited by applicant
Fan et al., "Illumina Universal Bead Arrays," Methods in Enzymology, 2006, 410:57-73. cited by applicant
Fang et al., "Fluoride-cleavable biotinylation phosphoramidite for 5′-end-labeling and affinity purification of synthetic oligonucleotides," Nucleic Acids Res.,
applicant
Faruqi et al., "High-throughput genotyping of single nucleotide polymorphisms with rolling circle amplification," BMC Genomics, Aug. 2001, 2:4, 10 pages.
Ferreira et al., "Photocrosslinkable Polymers for Biomedical Applications," Biomedical Engineering-Frontiers and Challenges, Prof. Reza, 2011, 22 pages. cit
Fiandaca et al., "Self-Reporting PNA/DNA Primers for PCR Analysis," Genome Research, Apr. 2001, 11:609-613. cited by applicant
Fire and Xu, "Rolling replication of short DNA circles," Proc. Natl. Acad. Sci., 92: 4641-4645, 1995. cited by applicant
Fischer et al., "Hematoxylin and eosin staining of tissue and cell sections," CSH Protoc., May 2008, 3(5):1-3. cited by applicant
Fodor et al., "Light-Directed, Spatially Addressable Parallel Chemical Synthesis," Science, 251(4995), 767-773, 1995. cited by applicant
Folch et al., "Microfabricated elastomeric stencils for micropatterning cell cultures," J Biomed Mater Res, Nov. 2000, 52(2):346-353. cited by applicant
Fox, "Applications of Ultra-high-Throughput Sequencing," Plant Systems Biology, Methods in Molecular Biology, Belostotsky (ed.), Humana Press, 2009, 55
Fredriksson et al., "Multiplexed protein detection by proximity ligation for cancer detection," Nature Methods, 4(4): 327-29, 2007. cited by applicant
Fredriksson et al., "Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer," Clin. Chem., 5(3):
Fredriksson et al., "Protein detection using proximity-dependent DNA ligation assays," Nature Biotech., 20: 473-77, 2002. cited by applicant
Frese et al., "Formylglycine Aldehyde Tag-Protein Engineering through a Novel Posttranslational Modification," ChemBioChem., 10: 425-27, 2009. cited by
Friedman et al., "The synthesis of high yields of full-length reverse transcripts of globin mRNA," Nucleic Acids Res., Oct. 1, 1977, 4(10):3455-3471. cited by
Fu et al., "Counting individual DNA molecules by the stochastic attachment of diverse labels," PNAS, 108: 9026-9031, 2011. cited by applicant
Fu et al., "Repeat subtraction-mediated sequence capture from a complex genome," Plant J., Jun. 2010, 62(5):898-909. cited by applicant
Fullwood et al., "Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses," Genome Res., 19: 521-532, 2009. cited
Galon et al., "The immune score as a new possible approach for the classification of cancer," J Transl Med., Jan. 2012, 10:1, 4 pages. cited by applicant
Gamper et al., "Gene expression profile of bladder tissue of patients with ulcerative interstitial cystitis," BMC Genomics, Apr. 28, 2009, 10(199):1-17. cited b
Gans et al., "Inkjet Printing of Polymers: State of the Art and Future Developments," Advanced Materials, Feb. 2004, 16(3):203-213. cited by applicant
Gao et al., "High density peptide microarrays. In situ synthesis and applications," Molecular Diversity, 8, 177-187, 2004. cited by applicant
Geiss et al., "Direct multiplexed measurement of gene expression with color-coded probe pairs," nature biotechnology, 2008, 26(3):317-325. cited by applican
Genbank Accession No. AC009495.1, "*Homo sapiens* clone NH0490102, *** Sequencing in Progress *** , 12 unordered pieces," Aug. 24, 1999, 53 pages. ci
Genbank Accession No. AC009495.5, "*Homo sapiens* BAC clone RP11-49012 from 2, complete sequence," Apr. 21, 2005, 32 pages. cited by applicant
Genbank Accession No. AC037198.2, "*Homo sapiens* chromosome 15 clone CTD-2033D15 map 15q14, *** Sequencing in Progress *** , 62 unordered piece
applicant
Genbank Accession No. AC087379.2, "*Homo sapiens* chromosome 11 clone RP11-396020 map 11, *** Sequencing in Progress *** , 5 ordered pieces," Jul. 6
Genbank Accession No. AC087741.1, "*Homo sapiens* chromosome 17 clone RP11-334C17 map 17, Low-Pass Sequence Sampling," Jan. 22, 2001, 18 pages.
Genbank Accession No. AC100826.1, "*Homo sapiens* chromosome 15 clone RP11-279F6 map 15, Low-Pass Sequence Sampling," Nov. 22, 2001, 21 pages. c
Genbank Accession No. AL445524.1, "*Homo sapiens* chromosome 1 clone RP11-295G20, Working Draft Sequence, 19 unordered pieces," Oct. 14, 2000, 47
Genome.ucsc.edu, [online], "Genome Browser Gateway," 2000, retrieved on Jun. 11, 2021, retrieved from URL<https://genome.ucsc.edu/cgi-bin/hgGateway>
Gerard et al., "Excess dNTPs minimize RNA hydrolysis during reverse transcription," Biotechniques, Nov. 2002, 33(5):984, 986, 988, 990. cited by applicant
Gerry et al., "Universal DNA Microarray Method for Multiplex Detection of Low Abundance Point Mutations," J. Mol. Biol., 1999, 292:251-262. cited by ap
Giam et al., "Scanning probe-enabled nanocombinatorics define the relationship between fibronectin feature size and stem cell fate," PNAS, Mar. 2012, 109(1
Gibson et al., "Enzymatic assembly of DNA molecules up to several hundred kilobases," Nat Methods., May 2009, 6(5):343-5. cited by applicant
Gilar et al., "Study of phosphorothioate-modified oligonucleotide resistance to 3′-exonuclease using capillary electrophoresis," J Chromatogr B Biomed Sci A
cited by applicant
Gill et al., "Nucleic acid isothermal amplification technologies: a review," Nucleosides Nucleotides Nucleic Acids, Mar. 2008, 27(3):224-43. cited by applican
Gilles et al., "Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips," Nat Biotechnol, Apr. 1999, 17(4):3
Glass et al., "SIMPLE: a sequential immunoperoxidase labeling and erasing method," J. Histochem. Cytochem., Oct. 2009, 57(10):899-905. cited by applican
Gloor, "Gene targeting in Drosophila," Methods Mol Biol., 2004, 260:97-114. cited by applicant
Glorioso et al., "Development and Application of Herpes Simplex Virus Vectors for Human Gene Therapy," Annu. Rev. Microbiol., 1995; 49:675-710, 1 page
Gnanapragasam, "Unlocking the molecular archive: the emerging use of formalin-fixed paraffin-embedded tissue for biomarker research in urological cancer,"
2009. cited by applicant
Goebl et al., "Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in ti
Jun. 2007, 35(4):541-548. cited by applicant
Goldkom and Prockop, "A simple and efficient enzymatic method for covalent attachment of DNA to cellulose. Application for hybridization-restriction analy
probes.", Nucleic Acids Res. 14:9171-9191, 1986. cited by applicant
Goldmeyer et al., "Development of a novel one-tube isothermal reverse transcription thermophilic helicase-dependent amplification platform for rapid RNA d
Diagnostics, American Society for Investigative Pathology and the Association for Molecular Pathology, Nov. 1, 2007, 9(5):639-644. cited by applicant
Goransson et al., "A single molecule array for digital targeted molecular analyses," Nucleic Acids Res., Nov. 25, 2009, 37(1):e7, 9 pages. cited by applicant
Goryshin et al., "Tn5 in vitro transposition," J Biol Chem., Mar. 1998, 273(13):7367-74. cited by applicant
Gotz et al., "Animal models of Alzheimer's disease and frontotemporal dementia," Nat Rev Neurosci., Jul. 2008, 9(7):532-44. cited by applicant
Graham et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA," Virology, Apr. 1973, 52(2):456-467, 3 pages (Abstract Only). cited
Grant et al., "Pathways and mechanisms of endocytic recycling," Nat. Rev. Mol. Cell Biol., Sep. 2009, 10(9):597-608. cited by applicant
Grigoryev, "How DNA microarrays are built," Bitesize Bio, first published Jul. 13, 2011, updated Oct. 2021, retrieved from URL <https://bitesizebio.com/720
microarrays/#:~:text=Microarrays%20evolved%20from%20a%20technique%20known%20as%20Southern,were%20constructed%20by%20immobilizing%20

11 pages. cited by applicant
Grokhovsky, “Specificity of DNA cleavage by ultrasound,” Molecular Biology, 2006, 40(2):276-283. cited by applicant
Grünweller et al., “Locked Nucleic Acid Oligonucleotides,” BioDrugs, Jul. 2007, 21(4): 235-243. cited by applicant
Gruttadauria et al., “Supported proline and proline-derivatives as recyclable organocatalysts,” Chemical Society Reviews, Aug. 1, 2008, 37(8):1666-1688. cite
Gudjonsson et al., “Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia,” J Mammary Gland Biol Neoplasia, Jul. 2005, 10(3):
Gunderson et al., “Decoding Randomly Ordered DNA Arrays,” Genome Research 14: 870-877, 2004. cited by applicant
Guo et al., “Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports,” Nucleic Acids Res., Dec.
applicant
Ha et al, “Self-assembly hollow nanosphere for enzyme encapsulation,” Soft Matter, Feb. 11, 2010, 6, 1405-1408, 10 pages. cited by applicant
Hadrup et al., “Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers,” Nat. Methods., Jul. 2009, 6(7), 520-
Hafner et al., “Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing,” Methods, Jan. 2008, 44(1):3-12. cited by appli
Hahnke et al., “Striptease on glass: validation of an improved stripping procedure for in situ microarrays,” J Biotechnol., Jan. 2007, 128(1):1-13. cited by appl
Hajduk et al., “Drug discovery: A question of library design,” Nature, Feb. 2011, 470(7332):42-43. cited by applicant
Hamaguchi et al., “Direct reverse transcription-PCR on oligo(dT)-immobilized polypropylene microplates after capturing total mRNA from crude cell lysates,
44(11):2256-63. cited by applicant
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,” Nature, 1993, 363:446-448. cited by applicant
Hammond et al., “Profiling cellular protein complexes by proximity ligation with dual tag microarray readout,” PLoS One, 2012, 7(7):e40405. cited by applic
Han et al., “3C and 3C-based techniques: the powerful tools for spatial genome organization deciphering”, Molecular Cytogenetics (2018) 11:21, 10 pages, 20
Hanauer et al., “Separation of nanoparticles by gel electrophoresis according to size and shape,” Nano Lett., Sep. 2007, 7(9):2881-5. cited by applicant
Hardenbol et al., “Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay,” Genome Res., Feb
applicant
Hardenbol et al., “Multiplexed genotyping with sequence-tagged molecular inversion probes,” Nature Biotechnol., Jun. 2003, 21(6):673-678. cited by applica
Harold, “Molecules into Cells: Specifying Spatial Architecture,” Microbiology and Molecular Biology Reviews, Dec. 2005, 69(4):544-564. cited by applicant
Harris et al., “Chloroplast ribosomes and protein synthesis,” Microbiol. Mol. Biol. Rev., Dec. 1, 1994, 58(4): 700-754. cited by applicant
Harris et al., “The design and application of target-focused compound libraries,” Comb Chem High Throughput Screen, Jul. 2011, 14(6):521-531. cited by app
Hattersley et al., “Development of a microfluidic device for the maintenance and interrogation of viable tissue biopsies,” Lab Chip., Nov. 2008, 8(11):1842-6.
Hayes et al., “Electrophoresis of proteins and nucleic acids: I-Theory,” BMJ, Sep. 1989, 299(6703):843-6. cited by applicant
He et al., “In situ synthesis of protein arrays,” Current Opinion in Biotechnology, 19:4-9, 2008. cited by applicant
He et al., “Printing protein arrays from DNA arrays,” Nature Methods, 5:175-77, 2008. cited by applicant
He et al., “Ribosome display: Cell-free protein display technology,” Briefings in Functional Genomics and Proteomics, Jul. 2002, 204-212. cited by applicant
He, “Cell-free protein synthesis: applications in proteomics and biotechnology,” New Biotechnology 25: 126-132, 2008. cited by applicant
Healy, “Nanopore-based single-molecule DNA analysis,” Nanomedicine (Lond), Aug. 2007, 2(4):459-81. cited by applicant
Hedskog et al., “Dynamics of HIV-1 Quasispecies during Antiviral Treatment Dissected using Ultra-Deep Pyrosequencing,” PLoS One, 5(7):e11345, 2010. ci
Hein et al., “Click Chemistry, A Powerful Tool for Pharmaceutical Sciences”, Pharm Res., 25(10):2216-2230, 2008. cited by applicant
Heiter et al., “Site-Specific DNA-nicking Mutants of the Heterodimeric Restriction Endonuclease R.BbvC,” J. Mol. Biol., 2005, 348:631-40. cited by applica
Hejatko et al., “In Situ Hybridization Techniques for mRNA Detection in Whole Mount *Arabidopsis* Samples,” Nature Protocols, 2006, 1(4):1939-1946. cited
Hendrickson et al., “High sensitivity multianalyte immunoassay using covalent DNA-labeled antibodies and polymerase chain reaction,” Nucleic Acid Resear
cited by applicant
Hessner et al., “Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes,” Clin Chem., Aug. 2000, 46
Hewitt et al., “Tissue Handling and Specimen Preparation in Surgical Pathology,” Arch. Pathol. Lab. Med., 2008, 132:1929-1935. cited by applicant
Hiatt et al., “Parallel, tag-directed assembly of locally-derived short sequence reads,” Nature Methods, 7(2): 119-25, 2010. cited by applicant
Higgins et al., “The nicking endonuclease N.BstNBI is closely related to Type IIs restriction endonucleases MlyI and PleI,” Nucleic Acids Res., 2001, 29:249
Hlubek et al., “Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer,” Int J Cancer., Nov. 2007, 121(9):1941-8. cited by applica
Ho et al., “Bacteriophage T4 RNA ligase 2 (gp24.1) exemplifies a family of RNA ligases found in all phylogenetic domains,” PNAS, Oct. 2002, 99(20):12709
Ho et al., “Characterization of an ATP-Dependent DNA Ligase Encoded by Chlorella Virus PBCV-1,” Journal of Virology, Mar. 1997, 71(3):1931-1937. cited
Hober et al., “Human protein atlas and the use of microarray technologies,” Curr Opin Biotechnol., Feb. 2008, 19(1):30-35. cited by applicant
Holmstrøm et al., “A highly sensitive and fast nonradioactive method for detection of polymerase chain reaction products,” Anal Biochem, Mar. 1993, 209(2):
Holscher et al., “Application of Laser-Assisted Microdissection for Tissue and Cell-Specific Analysis of RNA,” Progress in Botany, Jan. 2008, 69(3):141-167.
Hong et al., “Background-Free Detection of Single 5 nm Nanoparticles through Interferometric Cross-Polarization Microscopy,” Nano Letters, Jan. 4, 2011, 1
Howell et al., “Glycosylases and AP-cleaving enzymes as a general tool for probe-directed cleavage of ssDNA targets,” Nucleic Acids Research, Jan. 15, 2010
applicant
Howell et al., “iFRET: An Improved Fluorescence System for DNA-Melting Analysis,” Genome Research, 2002, 12:1401-1407. cited by applicant
Hoyer et al., “Electrostatic spraying: a novel technique for preparation of polymer coatings on electrodes,” Anal Chem, Nov. 1996, 68(21):3840-4. cited by ap
Hsuih et al., “Novel, Ligation-Dependent PCR Assay for Detection of Hepatitis C Virus in Serum,” Journal of Clinical Microbiology, Mar. 1996, 34(3):501-50
Hu et al., “High reproducibility using sodium hydroxide-stripped long oligonucleotide DNA microarrays,” Biotechniques, Jan. 2005, 38(1):121-4. cited by ap
Hycultbiotech.com, [online], “Immunohistochemistry, Paraffin” Apr. 2010, retrieved on Apr. 16, 2020, retrieved from
URL<https://www.hycultbiotech.com/media/wysiwyg/Protocol_Immunohistochemistry_Paraffin_2.pd f>, 3 pages. cited by applicant
Hytönen et al., “Design and construction of highly stable, protease-resistant chimeric avidins,” J Biol Chem., Mar. 2005, 280(11):10228-33. cited by applicant
Ichikawa et al., “In vitro transposition of transposon Tn3,” J Biol. Chem., Nov. 1990, 265(31):18829-32, Abstract. cited by applicant
Illumina Gene Expression Profiling, “Whole-Genome Expression Analysis Using the Sentrix Human-6 and HumanRef-8 Expression BeadChips,” Illumina, 20
Illumina, “M1_SamplePrepSlides,” Slides of Broad/Illumina Genome Analyzer Boot Camp, Feb. 2010, 76 pages. cited by applicant
Illumina, “M2_Cluster Generation,” Slides of Broad/Illumina Genome Analyzer (GA) Boot Camp, Feb. 2010, 45 pages. cited by applicant
Illumina, “M3_Sequencing,” Slides of Broad/Illumina Genome Analyzer (GA) Boot Camp, Feb. 2010, 73 pages. cited by applicant
Illumina.com [online], “Array-Based Gene Expression Analysis,” 2011, retrieved on Dec. 13, 2021, retrieved from
URL<https://www.illumina.com/documents/products/datasheets/datasheet_gene_exp_analysis.pdf>, 5 pages. cited by applicant
Im et al., “An Introduction to Performing Immunofluorescence Staining,” Biobanking: Methods and Protocols, Method in Molecular Biology, Yong (ed.), 201
applicant
Imbeaud et al., “Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces,” Nucleic Acid
pages. cited by applicant
Inoue and Wittbrodt, “One for All—A Highly Efficient and Versatile Method for Fluorescent Immunostaining in Fish Embryos,” PLoS One 6, e19713, 2011. c
Invitrogen, Immune Response Biomarker Profiling Service Report, Invitrogen, 2009, 1-33. cited by applicant
Jabara et al., Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. PNAS 108(50); 20166-20171, 2011. cited by applicant
Jain, “Transport of molecules, particles, and cells in solid tumors,” Annu. Rev. Biomed. Eng., 1999, 1:241-263. cited by applicant
Jamur and Oliver, “Permeabilization of cell membranes.,” Method Mal. Biol., 588: 63-66, 2010. cited by applicant
Janda et al., “16S rRNA Gene Sequencing for Bacterial Identification in the Diagnostic Laboratory: Pluses, Perils, and Pitfalls,” Journal of Clinical Microbiol

applicant
Jawhar et al., "Tissue Microarray: A rapidly evolving diagnostic and research tool," Annals of Saudi Medicine, Mar. 2009, 29(2):123-7. cited by applicant
Jeffers, "A Basic Subroutine for Geary's Contiguity Ratio," J. Royal Stat. Society, Series D, Dec. 1973, 22(4):299-302. cited by applicant
Jennane et al., "Photolithography of self-assembled monolayers: optimization of protecting groups by an electroanalytical method," Can. J Chem., Dec. 1996,
Jensen et al., "Zinc fixation preserves flow cytometry scatter and fluorescence parameters and allows simultaneous analysis of DNA content and synthesis, an
Cytometry A., Aug. 2010, 77(8):798-804. cited by applicant
Jones et al., Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. USA 105(11): 4283-4288, 2008. cited by applicant
Joos et al., "Covalent attachment of hybridizable oligonucleotides to glass supports," Anal Biochem., Apr. 1997, 247(1):96-101. cited by applicant
Ju et al, "Supramolecular dendrimer capsules by cooperative binding," Chem. Commun., Jan. 7, 2011, 47(1):268-270, 8 pages. cited by applicant
Jucá et al., "Effect of dimethyl sulfoxide on reverse transcriptase activity," Braz. J. Med. Biol. Res., Mar. 1995, 28(3):285-90. cited by applicant
Kainkaryam et al., "Pooling in high-throughput drug screening" Curr Opin Drug Discov Devel., May 2009, 12(3):339-50. cited by applicant
Kanehisa, "Use of statistical criteria for screening potential homologies in nucleic acid sequences", Nucleic Acids Res. 12: 203-213, 1984. cited by applicant
Kap et al., "Histological Assessment of PAXgene Tissue Fixation and Stabilization Reagents," PLoS One 6, e27704, 10 pages, 2011. cited by applicant
Kapteyn et al., "Incorporation of Non-Natural Nucleotides Into Template-Switching Oligonucleotides Reduces Background and Improves cDNA Synthesis Fr
Genomics, 2010, 11(413): 1-9. cited by applicant
Karlin et al., "Applications and statistics for multiple high-scoring segments in molecular sequences," Proc. Natl. Acad. Sci., Jun. 15, 1993, 90:5873-7. cited b
Kelleher et al., "Characterization of RNA Strand Displacement Synthesis by Moloney Murine Leukemia Virus Reverse Transcriptase," J Biol Chem, Apr. 199
Kibbe, "OligoCalc: an online oligonucleotide properties calculator," Nucleic Acids Res., Jul. 2007, 35:W43-6. cited by applicant
Kim et al., "Replication of DNA Microarrays Prepared by In Situ Oligonucleotide Polymerization and Mechanical Transfer," Anal Chem., 2007, 79:7267-727
Kim, "Development of Microdevices for Applications to Bioanalysis," Dissertation for the degree of Doctor of Philosophy, University of Texas at Austin, Aug
Kirby et al., "Cryptic plasmids of Mycobacterium avium: Tn552 to the rescue," Mol Microbiol., Jan. 2002, 43(1):173-86. cited by applicant
Kleckner et al., "Tn10 and IS10 transposition and chromosome rearrangements: mechanism and regulation in vivo and in vitro," Curr Top Microbiol Immunol
Koch et al., "Photochemical immobilization of anthraquinone conjugated oligonucleotides and PCR amplicons on solid surfaces," Bioconjugate Chem., Jul. 2
Kolb et al., "Click Chemistry: Diverse Chemical Function from a Few Good Reactions," Angew. Chem. Int. Ed., 40(11): 2004-2021, 2001. cited by applicant
Kolbert et al., "Ribosomal DNA sequencing as a tool for identification of bacterial pathogens," Curr Opin Microbiol, Jun. 1999, 2(3):299-305. cited by applica
Kong et al., "Duplex probes: a new approach for the detection of specific nucleic acids in homogenous assays," Analytics Chimica Acta, Sep. 2003, 491:135-1
König et al., "iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution," Nat Struct Mol Biol., Jul. 2010, 17(7):909-915. ci
Korbel et al., "Paired-End Mapping Reveals Extensive Structural Variation in the Human Genome," Science, 318(5849): 420-426, 2007. cited by applicant
Korlach et al., "Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nanostructures," P
1181, 2008. cited by applicant
Kozlov et al., "A High-Complexity Multiplexed Solution-Phase Assay for Profiling Protease Activity on Microarrays," Comb Chem High Throughput Screen,
Kozlov et al., "A Highly Scalable Peptide-Based Assay System for Proteomics," PLoS One, 7(6):e37441, 2012. cited by applicant
Kozlov et al., "A Method for Rapid Protease Substrate Evaluation and Optimization," Comb Chem High Throughput Screen, 9: 481-87, 2006. cited by applica
Kristensen et al., "High-Throughput Methods for Detection of Genetic Variation," BioTechniques, Feb. 2001, 30(2):318-332. cited by applicant
Kuhn et al., "A novel, high-performance random array platform for quantitative gene expression profiling," Genome Res, 2004, 14:2347-2356. cited by applic
Kuhn et al., "Poly(A) Tail Length Is Controlled by the Nuclear Poly(A)-binding Protein Regulating the Interaction between Poly(A) Polymerase and the Cleav
Factor," The Journal of Biologic Chemistry, Aug. 21, 2009, 284(34):22803-22814. cited by applicant
Kuijpers et al. "Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmun
Chem., Jan. 1, 1993, 4(1):94-102. cited by applicant
Kuiper et al, "Enzymes containing porous polymersomes as nano reaction vessels for cascade reactions," Org. Biomol, Chem, Oct. 15, 2008, 6(23):4315-4318
Kumar et al., "Template-directed oligonucleotide strand ligation, covalent intramolecular DNA circularization and catenation using click chemistry," J Am Ch
cited by applicant
Kurz et al., "cDNA-Protein Fusions: Covalent Protein-Gene Conjugates for the In Vitro Selection of Peptides and Proteins," ChemBioChem., 2: 666-72, 2001
Kwok, "High-throughput genotyping assay approaches," Pharmocogenomics, Feb. 2000, 1(1):95-100. cited by applicant
Kwon et al, Polyelectrolyte Gels-Fundamentals and Applications, Nov. 10, 2006, Polymer Journal, 38, pp. 1211-1219. cited by applicant
Lage et al., "Whole Genome Analysis of Genetic Alterations in Small DNA Samples Using Hyperbranched Strand Displacement Amplification and Array-CG
2003. cited by applicant
Lampe et al., "A purified mariner transposase is sufficient to mediate transposition in vitro," EMBO J., Oct. 1996, 15(19):5470-9. cited by applicant
Lamture et al., "Direct detection of nucleic acid hybridization on the surface of a charge coupled device," Nucleic Acid Res., Jun. 1994, 22(11):2121-5. cited b
Landegren et al., "A Ligase-Mediated Gene Detection Technique," Science, 1988, 241(4869):1077-1080. cited by applicant
Landegren et al., "Reading bits of genetic information: methods for single-nucleotide polymorphism analysis," Genome Res., Aug. 1998, 8(8):769-76. cited by
Langdale et al., "A rapid method of gene detection using DNA bound to Sephacryl", Gene 36: 201-210, 1985. cited by applicant
Larman et al., "Autoantigen discovery with a synthetic human peptidome," Nature Biotechnology, doi:1 0.1038/nbt. 1856, vol. 29, No. 6, pp. 535-541, 2011. c
Larsen et al., "Characterization of a recombinantly expressed proteinase K-like enzyme from a psychrotrophic *Serratia* sp," FEBS J., Jan. 2006, 273(1):47-60.
Larsson et al., "In situ detection and genotyping of individual mRNA molecules," Nat Methods, May 2010, 7(5):395-7. cited by applicant
Larsson et al., "In situ genotyping individual DNA molecules by target-primed rolling-circle amplification of padlock probes," Nat Methods, Dec. 2004, 1(3):
Lassmann et al., A Novel Approach For Reliable Microarray Analysis of Microdissected Tumor Cells From Formalin-Fixed and Paraffin-Embedded Colorecta
Med, 87, 211-224, 2009. cited by applicant
Laurell et al., "Chip integrated strategies for acoustic separation and manipulation of cells and particles," Chem. Soc. Rev., Mar. 2007, 36(3):492-506. cited by
Lee et al., "A novel COL3A1 gene mutation in patient with aortic dissected aneurysm and cervical artery dissections," Heart Vessels, Mar. 2008, 23(2):144-8.
Lee et al., "Cytokines in cancer immunotherapy," Cancers (Basel), Oct. 2011, 3(4):3856-3893. cited by applicant
Lee et al., "Hydrogels for Tissue Engineering," Chemical Reviews, 2001, 101(7):1869-1879. cited by applicant
Lee et al., "Improving the efficiency of genomic loci capture using oligonucleotide arrays for high throughput resequencing," BMC Genomics, Dec. 2009, 10:
Lee et al., "Protein nanoarrays generated by dip-pen nanolithography," Science, Mar. 2002, 295(5560):1702-1705. cited by applicant
Lenard, "Viral Membranes," Encyclopedia of Virology, Jul. 2008, pp. 308-314. cited by applicant
Leriche et al., "Cleavable linkers in chemical biology.", Bioorganic & Medicinal Chemistry, 20: 571-582, 2012. cited by applicant
Levene et al., "Zero-Mode Waveguides for Single-Molecule Analysis at High Concentrations," Science 299, 682-686, 2003. cited by applicant
Li et al., "A photocleavable fluorescent nucleotide for DNA sequencing and analysis," Proc. Natl. Acad. Sci., 100: 414-419, 2003. cited by applicant
Li et al., "Beyond Moran's I: Testing for Spatial Dependence Based on the Spatial Autoregressive Model," Geographical Analysis, Sep. 18, 2007, 39(4):357-3
Li et al., "DNA molecules and configurations in a solid-state nanopore microscope," Nat Mater., Sep. 2003, 2(9):611-5. cited by applicant
Li et al., "RASL-seq for Massively Parallel and Quantitative Analysis of Gene Expression," Curr Protoc Mol Biol., Apr. 2012, 4(13):1-10. cited by applicant
Life Technologies, "Illumina TotalPrep RNA Amplification Kit," Ambion, 2011, 17 pages. cited by applicant
Ligasová et al., "In situ reverse transcription: the magic of strength and anonymity," Nucleic Acids Research, 2010, 38(16):e167. cited by applicant
Lin et al., "Replication of DNA microarrays from zip code masters," J. Am. Chem. Soc., 2006, 128(10):3268-3272. cited by applicant
Linnarsson, "Recent advances in DNA sequencing methods—general principles of sample preparation," Experimental Cell Research, 316: 1339-1343, 2010. c

Liu et al. “Barcoded oligonucleotides ligated on RNA amplified for multiplexed and parallel in situ analyses,” Nucleic Acids Res., Mar. 8, 2021, 49(10):e58, 1
Liu et al., “Method for Quantitative Proteomics Research by Using Metal Element Chelated Tags Coupled with Mass Spectrometry,” Analytical Chemistry, 20
Liu et al., “Preparation and Characterization of Temperature-Sensitive Poly(N-isopropylacrylamide)-b-poly(d,l-lactide) Microspheres for Protein Delivery,” B
1793. cited by applicant
Liu et al., “Surface and interface control on photochemically initiated immobilization,” J Am Chem Soc., Nov. 2006, 128(43):14067-72. cited by applicant
Liu et al., An integrated and sensitive detection platform for biosensing application based on Fe@Au magnetic nanoparticles as bead array carries Biosensors
1448. cited by applicant
Lizardi et al., “Mutation detection and single-molecule counting using isothermal rolling-circle amplification,” Nat. Genet. 19: 225-232, 1998. cited by applic
Lopez-Otín et al., “Protease degradomics: a new challenge for proteomics,” Nat Rev Mol Cell Biol., Jul. 2002, 3(7):509-19. cited by applicant
Lu et al., “A microfluidic electroporation device for cell lysis,” Lab Chip., Jan. 2005, 5(1):23-29. cited by applicant
Lund et al., “Assessment of methods for covalent binding of nucleic acids to magnetic beads, Dynabeads, and the characteristics of the bound nucleic acids in
Acids Res., 16: 10861-80, 1988. cited by applicant
Lundberg et al., “High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus.,” Gene., 108(1): 1-6, 1991. cited by ap
Lundberg et al., “Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood,
2011. cited by applicant
Lundberg et al., “Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material,” Mol Cell Prote
cited by applicant
Lundin et al., “Increased throughput by parallelization of library preparation for massive sequencing,” PLoS One, Apr. 2010, 5(4):e10029, 7 pages. cited by ap
Lundquist et al., “Parallel confocal detection of single molecules in real time,” Opt. Lett. 33, 1026-1028, 2008. cited by applicant
Lyamichev et al., “Invader assay for SNP genotyping,” Methods Mol Biol., 2003, 212:229-40. cited by applicant
Lyamichev et al., “Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes,” Nat Biotechnol.,
applicant
Lyck, et al., “Immunohistochemical Markers for Quantitative Studies of Neurons and Glia in Human Neocortex,” J Histochem Cytochem 56, 201-21, 2008. ci
Lykidis et al., “Novel zinc-based fixative for high quality DNA, RNA and protein analysis,” Nucleic Acids Res., Jun. 2007, 35(12):e85, 10 pages. cited by app
Mabruk et al., “In situ hybridization: detecting viral nucleic acid in formalin-fixed, paraffin-embedded tissue samples,” Expert Rev. Mol. Diagn., 2004, 4(5):6
MacBeath et al., “Printing proteins as microarrays for high-throughput function determination,” Science, Sep. 2000, 289(5485):1760-1763. cited by applicant
MacIntyre, “Unmasking antigens for immunohistochemistry.,” Br J Biomed Sci. 58, 190-6, 2001. cited by applicant
Magaki et al., “An introduction to Performance of Immunohistochemistry,” Biobanking: Methods and Protocols, Method in Molecular Biology, Yong (ed.), 20
by applicant
Makaryus et al., “Coronary venous angioplasty and stenting for biventricular pacemaker left ventricular lead implantation,” Journal of Invasive Cardiology, 20
Malkov et al., “Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System.” BMC research notes., 20
Manz et al., “Phylogenetic Composition, Spatial Structure, and Dynamics of Lotic Bacterial Biofilms Investigated by Fluorescent in situ Hybridization and Co
Microb Ecol, May 1999, 37(4):225-237. cited by applicant
Marras, “Selection of fluorophore and quencher pairs for fluorescent nucleic acid hybridization probes,” Methods Mol Biol., 2006, 335:3-16. cited by applicar
Marsden et al., “3D small-molecule microarrays,” Chem. Commun., 2009, pp. 7107-7109. cited by applicant
Martin, “Cutadapt removes adapter sequences from high-throughput sequencing reads,” EMBnet Journal, 2011, 17(1):10-12. cited by applicant
Massey et al., “Fluorescence resonance energy transfer (FRET) for DNA biosensors: FRET pairs and Förster distances for various dye-DNA conjugates,” Ana
2):181-9. cited by applicant
Masuda et al., “Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples,
27(22):4436-4443. cited by applicant
Materna et al., “High accuracy, high-resolution prevalence measurement for the majority of locally expressed regulatory genes in early sea urchin developmen
5):177-184. cited by applicant
Mattheyses et al., “Imaging with total internal reflection fluorescence microscopy for the cell biologist,” J Cell Sci., Nov. 2010, 123(Pt 21):3621-3628. cited b
McCloskey et al., “Encoding PCR Products with Batch-stamps and Barcodes,” Biochem. Genet. 45:761-767, 2007. cited by applicant
Mcgee, “Structure and Analysis of Affymetrix Arrays,” UTSW Microarray Analysis Course, Oct. 28, 2005, 68 pages. cited by applicant
McKernan et al., “Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encod
2009. cited by applicant
Megason et al., “Imaging in Systems Biology,” Cell 130, Sep. 7, 2007, pp. 784-795. cited by applicant
Metzker “Sequencing technologies—the next generation,” Nature Reviews Genetics, 11: 31-46, 2010. cited by applicant
Meyer et al., “Fast evolving 18S rRNA sequences from Solenogastres (Mollusca) resist standard PCR amplification and give new insights into mollusk substit
Biol., Mar. 2010, 10:70, 12 pages. cited by applicant
Michael et al., “Randomly Ordered Addressable High-Density Optical Sensor Arrays,” Analytical Chemistry, American Chemical Society, Apr. 1998, 70:1242
Micke et al., “Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens,” Lab Invest., Feb. 2006, 86(2):202-11. cited by applicant
Miele et al., “Mapping cis- and trans-chromatin interaction networks using chromosome conformation capture (3C),” Methods Mol Biol., 2009, 464:105-21. c
Miller et al., “Basic Concepts of Microarrays and Potential Applications in Clinical Microbiology,” Clinical Microbiology Reviews, vol. 22, No. 4, pp. 611-63
Miller et al., “Rapid and Efficient Enzyme Encapsulation in a Dendrimer Silica Nanocomposite,” Macromolecular Bioscience, Oct. 25, 2006, 6(10):839-845.
Miner et al., “Molecular barcodes detect redundancy and contamination in hairpin-bisulfite PCR,” Nucleic Acids Res., Sep. 2004, 32(17):e135, 4 pages. cited
Mir et al., “Sequencing by cyclic ligation and cleavage (CycliC) directly on a microarray captured template,” Nucleic Acids Research, 37(1):e5, 8 pages, 2009
Mitra et al., “Digital genotyping and haplotyping with polymerase colonies,” Proc. Natl. Acad. Sci. USA, May 2003, 100(10):5926-5931. cited by applicant
Mitra et al., “Fluorescent in situ sequencing on polymerase colonies,” Anal Biochem, Sep. 2003, 320(1):55-65. cited by applicant
Mitra et al., “In situ localized amplification and contact replication of many individual DNA molecules,” Nucleic Acids Res., Dec. 1999, 27(24):e34, 6 pages.
Mitsuhashi et al., “Gene manipulation on plastic plates,” Nature 357: 519-520, 1992. cited by applicant
Mizusawa et al., “A bacteriophage lambda vector for cloning with BamHI and Sau3A,” Gene, 20: 317-322, 1982. cited by applicant
Mlecinik et al., “Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction,” J Clin Oncol., Feb.
Mohanty et al., “Bacterial/archaeal/organellar poly adenylation,” Wiley Interdiscip Rev RNA, Mar.-Apr. 2011, 2(2):256-76, 36 pages (Author Manuscript). cit
Morgan et al., “Characterization of the specific DNA nicking activity of restriction endonuclease N. BstNBI,” Biol. Chem., 2000, 381:1123-1125. cited by app
Mortazavi et al., “Mapping and quantifying mammalian transcriptomes by RNA-Seq,” Nature Methods, 5(7): 621-8, 2008. cited by applicant
Moses et al., “Museum of spatial transcriptomics,” Nature Methods, May 2022, 19:534-546. cited by applicant
Moshrefzadeh et al., “Nonuniform photobleaching of dyed polymers for optical waveguides,” Applied Physics Letters, 1993, 62:16-18. cited by applicant
Motea et al., “Terminal deoxynucleotidyl transferase: the story of a misguided DNA polymerase,” Biochim Biophys Acta., May 2010, 1804(5):1151-66. cited
Mueller et al., “RNA Integrity Number (RIN)—Standardization of RNA Quality Control,” Agilent Technologies, 2004, 8 pages. cited by applicant
Nadji et al., “Immunohistochemistry of tissue prepared by a molecular-friendly fixation and processing system,” Appl Immunohistochem Mol Morphol., Sep.
Nagahara et al., “Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease,” Nat Med., Mar. 2009, 15(
Nagai et al., “Site-specific DNA cleavage by antisense oligonucleotides covalently linked to phenazine di-N-oxide,” J Biol. Chem., Dec. 1991, 266(35):23994
Nakamura et al., “Biocompatible inkjet printing technique for designed seeding of individual living cells,” Tissue Eng, Nov. 2005, 11(11-12):1658-1666. cited

Nakao et al., “Myosin heavy chain gene expression in human heart failure,” J Clin Invest., Nov. 1997, 100(9):2362-70. cited by applicant
Nallur et al., “Signal amplification by rolling circle amplification on DNA microarrays,” Nucleic Acids Res., Dec. 1, 2001, 29(23):e118, 9 pages. cited by appl
Nam et al., “Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins,” Science, Sep. 26, 2003, 301(5641):1884-1886. cited by applican
Nandakumar et al., “How an RNA Ligase Discriminates RNA versus DNA Damage,” Molecular Cell, 2004, 16(2):211-221. cited by applicant
Nandakumar et al., “RNA Substrate Specificity and Structure-guided Mutational Analysis of Bacteriophage T4 RNA Ligase 2,” Journal of Biological Chemist
cited by applicant
Ng et al., “Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation,” Nature Methods, 2(2): 105-111, 2005. cite
Ng et al., “Massively parallel sequencing and rare disease,” Human Malec. Genetics, 19(2): R119-R124, 2010. cited by applicant
Ng et al., “Multiplex sequencing of paired-end ditags (MS-PET): a strategy for the ultra-high-throughput analysis of transcriptomes and genomes,” Nucleic A
10 pages. cited by applicant
Nichols et al., “RNA Ligases,” Curr Protoc Mol Biol., Oct. 2008, 84(1):3.15.1-3.15.4. cited by applicant
Nicholson, “Diffusion and related transport mechanisms in brain tissue,” Rep. Prog. Phys., Jun. 2001, 64(7):815-884. cited by applicant
Niedringhaus et al., “Landscape of next-generation sequencing technologies,” Anal Chem., Jun. 2011, 83(12):4327-41. cited by applicant
Niemeyer, “The developments of semisynthetic DNA-protein conjugates,” Trends Biotechnol, Sep. 2002, 20(9): 395-401. cited by applicant
Nikiforov et al., “The use of 96-well polystyrene plates for DNA hybridization-based assays: an evaluation of different approaches to oligonucleotide immobi
227(1):201-9. cited by applicant
Niklas et al., “Selective permeabilization for the high-throughput measurement of compartmented enzyme activities in mammalian cells,” Anal Biochem, Sep
applicant
Nilsson et al., “Padlock Probes: Circularizing Oligonucleotides for Localized DNA Detection,” Science, Sep. 30, 1994, 265(5181):2085-2088. cited by applica
Nilsson et al., “RNA-templated DNA ligation for transcript analysis,” Nucleic Acids Res., Jan. 2001, 29(2):578-81. cited by applicant
Nuovo, “In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets,” Methods, 2010, 52(4):3
Nuovo, “In situ PCR: protocols and applications.,” Genome Res, Feb. 1995, 4 (4):151-167. cited by applicant
Ohtsubo et al., “Bacterial insertion sequences,” Curr Top Microbiol Immunol., 1996, 204:1-26. cited by applicant
Oleinikov et al., “Self-assembling protein arrays using electronic semiconductor microchips and in vitro translation,” J Proteome Res, May-Jun. 2003, 2(3): 31
Olivier, “The Invader assay for SNP genotyping,” Mutat. Res., Jun. 2005, 573(1-2):103-110. cited by applicant
Oren et al., “Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure-function study,” Biochemistry, Feb. 1997, 36(7):1826-3
Osada et al., “Epitope mapping using ribosome display in a resconstituted cell-free protein synthesis system,” J Biochem, May 2009, 145(5): 693-700. cited b
O-Shannessy et al., “Detection and quantitation of hexa-histidine-tagged recombinant proteins on western blots and by a surface plasmon resonance biosensor
119-124, 1995. cited by applicant
Ostuni et al., “Patterning Mammalian Cells Using Elastomeric Membranes,” Langmuir, Aug. 2000, 16(20):7811-7819. cited by applicant
Ozsolak et al., “Digital transcriptome profiling from attomole-level RNA samples,” Genome Res., Apr. 2010, 20(4):519-25. cited by applicant
Palamanda et al., “Evaluation of CYP1A1 and CYP2B1/2 m-RNA Induction in Rat Liver Slices Using the NanoString® Technology: A Novel Tool for Drug D
metabolism letters, Nov. 3, 2009, 3(3):171-175. cited by applicant
Pandey et al., “Inhibition of terminal deoxynucleotidyl transferase by adenine dinucleotides. Unique inhibitory action of Ap5A,” FEBS Lett., Mar. 1987, 213(
Parameswaran et al., “A pyrosequencing-tailored nucleotide barcode design unveils opportunities for largescale sample multiplexing,” Nucleic Acids Research
applicant
Park et al., “Cancer gene therapy using adeno-associated virus vectors,” Front Biosci., Jan. 2008, 13:2653-59. cited by applicant
Park et al., “Detection of Hepatitis C Virus RNA Using Ligation-Dependent Polymerase Chain Reaction in Formalin-Fixed, Paraffin-Embedded Liver Tissues
Nov. 5, 1996, 149(5):1485-1491. cited by applicant
Park et al., “The Estimation of Breast Cancer Disease-Probability by Difference of Individual Susceptibility,” Cancer Res. Treat., Feb. 2003, 35(1):35-51, Abs
Patil et al., “DNA-based therapeutics and DNA delivery systems: a comprehensive review,” AAPS J, Apr. 2005, 7(1):E61-77. cited by applicant
Patton et al., “Rainbow's end: the quest for multiplexed fluorescence quantitative analysis in proteomics.” Current Opinion in Chemical Biology, Feb. 1, 2002,
Pawloski, “Photolithographic synthesis of high-density DNA probe arrays: Challenges and opportunities,” J. Vac. Sci. Technol. B, 2007, 25:2537-2546. cited b
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2011/031308, dated Oct. 9, 2012, 7 pages. cited by applicant
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2011/031308, dated May 25, 2011, 8 pages. cited by applicant
Pearson et al., “Improved tools for biological sequence comparison,” Proc. Natl. Acad. Sci., May 1988, 85:2444-2448. cited by applicant
Pellestor et al., “The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytogenetics,” Eur J Hum Genet., Sep. 2004, 12(9):694-700. cite
Pemov et al., “DNA analysis with multiplex microarray-enhanced PCR,” Nucl. Acids Res., Jan. 2005, 33(2):e11, 9 pages. cited by applicant
Penland et al., “RNA expression analysis of formalin-fixed paraffin-embedded tumors,” Laboratory Investigation, Apr. 2007, 87(4):383-391. cited by applican
Perler et al., “Intervening sequences in an Archaea DNA polymerase gene,” Pnas USA, Jun. 1992, 89(12): 5577-5581. cited by applicant
Perocchi et al., “Antisense artifacts in transcriptome microarray experiments are resolved by actinomycin D,” Nucleic Acids Res., 2007, 35(19):e128, 7 pages.
Petterson et al., “Generations of sequencing technologies,” Genomics, 2009, 105-111. cited by applicant
Pipenburg et al., “DNA detection using recombination proteins,” PLoS Biol., Jul. 2006, 4(7):e204, 7 pages. cited by applicant
Pirici et al., “Antibody elution method for multiple immunohistochemistry on primary antibodies raised in the same species and of the same subtypem,” J. His
57(6):567-75. cited by applicant
Piston et al., “Fluorescent protein FRET: the good, the bad and the ugly,” Trends Biochem Sci., Sep. 2007, 32(9):407-14. cited by applicant
Plasterk, “The Tcl/mariner transposon family,” Curr Top Microbiol Immunol., 1996, 204:125-43. cited by applicant
Pluen et al., “Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations,” Biophys J., Jul. 1999, 77(1):542-552. cited by a
Polsky-Cynkin et al., “Use of DNA Immobilizedon Plastic and Agarose Supports to Detect DNA by Sandwich Hybridization,” Clin. Chem. 31: 1438-1443, 19
Porreca et al., “Polony DNA sequencing,” Curr Protoc Mol Biol., Nov. 2006, Chapter 7, Unit 7.8, pp. 7.8.1-7.8.22. cited by applicant
Pringle et al., “In situ hybridization demonstration of poly-adenylated RNA sequences in formalin-fixed paraffin sections using a biotinylated oligonucleotide
Pathology, Aug. 1989, 158:279-286. cited by applicant
Proudfoot et al., “Integrating mRNA Processing with Transcription,” Cell, Feb. 22, 2002, 108:501-512. cited by applicant
U.S. Appl. No. 61/267,363, filed Dec. 7, 2009 (Year: 2009). cited by applicant
Punwaney et al., “Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and
western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction,” Head & Neck, Jan. 1999, 21(1):21-29. cited by applicant
Qiu et al., “Mutation detection using Surveyor nuclease,” Biotechniques, Apr. 2004, 36(4):702-707. cited by applicant
Raab et al., “Human tRNA genes function as chromatin insulators,” EMBO J., Jan. 2012, 31(2):330-50. cited by applicant
Rahimi et al, “Synthesis and Characterization of Thermo-Sensitive Nanoparticles for Drug Delivery Applications,” J. Biomed. Nanotechnol. Dec. 2008, 4(4):4
Raj et al., “Imaging individual mRNA molecules using multiple singly labeled probes,” Nature Methods, Oct. 2008, 5(10):877-879, 9 pages. cited by applican
Ramachandran et al., “Next-generation high-density self-assembling functional protein arrays,” Nature Methods, Jun. 2008, 5(6):535-538. cited by applicant
Ramanujan et al., “Diffusion and convection in collagen gels: implications for transport in the tumor interstitium,” Biophys. J., Sep. 2002, 83(3):1650-1660. c
Ranki et al., “Sandwich hybridization as a convenient method for the detection of nucleic acids in crude samples”, Gene 21: 77-85, cellulose, 1983. cited by ap
Rasila et al., “Flexibility in MuA transposase family protein structures: functional mapping with scanning mutagenesis and sequence alignment of protein hom
7(5):e37922, 14 pages. cited by applicant

Razonable, “Antiviral drugs for viruses other than human immunodeficiency virus,” Mayo Clinic Proceedings, Oct. 2011, 86(10):1009-26. cited by applicant
Reijenga et al., “Buffer Capacity, Ionic Strength and Heat Dissipation in Capillary Electrophoresis,” Journal of Chromatography A, Sep. 13, 1996, 744(1-2):14
Reinartz et al., “Massively parallel signature sequencing (MPSS) as a tool for in-depth quantitative gene expression profiling in all organisms,” Brief Funct Ge
104. cited by applicant
Rettig et al., “Large-scale single-cell trapping and imaging using microwell arrays,” Anal Chem, Sep. 2005, 77(17):5628-5634. cited by applicant
Reznikoff, “Tn5 as a model for understanding DNA transposition,” Mol Microbiol., Mar. 2003, 47(5):1199-206. cited by applicant
Ristova et al., “Study of hydrogenated amorphous silicon thin films as a potential sensor for He—Ne laser light detection,” Applied Surface Science, Sep. 200
Roberts et al., “RNA-peptide fusions for the in vitro selection of peptides and proteins,” PNAS USA, Nov. 1997, 94: 12297-122302. cited by applicant
Robins et al., “Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells,” Blood, Nov. 5, 2009, 114(19):4099-4107. cited by applicant
Robinson et al., “Small-sample estimation of negative binomial dispersion, with applications to SAGE data,” Biostatistics, Apr. 2008, 9(2):321-332. cited by a
Rogers et al., “Immobilization of oligonucleotides onto a glass support via disulfide bonds: A method for preparation of DNA microarrays,” Anal Biochem., Ja
applicant
Rogers et al., “Use of a novel cross-linking method to modify adenovirus tropism,” Gene Ther., Dec. 1997, 4(12):1387-92. cited by applicant
Ronaghi et al., “A sequencing method based on real-time pyrophosphate,” Science, Jul. 1998, 281(5375): 363-365. cited by applicant
Ronaghi et al., “Real-time DNA sequencing using detection of pyrophosphate release,” Analytical Biochemistry, Nov. 1996, 242(1):84-89. cited by applicant
Ronaghi, “Pyrosequencing sheds light on DNA sequencing,” Genome Res, Jan. 2001, 11(1):3-11. cited by applicant
Rosenthal et al., “Cell patterning chip for controlling the stem cell microenvironment,” Biomaterials, Jul. 2007, 28(21):3208-3216. cited by applicant
Rouillard et al., “OligoArray 2.0: design of oligonucleotide probes for DNA microarrays using a thermodynamic approach,” Nuc. Acid Research, Jun. 2003, 3
Rountenberg et al., “Microfluidic probe: a new tool for integrating microfluidic environments and electronic wafer-probing,” Lab Chip, Oct. 2009, 10(1):123-
Rubin et al., “Whole-genome resequencing reveals loci under selection during chicken domestication.,” Nature, Mar. 2010, 464: 587-591. cited by applicant
Rubina et al., “Hydrogel-based protein microchips: manufacturing, properties, and applications,” Biotechniques, May 2003, 34(5):1008-14. cited by applicant
Rush et al., “New Aldehyde Tag Sequences Identified by Screening Formylglycine Generating Enzymes in Vitro and in Vivo,” J. of American Chemical Socie
cited by applicant
Rusk, “Tracing Cell Lineage with 5hmC,” Nature Methods, 2016, 13:710-711. cited by applicant
Russell et al., “Molecular mechanisms of late endosome morphology, identity and sorting,” Curr. Opin. Cell Bio., Aug. 2006, 18(4):422-428. cited by applicar
Samuelson et al., “The isolation of strand-specific nicking endonucleases from a randomized SapI expression library,” Nucleic Acids Res., 2004, 32:3661-367
San Paulo et al., “High-resolution imaging of antibodies by tapping-mode atomic force microscopy: attractive and repulsive tip-sample interaction regimes,” E
1605. cited by applicant
Sano et al., “Immuno-PCR: Very Sensitive Antigen Detection by Means of Specific Antibody-DNA Conjugates,” Science, Oct. 2, 1992, 258(5079):120-122. c
Schellings et al., “Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction,” J Exp Med., Jan. 2009, 206(1):1
Schena et al., “Quantitative monitoring of gene expression patterns with a complementary DNA microarray,” Science, Oct. 1995, 270(5235):467-470. cited by
Schena et al., “Entering the Postgenome Era,” Science, 1995, 270:368-9, 371. cited by applicant
Schlapak et al., “Glass surfaces grafted with high-density poly (ethylene glycol) as substrates for DNA oligonucleotide microarrays,” Langinuir, Jan. 2006, 22
Schmitt et al., “Detection of ultra-rare mutations by next-generation sequencing,” PNAS (2012) 109:14508-14523. cited by applicant
Scholz et al., “The Molecular Chaperone Hsp90 Is Required for Signal Transduction by Wild-Type Hck and Maintenance of Its Constitutively Active Counter
2001, 12(8):409-417. cited by applicant
Schouten et al., “Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification,” Nucleic Acids Res., Jun. 2002, 30
Schroeder et al., “The RIN: an RNA integrity No. for assigning integrity values to RNA measurements,” BMC Molecular Biology, Jan. 2006, 7:3, 14 pages. ci
Schweitzer et al., “Immunoassays with rolling circle DNA amplification: A versatile platform for ultrasensitive antigen detection,” Proc. Natl Acad. Sci. USA,
by applicant
Schweitzer et al., “Multiplexed protein profiling on microarrays by rolling-circle amplification,” Nature Biotechnology, Apr. 2002, 20(4):359-365. cited by ap
Schwers et al., “A high-sensitivity, medium-density, and target amplification-free planar waveguide microarray system for gene expression analysis of formali
tissue,” Clin. Chem., Nov. 2009, 55(11):1995-2003. cited by applicant
Scicchitano et al., “Preliminary Comparison of Quantity, Quality, and Microarray Performance of RNA Extracted From Formalin-fixed, Paraffin-embedded, a
Histochemistry & Cytochemistry, 2006, 54(11):1229-1237. cited by applicant
ScienceDirect.com [online], “Plant Fibers,” Definition, 2011, retrieved on Apr. 13, 2022, retrieved from URL<https://www.sciencedirect.com/topics/agricultu
fibers>, 9 pages. cited by applicant
Sekar et al., “Fluorescence resonance energy transfer (FRET) microscopy imaging of live cell protein localizations,” J Cell Biol., Mar. 2003, 160(5):629-33. c
Sel et al., “Feasibility of Employing Model-Based Optimization of Pulse Amplitude and Electrode Distance for Effective Tumor Electropermeabilization,” IE
Engineering, May 2007, 54(5):773-781. cited by applicant
Sergeeva et al., “Display technologies: Application for the discovery of drug and gene delivery aaents,” Advanced Drug Delivery Reviews (2006) 58(15):1622
Seurynck-Servoss et al., “Evaluation of Surface Chemistries for Antibody Microarrays”, Anal Biochem., 371(1): 105-115, 2007. cited by applicant
Shalon et al., “A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization,” Genome Res., Jul. 1996, 6(7
Shastry, “SNPs in disease gene mapping, medicinal drug development and evolution,” J. Hum. Genet., 2007, 52:871-880. cited by applicant
Shelbourne et al., “Fast copper-free click DNA ligation by the ring-strain promoted alkyne-azide cycloaddition reaction.”, Chem. Commun., 47: 6257-6259, 2
Shendure et al., “Accurate Multiplex Polony Sequencing of an Evolved Bacterial Genome,” Science, 2005, 309:1728-1732. cited by applicant
Shi et al., “The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements,” Nature Biotec
by applicant
Shi, “Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies,” Clin. Chem., Feb. 2001, 47(2):164-
Shibata et al., “Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction,” J Exp Med., Jan. 1988, 167(1):225-30.
Shirai et al., “Novel Tools for Analyzing Gene Expressions in Single Cells,” The 5th International Workshop on Approaches to Single-Cell Analysis, The Univ
page. cited by applicant
Shoemaker et al., “Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy,” Nature genetics (1996) 1
Shults et al., “A multiplexed protein kinase assay,” Chem Bio Chem (2007) 8:933-942. cited by applicant
Sievertzon et al., “Transcriptome analysis in primary neural stem cells using a tag cDNA amplification method,” BMC Neuroscience, Dec. 2005, 6: 28. cited b
Simonis et al., “Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C),” Nat Genet., N
applicant
Slomovic et al., “Addition of poly(A) and poly(A)-rich tails during RNA degradation in the cytoplasm of human cells,” Proc Natl Acad Sci USA, Apr. 2010, 1
Slonim and Yanai, “Getting started in gene expression microarray analysis,” Plos Computational Biology, 2009, 5(10):e1000543. cited by applicant
Soderberg et al. “Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay,” Methods, Jul. 2008, 45(3):227-23
Soderberg et al., “Direct observation of individual endogenous protein complexes in situ by proximity ligation,” Nature Methods, 2006, 3:995-1000. cited by a
Soen et al., “Detection and Characterization of Cellular Immune Responses Using Peptide-MHC Microarrays,” PLoS Biology, Dec. 22, 2003, 1(3):429-438. c
Son et al., “A platform for ultrasensitive and selective multiplexed marker protein assay toward early-stage cancer diagnosis,” Nanomedicine, Feb. 7, 2007, 2(
Soni and Meller, “Progress toward ultrafast DNA sequencing using solid-state nanopores,” Clin Chem., 2007, 53: 1996-2001. cited by applicant
Spiess et al., “A highly efficient method for long-chain cDNA synthesis using trehalose and betaine,” Anal. Biochem., Feb. 2002, 301(2):168-74. cited by appl

Spurgeon et al., “High Throughput Gene Expression Measurement with Real Time PCR in a Microfluidic Dynamic Array,” Plos ONE, 2008, 3(2):e1662. cited
Stahl et al., “Visualization and analysis of gene expression in tissue sections by spatial transcriptomics,” Science, Jul. 2016, 353(6294):78-82. cited by applica
Stahl et al., “Visualization and analysis of gene expression in tissue sections by spatial transcriptomics,” Science, Jun. 2016, Supplementary Materials, 353(62
applicant
Stanton et al., “Altered patterns of gene expression in response to myocardial infarction,” Circulation research, May 12, 2000, 86(9), 939-945. cited by applica
Stevens Jr. et al., “Enhancement of phosphoprotein analysis using a fluorescent affinity tag and mass spectrometry,” Rapid Commun Mass Spectrom, 2005, 19
Stimpson et al., “Real-time detection of DNA hybridization and melting on oligonucleotide arrays by using optical wave guides,” Proc Natl Acad Sci USA, Ju
applicant
Stoddart et al., “Single-nucleotide discrimination in immobilized DNA oligonucleotides with a biological nanopore,” PNAS U S A., May 2009, 106(19):7702-
Stougaard et al., “In situ detection of non-polyadenylated RNA molecules using Turtle Probes and target primed rolling circle PRINS,” BMC Biotechnology, I
applicant
Stroh et al., “Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo,” Nat Med., Jun. 2005, 11(6):678-82. cited by applicant
Subramanian et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” PNAS, Oct. 2005, 102(43
Suh et al., “A simple soft lithographic route to fabrication of poly (ethylene glycol) microstructures for protein and cell patterning,” Biomaterials, Feb. 2004, 2
Sumitomo et al., “Ca2+ ion transport through channels formed by—hemolysin analyzed using a microwell array on a Si substrate,” Biosensors and Bioelectro
applicant
Summersgill et al., “Fluorescence In Situ Hybridization Analysis of Formalin Fixed Paraffin Embedded Tissues, Including Tissue Microarrays,” Chapter 4, Br
Biology 659, 2010, 51-70, 2010. cited by applicant
Sun et al., “Direct immobilization of DNA probes on non-modified plastics by UV irradiation and integration in microfluidic devices for rapid bioassay,” Anal
cited by applicant
Surzhik et al., “Template-dependent biosynthesis of poly(G)×poly (C) and its antiviral activity in vitro and in vivo,” Antiviral Res., May 1988, 38(2):131-40. c
Sutherland et al., “Utility of formaldehyde cross-linking and mass spectrometry in the study of protein-protein interactions,” J. Mass Spectrom., Jun. 2008, 43
Swartz et al., “Interstitial flow and its effects in soft tissues,” Annu Rev Biomed Eng., 2007, 9:229-56. cited by applicant
Syková et al., “Diffusion in brain extracellular space,” Physiol Rev., Oct. 2008, 88(4):1277-340. cited by applicant
Tai et al., “Replication-competent retrovirus vectors for cancer gene therapy,” Front Biosci., Jan. 2008, 13:3083-95. cited by applicant
Takahashi et al., “In Vitro Selection of Protein and Peptide Libraries Using mRNA Display,” Nucleic Acid and Peptide Aptamers: Methods and Protocols (200
applicant
Tan et al., “Parylene peel-off arrays to probe the role of cell-cell interactions in tumour angiogenesis,” Integr Biol (Camb), Oct. 2009, 1(10):587-594. cited by
Tang et al., “mRNA-Seq whole-transcriptome analysis of a single cell,” Nat Methods, 2009, 6:377-382. cited by applicant
Tang et al., “RNA-Seq analysis to capture the transcriptome landscape of a single cell.,” Nat Protoc., 5:516-35, 2010. cited by applicant
Taniguchi et al., “Quantitative analysis of gene expression in a single cell by qPCR,” Nature Methods, 6, pp. 503-506, 2009. cited by applicant
Tawfik et al., “Man-made cell-like compartments for molecular evolution,” Nat Biotechnol., Jul. 1998, 16(7):652-6. cited by applicant
Taylor et al., “Microfluidic local perfusion chambers for the visualization and manipulation of synapses,” Neuron., Apr. 2010, 66(1):57-68, 25 pages. cited by
Taylor et al., “Mitochondrial DNA mutations in human disease.” Nature Reviews Genetics. May 2005, 6(5):389-402. cited by applicant
Tecott et al., “In Situ Transcription: Specific Synthesis of Complementary DNA in Fixed Tissue Sections,” Science, 1988, 240:1661-1664. cited by applicant
Tegtmeyer et al., “Alternative Interactions of the SV40 A Protein with DNA,” Virology, 1981, 115:75-87. cited by applicant
Thacker et al., “Alkaline Hydrolysis—Carcass Disposal: A Comprehensive Review,” National Agriculture Biosecurity Center, Aug. 2004, Chapter 6, pp. 1-12.
Thiery et al., “Multiplex target protein imaging in tissue sections by mass spectrometry—TAMSIM,” Rapid Commun. Mass Spectrom., 2007, 21:823-829. cit
Thorne et al., “In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space,” Proc Natl Acad Sci USA, Apr. 2006,
applicant
Thornton, “High rate thick film growth.” Annual review of materials science, Aug. 1977, 7(1):239-60. cited by applicant
Tian et al., “Antigen peptide-based immunosensors for rapid detection of antibodies and antigens,” Anal Chem May 26, 2009, 81 (13):5218-5225. cited by app
Tijssen et al., “Overview of principles of hybridization and the strategy of nucleic acid assays” in Techniques in Biochemistry and Molecular Biology—Hybri
1993, 24(Chapter 2), 65 pages. cited by applicant
Timofeev et al., “Regioselective immobilization of short oligonucleotides to acrylic copolymer gels,” Nucleic Acids Res., Aug. 1996, 24(16):3142-8. cited by
Tolbert et al., “New Methods for Proteomic Research: Preparation of Proteins with N-Terminal Cysteines for Labeling and Conjugation,” Angewandte Chemi
41(12):2171-4. cited by applicant
Totet et al., “Immunocompetent infants as a human reservoir for Pneumocystis jirovecii: rapid screening by non-invasive sampling and real-time PCR at the m
gene,” J Eukaryot Microbiol., 2003, pp. 668-669. cited by applicant
Toubanaki et al., “Dry-reagent disposable biosensor for visual genotyping of single nucleotide polymorphisms by oligonucleotide ligation reaction: applicatio
Mutat., Aug. 2008, 29(8):1071-8. cited by applicant
Toy et al., “A Simple Plastic Perfusion Chamber for Continuous Maintenance and Cinematography of Tissue Cultures,” Experimental Cell Research, 1958, 14
Trevino et al., “DNA Microarrays: a Powerful Genomic Tool for Biomedical and Clinical Research,” Mol Med, 2007, 13(9-10):527-541. cited by applicant
Twyman et al., “Techniques Patents for SNP Genotyping,” Pharmacogenomics, Jan. 2003, 4(1):67-79. cited by applicant
Tzanetakis et al., “The use of reverse transcriptase for efficient first- and second-strand cDNA synthesis from single- and double-stranded RNA templates,” J V
7. cited by applicant
Ueno et al., “cDNA Display: Rapid Stabilitzation of mRNA Display,” Antibody-Drug Conjugates, Methods in Molecular Biology, Jan. 2012, pp. 113-135. cite
Ulery et al., “Biomedical Applications of Biodegradable Polymers,” J Polym Sci B Polym Phys., Jun. 2011, 49(12):832-864. cited by applicant
U.S. Appl. No. 60/416,118 Fan et al., Multiplex Nucleic Acid Analysis Using Archived or Fixed Samples, filed Oct. 3, 2002, 22 pages. cited by applicant
Valencia et al., “mRNA-Display-Based Selections for Proteins with Desired Functions: A Protease-Substrate Case Study.” Biotechnology progress, May 2008
Valley et al., “Optoelectronic tweezers as a tool for parallel single-cell manipulation and stimulation,” IEEE Trans Biomed Circuits Syst., Dec. 2009, 3(6):424
Van Gelder et al., “Amplified RNA synthesized from limited quantities of heterogeneous cDNA,” Proc. Natl. Acad. Sci. USA 87, 1663-1667, 1990. cited by ap
Van Ness et al., “A versatile solid support system for oligodeoxynucleotide probe-based hybridization assays”, Nucleic Acids Res. 19: 3345-3350, 1991. cited
Vandenbroucke et al., “Quantification of splice variants using real-time PCR,” Nucleic Acids Research, 2001, 29(13):e68, 7 pages. cited by applicant
Vasiliskov et al., “Fabrication of microarray of gel-immobilized compounds on a chip by copolymerization,” Biotechniques, Sep. 1999, 27(3):592-606. cited b
Velculescu et al., “Serial analysis of gene expression.” Science, Oct. 20, 1995, 270(5235):484-7. cited by applicant
Verma et al., “Modified Oligonucleotides: Synthesis and Strategy for Users,” Annual Review of Biochemistry, 1998, 67(1):99-134. cited by applicant
Vermesh et al., “High-density, multiplexed patterning of cells at single-cell resolution for tissue engineering and other applications,” Angew Chem Int Ed Engl
by applicant
Villa et al., “Partial V(D)J Recombination Activity Leads to Omenn Syndrome,” Cell, May 29, 1998, 93:885-896. cited by applicant
Villemejane et al., “Physical methods of nucleic acid transfer: general concepts and applications,” British Journal of Pharmacology, 2009, 157:207-219. cited b
Vincent et al., “Helicase-dependent isothermal DNA amplification,” EMBO Rep., Aug. 2004, 5(8):795-800. cited by applicant
Viollet et al., “T4 RNA ligase 2 truncated active site mutants: improved tools for RNA analysis,” BMC Biotechnol., Jul. 2011, 11:72, 14 pages. cited by applic
viralzone.com, “Coronaviridae,” viralzone.com, available on or before May 21, 2017, retreived on Mar. 20, 2025, retrieved from URL
<https://web.archive.org/web/20200525133654/https://viralzone.expasy.org/30>, 2 pages. cited by applicant

Voelkerding et al., “Next-Generation Sequencing: From Basic Research to Diagnostics,” Clinical Chemistry, 2009, 55(4):641-658. cited by applicant
Vogelstein et al., “Digital PCR,” Proceedings of the National Academy of Sciences, Aug. 3, 1999, 96:9236-9241. cited by applicant
Wade et al., “Genome sequence, comparative analysis, and population genetics of the domestic horse.,” Science., 326: 865-7, 2009. cited by applicant
Waichman et al., “Functional immobilization and patterning of proteins by an enzymatic transfer reaction.” Analytical chemistry, Jan. 21, 2010, 82(4):1478-85
Walker et al., “Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system,” Proc. Natl. Acad. Sci. USA, 1992, 89:392-396. cit
Walker et al., “Strand displacement amplification—an isothermal, in vitro DNA amplification technique.” Nucleic acids research. Apr. 11, 1992, 1992, 20(7):1
Walker et al., Ed., “Chapter 1: Basic Techniques in Molecular Biology,” Medical Biomethods Handbook, Humana Press, Totowa, New Jersey, 2005, 19 pages.
Wang “Preparation of DNA substrates for in vitro mismatch repair,” Mol. Biotechnol., 2000, 15:97-104. cited by applicant
Wang et al., “Mutations in NEXN, a Z-disc gene, are associated with hypertrophic cardiomyopathy,” Am J Hum Genet., Nov. 2010, 87(5):687-93. cited by app
Wang et al., “Paramagnetic microspheres with core-shell-ed structures,” Journal of Materials Science, Apr. 2012, 47(16):5946-54. cited by applicant
Wang et al., “Single cell analysis: the new frontier in ‘omics’,” Trends Biotechnol., 28: 281-90, 2010. cited by applicant
Wang et al., “High-fidelity mRNA amplification for gene profiling.” Nature biotechnology. Apr. 2000, 18(4):457-459. cited by applicant
Wang, “RNA amplification for successful gene profiling analysis,” J Transl Med., Jul. 2005, 3:28, 11 pages. cited by applicant
Watanabe et al., “Cellular networks involved in the influenza virus life cycle,” Cell Host & Microbe, Jun. 2010, 7(6):427-39. cited by applicant
Waxman et al., “De-regulation of common housekeeping genes in hepatocellular carcinoma,” BMC Genomics, 2007, 1-9. cited by applicant
Weichhart et al., “Functional selection of vaccine candidate peptides from *Staphylococcus aureus* whole-genome expression libraries in vitro,” Infection and I
cited by applicant
Weinreich et al., “Evidence that the cis Preference of the Tn5 Transposase is Caused by Nonproductive Multimerization,” Genes and Development, Oct. 1994
Wheeler et al., “Microfluidic device for single-cell analysis,” Analytical Chemistry, Jul. 2003, 75(14):3581-3586. cited by applicant
Wiedmann et al., “Ligase chain reaction (LCR)—overview and applications,” PCR Methods Appl., Feb. 1994, 3(4):S51-64. cited by applicant
Wikipedia.org [online], “Random hexamer,” Jan. 2012, Retrieved on Jan. 21, 2022, retrieved from URL<https://en.wikipedia.org/w/index.php?title=Random_
page. cited by applicant
Williams et al., “Disc electrophoresis in polyacrylamide gels: extension to new conditions of pH and buffer,” Annals of the New York Academy of Sciences, D
applicant
Williams, “RAC reviews serious adverse event associated with AAV therapy trial,” Mol Ther., Dec. 2007, 15(12):2053-54. cited by applicant
Willi-Monnerat et al., “Comprehensive spatiotemporal transcriptomic analyses of the ganglionic eminences demonstrate the uniqueness of its caudal subdivisi
Nueorsciences 37(4):845-856, 2008. cited by applicant
Wilson et al., “New transposon delivery plasmids for insertional mutagenesis in Bacillus anthracis,” J Microbiol Methods, Dec. 2007, 71(3):332-5. cited by ap
Wolf et al., “Rapid hybridization kinetics of DNA attached to submicron latex particles”, Nucleic Acids Res. 15: 2911-2926, 1987. cited by applicant
Wolf et al., “tadA, an essential tRNA-specific adenosine deaminase from Escherichia coli,” EMBO J., Jul. 15, 2002, 21(14):3841-3851. cited by applicant
Wong et al., “Direct Site-Selective Covalent Protein Immobilization Catalyzed by a Phosphopantetheinyl Transferase,” J. Am. Chem Soc., 2008, 130:12456-6
Woo et al., “A Comparison of cDNA, Oligonucleotide, and Affymetrix GeneChip Gene Expression Microarray Platforms,” Journal of Biomolecular Techniqu
applicant
Wood et al., “Single cell trapping and DNA damage analysis using microwell arrays,” PNAS, Jun. 2010, 107(22):10008-10013. cited by applicant
Worthington et al., “Cloning of random oligonucleotides to create single-insert plasmid libraries,” Analyt. Biochem, 2001, 294:169-175. cited by applicant
Wright et al., “Reusable, reversibly sealable parylene membranes for cell and protein patterning,” J Biomed Mater Res A., May 2008, 85(2):530-538. cited by
Wu et al., “Detection DNA Point Mutation with Rolling-Circle Amplification Chip,” Bioinformatics & Biomed Eng Conference, Piscataway, NJ, 2010, pp. 1-
Wu et al., “Detection DNA Point Mutation with Rolling-Circle Amplification Chip,” Bioinformatics and Biomedical Engineering (ICBBE), 2010 4th Internati
NJ, USA, Jun. 18, 2010, 1-4 pages. cited by applicant
Xiao et al., “Direct determination of haplotypes from single DNA molecules,” Nature Methods, 2009, 6(3):199-201. cited by applicant
Xie et al., “CryoFISH: Fluorescence In Situ Hybridization on Ultrathin Cryosections,” Fluorescence in situ Hybridization (FISH), Jul. 2010, pp. 221-230. cite
Xu et al., “Engineering a nicking endonuclease N.AlwI by domain swapping,” Proc. Natl. Acad. Sci. USA, 2001, 98:12990-12995. cited by applicant
Yamamoto et al., “Generation of stable co-cultures of vascular cells in a honeycomb alginate scaffold,” Tissue Eng Part A, Jan. 1, 2010, 16(1):299-308. cited b
Yan et al., “Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38
signaling pathways,” Hum Gene Ther., Oct. 2009, 20(10):1190-200. cited by applicant
Yang et al., “Nucleoside alpha-Thiotriphosphates, Polymerases and the Exonuclease III Analysis of Oligonucleotides Containing Phosphorothioate Linkages,”
2007, 35(9):3118-3127. cited by applicant
Yao et al., “Influence of laser parameters on nanoparticle-induced membrane permeabilization,” Journal of Biomedical Optics, 2009, 14(5):054034, 7 pages. c
Yasukawa et al., “Effects of organic solvents on the reverse transcription reaction catalyzed by reverse transcriptases from avian myeloblastosis virus and Mol
Biotechnol Biochem., 2010, 74(9):1925-30. cited by applicant
Yeakley et al., “Profiling alternative splicing on fiber-optic arrays,” Nature Biotechnology, Apr. 2002, 20(4):353-358. cited by applicant
Yershov et al., “DNA analysis and diagnostics on oligonucleotide microchips,” Proc. Natl. Acad. Sci. USA, May 1996, 93(10):4913-4918. cited by applicant
Yet et al., “Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice,” Circ Res., Jul. 2001, 89(2):
Yin et al., “Genetically encoded short peptide tag for versatile protein labeling by Sfp phosphopantetheinyl transferase,” PNAS, 2005, 102(44):15815-20. cite
Yonezawa et al., “DNA display for in vitro selection of diverse peptide libraries,” Nucleic Acids Research , 2003, 31 (19):e118. cited by applicant
Yusof et al., “Inkjet-like printing of single-cells,” Lab Chip, Jul. 2011, 11(14):2447-2454. cited by applicant
Zhang et al., “A novel mechanism of transposon-mediated gene activation,” PLoS Genet., Oct. 2009, 5(10):e1000689, 10 pages. cited by applicant
Zhang et al., “A self-assembly pathway to aligned monodomain gels,” Nat Mater, Jul. 2010, 9(7):594-601, 12 pages (Author Manuscript). cited by applicant
Zhang et al., “Binding-induced DNA assembly and its application to yoctomole detection of proteins,” Anal Chem (2012) 84(2):877-884. cited by applicant
Zhang et al., “Single-base mutational analysis of cancer and genetic diseases using membrane bound modified oligonucleotides,” Nucleic Acids Res., Jul. 199
Zhang et al., “Stripping custom microRNA microarrays and the lessons learned about probe-slide interactions,” Anal Biochem., Mar. 2009, 386(2):222-7. cite
Zhao et al., “Ultrasensitive DNA detection using highly fluorescent bioconjugated nanoparticles,” Journal American Chemical Society, 2003, 125:11474-1147
Zheng et al., Origins of human mitochondrial point mutations as DNA polymerase mediated errors. Mutat. Res. 599(1-2): 11-20, 2006. cited by applicant
Zheng, “Spectroscopy-based quantitative fluorescence resonance energy transfer analysis,” Methods Mol Biol., 2006, 337:65-77. cited by applicant
Zhou et al., “Analysis of the expression profile of Dickkopf-1 gene in human glioma and the associate with tumor malignancy,” Journal of Experimental & Cl
29(138):1-7. cited by applicant
Zhou et al., “Genetically encoded short peptide tags for orthogonal protein labeling by Sfp and AcpS phosphopantetheinyl transferases,” ACS Chemical Biol.,
Zhu et al., “Engineering strand-specific DNA nicking enzymes from the type IIS restriction endonucleases BsaI, BsmBI, and BsmAI,” J. Mol. Biol., 2004, 337
Zhu et al., “Reverse Transcriptase Template Switching: A SMART Approach for Full-Length cDNA Library Construction,” BioTechniques, 2001, 30(4): 892-8
Zieba et al., “Bright-field microscopy visualization of proteins and protein complexes by in situ proximity ligation with peroxidase detection,” Clin Chem, Jan
applicant
Zilberman et al., “Genome-wide analysis of DNA methylation patterns,” Development (2007) 134:3959-3965. cited by applicant
Zimmerman et al., “Chapter 13, Imaging of Cells and Tissue with Mass Spectrometry,” Methods in Cell Biology, Biophysical Tools for Biologists, vol. Two: I
390. cited by applicant
Zuker, “Mfold web server for nucleic acid folding and hybridization prediction,” Nucleic Acids Res., Jul. 2003, 31(13):3406-15. cited by applicant

Cellosaurus, “Cellosaurus Hs 742.Sk (CVCL_0887),” cellosaurus.org, Apr. 4, 2012, retrieved on May 23, 2025, retrieved from URL <https://www.cellosaurus
applicant
Cellosaurus, “Cellosaurus MDA-MB-231 (CVCL_0062),” cellosaurus.org, Apr. 4, 2012, retrieved on May 23, 2025, retrieved from URL <https://www.cellosa
cited by applicant
Litosh et al., “Improved nucleotide sensitivity and termination of 3′-OH unblocked reversible terminators by molecular tuning of 2-nitrobenzyl alkylated HOM
Research, Jan. 11, 2011, 339(6):E39, 13 pages. cited by applicant
Manning et al., “Benefits and pitfalls of secondary antibodies: why choosing the right secondary is of primary importance,” PLoS One, 2012, 7(6):e38313, 11
Pray, “Eukaryotic Genome Complexity,” Nature Education, 2008, 1(1):96, pp. 1-4. cited by applicant
Simon et al., “Immunohistochemical analysis of tissue microarrays,” Methods Mol Biol., 2010, 664:113-26. cited by applicant
Webb et al., “Chapter 2: Epi-Fluorescence Microscopy,” Cell Imaging Techniques, Methods in Molecular Biology, 2012, 931:29-59. cited by applicant

---

Primary Examiner: Bhat; Narayan K

Attorney, Agent or Firm: Fish & Richardson P.C.

Background/Summary

CROSS-REFERENCE TO RELATED APPLICATIONS (1) This application is a continuation of U.S. patent application Ser. No. 18/972,148, filed Dec. 6, 2024, which is a continuation of U.S. patent application Ser. No. 18/793,359, filed on Aug. 2, 2024, which is a continuation of U.S. patent application Ser. No. 18/100,127, filed on Jan. 23, 2023, which is a continuation of U.S. patent application Ser. No. 17/878,519, filed on Aug. 1, 2022, now U.S. Pat. No. 11,560,587, which is a continuation of U.S. patent application Ser. No. 17/556,588, filed Dec. 20, 2021, now U.S. Pat. No. 11,401,545, which is a continuation of U.S. patent application Ser. No. 17/223,669, filed Apr. 6, 2021, now U.S. Pat. No. 11,208,684, which is a continuation of U.S. patent application Ser. No. 17/030,230, filed Sep. 23, 2020, now U.S. Pat. No. 11,384,386, which is a continuation of U.S. patent application Ser. No. 16/988,284, filed Aug. 7, 2020, now U.S. Pat. No. 10,961,566, which is a continuation of U.S. patent application Ser. No. 16/414,213, filed May 16, 2019, now U.S. Pat. No. 10,787,701, which is a continuation of U.S. patent application Ser. No. 16/402,098, filed May 2, 2019, now U.S. Pat. No. 10,472,669, which is a continuation of U.S. patent application Ser. No. 16/276,235, filed Feb. 14, 2019, now U.S. Pat. No. 10,480,022, which is a continuation application of U.S. patent application Ser. No. 15/187,661, filed Jun. 20, 2016, now U.S. Pat. No. 10,308,982, which is a continuation of U.S. patent application Ser. No. 13/080,616, filed Apr. 5, 2011, now U.S. Pat. No. 9,371,598, which claims the benefit of U.S. Provisional Patent Application No. 61/321,124, filed Apr. 5, 2010, each of which are herein incorporated by reference.

FIELD OF THE INVENTION

(1) This invention relates to assays of biological molecules, and more particularly to assays for determining spatial distributions of a large number of biological molecules in a solid sample simultaneously.

BACKGROUND OF THE INVENTION

(2) In the following discussion certain articles and methods will be described for background and introductory purposes. Nothing contained herein is to be construed as an “admission” of prior art. Applicant expressly reserves the right to demonstrate, where appropriate, that the articles and methods referenced herein do not constitute prior art under the applicable statutory provisions.

(3) Comprehensive gene expression analysis and protein analysis have been useful tools in understanding mechanisms of biology. Use of these tools has allowed the identification of genes and proteins involved in development and in various diseases such as cancer and autoimmune disease. Conventional methods such as in situ hybridization and other multiplexed detection of different transcripts have revealed spatial patterns of gene expression and have helped shed light on the molecular basis of development and disease. Other technologies that have enabled the quantitative analysis of many RNA sequences per sample include microarrays (see Shi, et al., Nature Biotechnology, 24(9):1151-61 (2006); and Slonim and Yanai, Plos Computational Biology, 5(10):e1000543 (2009)); serial analysis of gene expression (SAGE) (see Velculescu, et al, Science, 270(5235):484-87 (1995)), high-throughput implementations of qPCR (see Spurgeon, et al., Plos ONE, 3(2):e1662 (2008)) and in situ PCR (see Nuovo, Genome Res., 4:151-67 (1995)). As useful as these methods are, however, they do not enable simultaneous measurement of the expression of many genes or the presence and/or activity of multiple proteins at many spatial locations in a sample. Laser capture microdissection has permitted the analysis of many genes at a small number of locations, but it is very expensive, laborious, and does not scale well. Certain PCR assays in a 2D format preserve spatial information (see Armani, et al., Lab on a Chip, 9(24):3526-34 (2009)), but these methods have low spatial resolution because they rely on physical transference of tissue into wells, which also prevents random access to tissue samples and high levels of multiplexing.

(4) At present, no practical method exists to analyze at high resolution the spatial expression patterns of large numbers of genes, proteins, or other biologically active molecules simultaneously. There is thus a need for reproducible, high-resolution spatial maps of biological molecules in tissues. The present invention addresses this need.

SUMMARY OF THE INVENTION

(5) This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. Other features, details, utilities, and advantages of the claimed subject matter will be apparent from the following written Detailed Description including those aspects illustrated in the accompanying drawings and defined in the appended claims.

(6) The invention encompasses assay systems that provide high-resolution spatial maps of biological activity in tissues. The assay system comprises an assay capable of high levels of multiplexing where encoded probes are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature. In short, the present invention provides the ability to look at many biological targets in many locations, providing the resolution of in situ hybridization with the highly-parallel data analysis of sequencing.

(7) Thus, in some embodiments, the invention provides an assay system to determine spatial patterns of abundance or activity or both of multiple biological targets at multiple sites in a sample, where the assay system performs the following steps: providing a sample affixed to a support; delivering encoded probes for the multiple biological targets to the multiple sites in the sample in a known spatial pattern, where each encoded probe comprises a probe region that may interact with the biological targets and a coding tag that identifies a location of the site to which the encoded probe was delivered; allowing the encoded probes to interact with the biological targets; separating encoded probes that interact with the biological targets from encoded probes that do not interact with the biological targets; determining all or a portion of a sequence of the encoded probes, and associating the abundance or activity or both of the multiple biological targets to the locations of the sites in the sample.

(8) In particular aspects of the invention the biological targets comprise nucleic acids and the encoded probes are oligonucleotides, and in some aspects, there are two encoded probes for each of the multiple nucleic acid targets. In some aspects, the multiple biological targets comprise proteins, the probe regions of the encoding probes are proteins and the coding tags comprise oligonucleotides. In some aspects the multiple biological targets comprise enzymes. In some aspects the probe regions of the encoded probes comprise antibodies, aptamers or small molecules.

(9) Some aspects of the assay system further comprise an amplification step between the separating step and the determining step. In some aspects,

the determining step is performed by nucleic acid sequencing, and in preferred aspects, the sequencing is high-throughput digital nucleic acid sequencing.
(10) In some aspects of the invention, the product of the multiple biological targets being assayed and the multiple sites in the sample is greater than 20, in some aspects product of the multiple biological targets being assayed and the multiple sites in the sample is greater than 50, in some aspects the product of the multiple biological targets being assayed and the multiple sites in the sample is greater than 75, 100, 150, 500, 750, 1,000, 5,000, 10,000, 25,000, 50,000, 100,000, 500,000, or 1,000,000 or more. In other aspects, the sequence of at least fifty thousand encoding probes are determined in parallel, in other aspects the sequence of at least one hundred thousand encoding probes are determined in parallel, in some aspects the sequence of at least five hundred thousand encoding probes are determined in parallel, and in some aspects the sequence of at least one million, ten million, one hundred million, one billion, ten billion, one hundred billion or more encoding probes are determined in parallel.
(11) In some aspects, the known spatial pattern is determined by histological features of the sample. Also in some aspects, software programmed hardware performs at least two steps of the delivering step, the separation step, the determining step and the associating step.
(12) In some aspects, the probe regions of the encoded probes are proteins and the separating step is accomplished by encoded probes that interact with the biological targets being captured by an affinity capture agent. In some aspects the probe regions of the encoding probes are nucleic acids and the separating step is accomplished by a washing of the sample.
(13) In other embodiments there is provided an assay system to determine spatial patterns of abundance or activity or both of multiple nucleic acid targets at multiple sites in a sample, where the assay system performs the following steps: providing a sample affixed to a support; delivering oligonucleotide probes for multiple nucleic acid targets to the multiple sites in the sample in a known spatial pattern; allowing the oligonucleotide probes to hybridize with the nucleic acid targets; washing unhybridized encoded oligonucleotide probes from the sample; delivering one or more encoding agents to locations of the multiple sites in the sample according to a known spatial pattern, where the combination of encoding agents delivered to each site is different; coupling the encoding agents and the oligonucleotide probes to form encoded probes; determining all or a portion of a sequence of the encoded probes using high-throughput sequencing, and associating the abundance or activity or both of multiple biological targets to the locations of multiple sites in the sample.
(14) Other embodiments of the invention provide an assay system to determine spatial patterns of abundance or activity or both of multiple protein targets at multiple sites in a sample, where the assay system performs the following steps: providing a sample affixed to a support; delivering encoded probes for the multiple protein targets to the multiple sites in the sample in a known spatial pattern, where each encoded probe comprises a protein probe region that may interact with the protein targets and a coding tag that identifies a location of the site to which the encoded probe was delivered and the protein probe region of the encoding probe of which the coding tag is part; allowing the encoded probes to interact with the protein targets; separating encoded probes that interact with the protein targets from encoded probes that do not interact with the protein targets; determining all or a portion of a sequence of the encoded probes by high throughput sequencing, and associating the abundance or activity or both of the multiple protein targets to the locations of the multiple sites in the sample.
(15) Other embodiments provide an assay system to determine spatial patterns of abundance or activity or both of multiple biological targets at multiple sites in a sample, where the assay system performs the following steps: providing a sample affixed to a support; delivering encoded probes for the multiple biological targets to the multiple sites in the sample in a known spatial pattern, where each encoded probe comprises a probe region that may interact with the biological targets and a coding tag that identifies a location of the site to which the encoded probe was delivered and identifies the biological target; allowing the encoded probes to interact with the biological targets; determining all or a portion of a sequence of the encoded probes, and associating the abundance or activity or both of the multiple biological targets to the locations of the sites in the sample.
(16) The assay system of the invention can utilize various detection mechanisms, based on the molecules to be detected and the reagents needed for such detection system. Exemplary methods that can be used with the assay systems of the invention are described in more detail below.

Description

DESCRIPTION OF THE FIGURES
(1) FIG. **1** provides a simplified overview of the assay system of the present invention.
(2) FIG. **2** provides a simplified overview of one embodiment of the assay system of the present invention for detecting nucleic acids.
(3) FIG. **3** is a representational depiction of one embodiment of the assay overviewed in FIG. **2**.
(4) FIG. **4**A-C illustrates a general mechanism for one embodiment of a combinatorial encoding scheme of the assay systems of the invention. FIG. **4**A shows two target-specific/encoding oligonucleotide constructs specifically bound to a target nucleic acid of interest in a sample. FIG. **4**B shows a scheme for delivering twenty different coding tags, a1 through a10 and b1 through b10, to a sample to form a 10×10 coding tag grid. FIG. **4**C shows a tissue section sample to which the coding tags are delivered, forming the coding tag grid in the sample.
(5) FIG. **5** provides a simplified, specific example of the embodiment of a combinatorial encoding scheme shown in FIG. **4**.
DEFINITIONS
(6) The terms used herein are intended to have the plain and ordinary meaning as understood by those of ordinary skill in the art. The following definitions are intended to aid the reader in understanding the present invention, but are not intended to vary or otherwise limit the meaning of such terms unless specifically indicated.
(7) The term “antibody” as used herein is intended to refer to an entire immunoglobulin or antibody or any functional fragment of an immunoglobulin molecule which is capable of specific binding to an antigen (antibodies and antigens are “binding partners” as defined herein). “Antibody” as used herein is meant to include the entire antibody as well as any antibody fragments capable of binding the antigen or antigenic fragment of interest. Examples of such peptides include complete antibody molecules, antibody fragments, such as Fab, F(ab′)2, CDRS, VL, VH, and any other portion of an antibody which is capable of specifically binding to an antigen. Antibodies for assays of the invention are immunoreactive or immunospecific for, and therefore specifically and selectively bind to, proteins either detected (i.e., biological targets) or used for detection (i.e., probes) in the assays of the invention.
(8) The term “binding agent” as used herein refers to any agent that specifically binds to a biological molecule of interest
(9) “Complementary” or “substantially complementary” refers to the hybridization or base pairing or the formation of a duplex between nucleotides or nucleic acids, such as, for instance, between the two strands of a double-stranded DNA molecule or between an oligonucleotide primer and a primer binding site on a single-stranded nucleic acid. Complementary nucleotides are, generally, A and T (or A and U), or C and G. Two single-stranded RNA or DNA molecules are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared and with appropriate nucleotide insertions or deletions, pair with at least about 80% of the other strand, usually at least about 90% to about 95%, and even about 98% to about 100%).
(10) “Hybridization” refers to the process in which two single-stranded polynucleotides bind non-covalently to form a stable double-stranded polynucleotide, The resulting (usually) double-stranded polynucleotide is a “hybrid” or “duplex,” “Hybridization conditions” will typically include salt concentrations of approximately less than 1M, often less than about 500 mM and may be less than about 200 mM. A “hybridization buffer” is a buffered salt solution such as 5% SSPE, or other such buffers known in the art. Hybridization temperatures can be as low as 5° C., but are typically greater than 22° C., and more typically greater than about 30° C., and typically in excess of 37° C. Hybridizations are often performed under stringent conditions, i.e., conditions under which a primer will hybridize to its target subsequence but will not hybridize to the other, non-complementary sequences. Stringent conditions are sequence-dependent and are different in different circumstances. For example, longer fragments

may require higher hybridization temperatures for specific hybridization than short fragments. As other factors may affect the stringency of hybridization, including base composition and length of the complementary strands, presence of organic solvents, and the extent of base mismatching, the combination of parameters is more important than the absolute measure of any one parameter alone. Generally stringent conditions are selected to be about 5° C. lower than the T.sub.m for the specific sequence at a defined ionic strength and pH. Exemplary stringent conditions include a salt concentration of at least 0.01 M to no more than 1M sodium ion concentration (or other salt) at a pH of about 7.0 to about 8.3 and a temperature of at least 25° C. For example, conditions of 5xSSPE (750 mM NaCl, 50 mM sodium phosphate, 5 mM EDTA at pH 7.4) and a temperature of approximately 30° C. are suitable for allele-specific hybridizations, though a suitable temperature depends on the length and/or GC content of the region hybridized.

(11) "Ligation" means to form a covalent bond or linkage between the termini of two or more nucleic acids, e.g., oligonucleotides and/or polynucleotides, in a template-driven reaction. The nature of the bond or linkage may vary widely and the ligation may be carried out enzymatically or chemically. As used herein, ligations are usually carried out enzymatically to form a phosphodiester linkage between a 5′ carbon terminal nucleotide of one oligonucleotide with a 3′ carbon of another nucleotide.

(12) "Nucleic acid", "oligonucleotide", "oligo" or grammatical equivalents used herein refers generally to at least two nucleotides covalently linked together. A nucleic acid generally will contain phosphodiester bonds, although in some cases nucleic acid analogs may be included that have alternative backbones such as phosphoramidite, phosphorodithioate, or methylphophoroamidite linkages; or peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with bicyclic structures including locked nucleic acids, positive backbones, non-ionic backbones and non-ribose backbones. Modifications of the ribose-phosphate backbone may be done to increase the stability of the molecules; for example, PNA:DNA hybrids can exhibit higher stability in some environments.

(13) "Primer" means an oligonucleotide, either natural or synthetic, that is capable, upon forming a duplex with a polynucleotide template, of acting as a point of initiation of nucleic acid synthesis and being extended from its 3′ end along the template so that an extended duplex is formed. The sequence of nucleotides added during the extension process is determined by the sequence of the template polynucleotide. Primers usually are extended by a DNA polymerase.

(14) The term "SNP" or "single nucleotide polymorphism" refers to a genetic variation between individuals; e.g., a single nitrogenous base position in the DNA of organisms that is variable. SNPs are found across the genome; much of the genetic variation between individuals is due to variation at SNP loci, and often this genetic variation results in phenotypic variation between individuals. SNPs for use in the present invention and their respective alleles may be derived from any number of sources, such as public databases (U.C. Santa Cruz Human Genome Browser Gateway or the NCBI dbSNP website, or may be experimentally determined as described in U.S. Pat No. 6,969,589; and US Pub. No. 2006/0188875 entitled "Human Genomic Polymorphisms." Although the use of SNPs is described in some of the embodiments presented herein, it will be understood that other biallelic or multi-allelic genetic markers may also be used. A biallelic genetic marker is one that has two polymorphic forms, or alleles. As mentioned above, for a biallelic genetic marker that is associated with a trait, the allele that is more abundant in the genetic composition of a case group as compared to a control group is termed the "associated allele," and the other allele may be referred to as the "unassociated allele." Thus, for each biallelic polymorphism that is associated with a given trait (e.g., a disease or drug response), there is a corresponding associated allele. Other biallelic polymorphisms that may be used with the methods presented herein include, but are not limited to multinucleotide changes, insertions, deletions, and translocations. It will be further appreciated that references to DNA herein may include genomic DNA, mitochondrial DNA, episomal DNA, and/or derivatives of DNA such as amplicons, RNA transcripts, cDNA, DNA analogs, etc. The polymorphic loci that are screened in an association study may be in a diploid or a haploid state and, ideally, would be from sites across the genome.

(15) The term "selectively binds", "selective binding" and the like as used herein, when referring to a binding partner (e.g. protein, nucleic acid, antibody or other affinity capture agent, etc.), refers to a binding reaction of two or more binding partners with high affinity and/or complementarity to ensure selective hybridization under designated assay conditions. Typically, specific binding will be at least three times the standard deviation of the background signal. Thus, under designated conditions the binding partner binds to its particular "target" molecule and does not bind in a significant amount to other molecules present in the sample.

(16) "Sequencing", "sequence determination" and the like means determination of information relating to the nucleotide base sequence of a nucleic acid. Such information may include the identification or determination of partial as well as full sequence information of the nucleic acid. Sequence information may be determined "with varying degrees of statistical reliability or confidence. In one aspect, the term includes the determination of the identity and ordering of a plurality of contiguous nucleotides in a nucleic acid, "High throughput digital sequencing" or "next generation sequencing" means sequence determination using methods that determine many (typically thousands to billions) of nucleic acid sequences in an intrinsically parallel manner, i.e. where DNA templates are prepared for sequencing not one at a time, but in a bulk process, and where many sequences are read out preferably in parallel, or alternatively using an ultra-high throughput serial process that itself may be parallelized. Such methods include but are not limited to pyrosequencing (for example, as commercialized by 454 Life Sciences, Inc., Branford, CT); sequencing by ligation (for example, as commercialized in the SOLiD™ technology, Life Technology, Inc., Carlsbad, CA); sequencing by synthesis using modified nucleotides (such as commercialized in TruSeq™ and HiSeq™ technology by Illumina, Inc., San Diego, CA, HeliScope™ by Helicos Biosciences Corporation, Cambridge, MA, and PacBio RS by Pacific Biosciences of California, Inc., Menlo Park, CA), sequencing by ion detection technologies (Ion Torrent, Inc., South San Francisco, CA); sequencing of DNA nanoballs (Complete Genomics, Inc., Mountain View, CA); nanopore-based sequencing technologies (for example, as developed by Oxford Nanopore Technologies, LTD, Oxford, UK), and like highly parallelized sequencing methods.

(17) The term "T.sub.m" is used in reference to the "melting temperature." The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. Several equations for calculating the T.sub.m of nucleic acids are well known in the art. As indicated by standard references, a simple estimate of the T.sub.m value may be calculated by the equation, T.sub.m=81.5+0.41 (% G+C), when a nucleic acid is in aqueous solution at 1M NaCl (see e.g., Anderson and Young, Quantitative Filter Hybridization, in *Nucleic Acid Hybridization* (1985)). Other references (e.g., Allawi and SantaLucia, Jr., Biochemistry, 36:10581-94 (1997)) include alternative methods of computation which take structural and environmental, as well as sequence characteristics into account for the calculation of T.sub.m.

DETAILED DESCRIPTION OF THE INVENTION

(18) The practice of the techniques described herein may employ, unless otherwise indicated, conventional techniques and descriptions of organic chemistry, polymer technology, molecular biology (including recombinant techniques), cell biology, biochemistry, and sequencing technology, which are within the skill of those who practice in the art. Such conventional techniques include polymer array synthesis, hybridization and ligation of polynucleotides, and detection of hybridization using a label. Specific illustrations of suitable techniques can be had by reference to the examples herein. However, other equivalent conventional procedures can, of course, also be used. Such conventional techniques and descriptions can be found in standard laboratory manuals such as Green, et al., Eds., *Genome Analysis: A Laboratory Manual Series* (Vols. I-IV) (1999); Weiner, Gabriel, Stephens, Eds., *Genetic Variation: A Laboratory Manual* (2007); Dieffenbach, Dveksler, Eds., *PCR Primer: A Laboratory Manual* (2003); Bowtell and Sambrook, *DNA Microarrays: A Molecular Cloning Manual* (2003); Mount, *Bioinformatics: Sequence and Genome Analysis* (2004); Sambrook and Russell, *Condensed Protocols from Molecular Cloning: A Laboratory Manual* (2006); and Sambrook and Russell, *Molecular Cloning: A Laboratory Manual* (2002) (all from Cold Spring Harbor Laboratory Press); Stryer, *Biochemistry* (4th Ed.) (1995) W.H, Freeman, New York N.Y.; Gait, "*Oligonucleotide Synthesis: A Practical Approach*" (2002) IRL Press, London; Nelson and Cox, Lehninger, *Principles of Biochemistry* (2000) 3.sup.rd Ed., W. H. Freeman Pub., New York, N.Y,; and Berg, et al., *Biochemistry* (2002) 5.sup.th Ed., W. H. Freeman Pub., New York, N.Y., all of which are herein incorporated in their entirety by reference for all purposes.

(19) Note that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a nucleic acid” refers to one or more nucleic acids, and reference to “the assay” includes reference to equivalent steps and methods known to those skilled in the art, and so forth.
(20) Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing devices, formulations and methodologies that may be used in connection with the presently described invention.
(21) Where a range of values is provided, it is understood that each intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the invention,
(22) In the following description, numerous specific details are set forth to provide a more thorough understanding of the present invention. However, it will be apparent to one of skill in the art that the present invention may be practiced without one or more of these specific details. In other instances, well-known features and procedures well known to those skilled in the art have not been described in order to avoid obscuring the invention.
The Invention in General
(23) The assay systems of the invention provide spatially-encoded, multiplexed assays comprising 1) an assay capable of high levels of multiplexing with an efficient spatial encoding scheme; 2) instrumentation capable of delivering reagents according to a spatial pattern; and 3) decoding determined by a readout that is digital in nature. The assay systems of the invention detect the presence or absence and relative amount of a biological target or biological activity indicative of a biological target, as well as the location of the biological target or activity in a biological sample, e.g., a tissue section or other biological structure disposed upon a support such as a microscope slide or culture dish.
(24) The assay system further provides instrumentation with an ability to deliver reagents in a spatially-defined pattern. This instrumentation, together “with software, reagents and protocols, provides a key component of the highly innovative assay system of the invention, allowing for measurement of numerous biological targets or activities in a meaningful spatial environment, including gene expression and peptide localization, An encoding scheme used in these assay systems allows one to determine the location of biological targets or activity (or lack thereof) in the biological samples after the products of the multiplexed assay are removed from the biological sample and pooled for analysis. Decoding of the encoding scheme can be performed by, e.g., next-generation sequencing, which easily provides millions to trillions of data points at low cost. The assay results such as the amount or activity of biological targets can then be mapped back to specific location in the biological sample. The assay systems open a new analytical window into the complex spatial patterns of cellular function and regulation in biological samples.
(25) A simplified overview of the assay system **100** of the present invention is provided at FIG. **1**, At step **110**, a biological sample affixed to a support is provided. The biological sample contains biological targets of interest. Biological targets can include any molecule of interest, such as nucleic acids (including, e.g, RNA transcripts, genomic DNA sequences, cDNAs, amplicons, or other nucleic acid sequences) and proteins, enzymes and the like. At step **120**, encoded probes are delivered to the biological sample according to a known spatial pattern. Encoded probes comprise probes, which can interact “with biological targets of interest, and coding tags, which identify the positions in the sample of the biological targets being assayed, and thus can be used to link assay results back to locations in the sample. Coding tags in most embodiments are oligonucleotides. However, coding tags may also be mass tags, fluorescent labels, or other moieties.
(26) In some embodiments, the probe and coding tag portions of the encoded probe are pre-coupled before being delivered to the biological sample, For example, in the case where the encoded probes are oligonucleotides, both the probe and coding tag sequence can be synthesized as a single oligonucleotide. Alternatively, the probe and coding tag portions of the encoding probes can be synthesized or obtained separately and combined before delivery to the biological sample (e.g., two separate oligonucleotides can be synthesized and coupled by, e.g., ligation; or an antibody and an oligonucleotide can be prepared separately and conjugated before delivery to the biological sample). Also, as is described in FIGS. **2**-**5**, the probes and the coding tags (in encoding oligonucleotides) are synthesized separately, and are delivered to the biological sample at different steps (e.g., probes first and coding tags thereafter, or vice versa) in the assay.
(27) At step **130**, the encoded probes are allowed to react or interact with the biological targets, i.e., conditions are provided to allow e.g., oligonucleotides to hybridize to nucleic acid targets, enzymes to catalyze reactions with protein targets, antibodies to bind epitopes, etc. In the case where the biological targets are nucleic acids, the encoded probes are typically oligonucleotides and hybridize to the target nucleic acids. In the case that the biological targets are proteins, the encoded probes typically are aptamers, small molecules, or oligonucleotide-conjugated proteins that interact with target proteins by binding to them or by reacting with them (that is, one of the proteins is a substrate for the other). Encoding oligonucleotides may be coupled to the probes (proteins) by conjugation, chemical or photo-crosslinking via suitable groups and the like.
(28) Once encoded probes interact with the biological targets, the encoded probes that interacted with the biological targets must be separated from the encoded probes that did not interact with the biological targets at step **140**. In the case where the biological targets are nucleic acids and the encoded probes are oligonucleotides, the separation can be accomplished by, e.g., washing the unhybridized encoded probes from the sample. Similarly, for other assays that are based on affinity binding, including those using aptamer, small molecule, and protein probes, washing steps can be used to remove low affinity binders. In the case where the probe is transformed via interaction with the target, e. g., in the case of a peptide, e.g., via cleavage by a protease or phosphorylation by a kinase, it is convenient to collect, all encoded probes—both encoded probes that interacted with the biological targets and were transformed and encoded probes that were not transformed. After collection or pooling, an antibody or other affinity capture agent can be used to capture probes that were transformed by addition of a moiety (e.g., a phosphate group). In cases where probes have been transformed via cleavage, the transformed probes can be separated, e.g., by capturing the non-transformed probes via a tag that is removed from the transformed probes during the transformation (e.g., by cleavage), or by adding a new tag at the site of cleavage.
(29) Once the reacted (transformed) or interacted encoded probes are separated from the unreacted or un-interacted encoded probes, the sequence of the reacted and/or interacted encoded probes is determined at step **150** by, preferably, sequencing. The sequence of the encoded probes allows the mapping of the assay results at step **160** back to locations in the biological sample.
(30) FIG. **2** provides a simplified overview of an assay system **200** of the present invention embodying an efficient implementation of a combinatorial coding scheme for the encoding of spatial information. For purposes of this overview, the probes are oligonucleotides, but as explained elsewhere, other types of probes can also be used. In step **210**, a biological sample affixed to a support, e.g., a tissue sample or other biological structure, is provided. In step **220**, one or more oligonucleotide probes are delivered to the biological sample, where the oligonucleotide probes are capable of hybridizing with biological targets in the biological sample. In step **230**, the oligonucleotide probes are allowed to interact with (hybridize to) the nucleic acid targets; that is, appropriate conditions are provided where oligonucleotide probes can hybridize to the target nucleic acids.
(31) In step **240**, the oligonucleotide probes that did not hybridize to target nucleic acids are removed, and thereby separated from oligonucleotide probes that did hybridize to target nucleic acids. In this embodiment, separation can be accomplished by, e.g., washing the sample to remove unhybridized oligonucleotide probes. Next, in step **250**, encoding oligonucleotides (the encoding agents) are delivered to the biological sample according to a chosen spatial pattern, where the encoding oligonucleotides comprise coding tags that are used to encode the location of biological targets in the biological sample. Note that in contrast to the assay system of FIG. **1**, here the probes and encoding agents (encoding oligonucleotides) are delivered in separate steps. In step **260**, the encoding oligonucleotides are coupled to the oligonucleotide probes to create encoded probes. In this case where the probes are oligonucleotides, the encoding oligonucleotides may be coupled to the oligonucleotides probes by, e.g., ligation.

Alternatively, the information in the encoding oligonucleotides can be transferred by using a DNA polymerase to extend a probe oligonucleotide that acts as a primer, and thereby copy and incorporate the sequence of the encoding oligonucleotides.

(32) In step **270**, the sequence of the coding tags in the encoded probes as well as the sequence or a portion of the sequence of the probe itself is determined, and in step **280**, the target nucleic acids are mapped back to the biological sample. In some embodiments, the abundance of sequences reveals the relative quantity of biological targets at the location. Although this embodiment shows the individual steps in a particular order, so as to better explain the invention, the precise order of the steps can be varied. For example, steps **220** and **250** can be combined, so that a mixture of the probes and encoding oligonucleotides is delivered according to a chosen spatial pattern. Coupling step **260** can then be carried out immediately after the combined steps **220** and **250**, or concomitantly with them. In this case, step **240** would then occur after step **260**. It can therefore be appreciated that the two key results of this series of steps, i.e., the location-specific encoding of probe molecules and the separation of probe molecules based on their ability to interact with corresponding target molecules, can be accomplished with some flexibility in the implementation of the particular steps. Similarly, there is considerable flexibility in the design of the coding scheme. As described infra, the assays of the invention are particularly amenable to combinatorial methods.

(33) Thus, the present invention provides an ability to look at many different biological targets in many locations, providing the resolution of in situ hybridization with the highly-parallel data analysis of sequencing. In some embodiments, the sum of the multiple biological targets being assayed and the multiple sites in the biological sample is greater than 20, in other embodiments, the sum of the multiple biological targets being assayed and the multiple sites in the biological sample is greater than 50, in other embodiments, the sum of the multiple biological targets being assayed and the multiple sites in the biological sample is greater than 100, greater than 500, 1,000, 10,000, 25,000, 100,000, 500,000, 1,000,000. It will be appreciated that, due to the spatial encoding dimension of the invention, even much larger numbers can be contemplated. For example, assaying 10,000 targets per location×10,000 locations would generate 10.sup.8 different assays, and even larger numbers than these can easily be contemplated, particularly if spatial locations with resolution on the order of that of single cells are utilized. Further, in embodiments where high-throughput digital sequencing is employed, the sequences of at least 1,000 encoding probes are typically determined in parallel. More typically, using a digital readout, it is desirable to obtain multiple sequence reads for each assay (defined by a probe and a spatial location code). It is desirable to obtain an average of at least 3 copies per assay, and more typically at least 10 or at least 30 copies per assay, depending on the design of the experiment and requirements of the assay. For a quantitative readout with suitable dynamic range, it may be desirable to obtain at least 1,000 reads per assay. Therefore, if 1,000,000 assays are carried out, the number of sequence reads may be 1 billion or more. With high-throughput digital sequencing, and allowing for redundancy, the sequence of at least 10,000 encoding probes are determined in parallel, or the sequence of at least 100,000, 500,000, 1,000,000, 10,000,000, 100,000,000, 1,000,000,000 or more encoding probes are determined in parallel.

Assays

(34) The assay portion of the assay systems of the present invention comprise the following general steps: delivering probes and encoding agents where the encoding agents (in some embodiments pre-coupled to the probes) are delivered to the sample according to a known spatial pattern, allowing the probes to interact or react with biological targets in the sample, and, if the probes and encoding agents have not been pre-coupled, coupling the encoding agents to probes.

(35) The samples of the present invention include virtually any biological sample or samples that can be affixed to a support or provided essentially in a two-dimensional manner, where the ability to tie an assayed biological target or activity back to the location within the biological sample is important. Exemplary biological samples include tissue sections (e.g., including whole animal sectioning and tissue biopsies), cell populations on slides or culture dishes, and the like. The assay systems of the invention are particularly advantageous in that they are compatible with numerous biological sample types, including fresh samples, such as primary tissue sections, and preserved samples including but not limited to frozen samples and paraformalin-fixed, paraffin-embedded (FFPE) samples. An important aspect of the assay systems of the invention is that the biological samples are immobilized on a substrate surface having discrete, independently measurable areas.

(36) The biological targets to be detected can be any biological molecules including but not limited to proteins, nucleic acids, lipids, carbohydrates, ions, or multicomponent complexes containing any of the above. Examples of subcellular targets include organelles, e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplasts, endocytic vesicles, exocytic vesicles, vacuoles, lysosomes, etc.

(37) In some particular embodiments, the assay system is used to analyze nucleic acids, e.g., by genotyping, quantitation of DNA copy number or RNA transcripts, localization of particular transcripts within samples, and the like. FIG. **3** illustrates an overall scheme for an exemplary assay for, e.g., detecting single nucleotide polymorphisms (SNPs) that can be used with the assay system of the invention. In FIG. **3**, two oligonucleotide probes are provided. Each oligonucleotide probe comprises a target-specific region (located on either side of the SNP to be analyzed) seen at **305** and **307**, and ligation regions, seen at **301** and **303**, The oligonucleotide probes are allowed to hybridize to a target nucleic acid (not shown) in the biological sample. At step **302**, one of the oligonucleotide probes is extended to incorporate the SNP sequence and ligated to the other probe to form an extended probe comprising target nucleic acid region **309** and ligation regions **301** and **303**.

(38) Two encoding agents, both comprising a coding tag (seen at **315** and **317**), a ligation region (seen at **311** and **313**), and a primer region (seen at **319** and **321**) are combined with and ligated to the extended probe at step **304** to form an encoded target-specific oligonucleotide. Again, in contrast with FIG. **1**, the probes and encoding agents are delivered at separate steps. Doing so allows use of the combinatorial embodiments described infra. In preferred embodiments, the encoding oligonucleotides within a pair of encoding oligonucleotides ligate specifically to one side of the target sequence or the other (i.e., 5′ or 3′ of the target sequence) in step **306**. Also, typically, the ligation and primer regions of the encoding oligonucleotides and probes are universal; that is, the set of ligation and primer regions used in constructing the probes and encoding oligonucleotides are constant, and only the target-specific regions of the probes and the coding tags of the encoding oligonucleotides differ. However, again in alternative embodiments, the ligation and primer regions are not universal and differ between probes and encoding agents.

(39) Following ligation, the encoded probes are eluted, pooled, and, optionally, sequencing adapters are added to the encoded probes via PCR. In alternative embodiments, sequencing primers may be ligated to the encoding oligonucleotides, or sequencing primer sequences can be included as part of the encoding oligonucleotide. As seen in FIG. **3**, each sequencing adapter comprises primer region **319** or **321**, compatible with the primer regions **319** and **321** on the encoded probes. The final construct comprising first adapter **327**, first primer region **319**, first coding tag **315**, ligation regions **311** and **301**, target region **309**, ligation regions **313** and **303**, second coding tag **317**, second primer region **325** and second adapter **329** is now ready for input into a digital high-throughput sequencing process.

(40) A combination of extension and ligation reactions are exemplified in FIG. **3**, but it should be appreciated that a variety of reactions may be used to couple the encoding oligonucleotides to the target-specific oligonucleotides, including ligation only (e.g., for oligonucleotides that hybridize to contiguous portions of the target nucleic acid sequence). Alternatively, an assay utilizing an additional oligonucleotide, such as in the GOLDENGATE® assay (see Fan, et al., Cold Spring Symp. Quant. Biol., 68:69-78 (2003); (Ilumina, Inc., San Diego, CA)), may be employed.

(41) In other embodiments, the assay system of the invention also can be used to analyze peptides or proteins, the presence of antibodies, enzymatic and other protein activities, posttranslational modifications, active and non-active forms of peptides, as well as peptide isoforms in a biological sample. Accordingly, the probes may comprise an active region of an enzyme, a binding domain of an immunoglobulin, defined domains of proteins, whole proteins, synthetic peptides, peptides with introduced mutations, aptamers and the like.

(42) In certain aspects, the probes are substrates for enzymes or proenzymes, e.g., kinases, phosphatases, zymogens, proteases, or fragments thereof. In certain aspects, the probes are phosphorylation substrates used to detect proteins involved in one or more signal transduction pathways, e.g., a kinase or a phosphatase. In another specific aspect of the invention, the probes are specific protease substrates that associate only with individual proteases or classes of proteases. In other aspects, the probes are different processed forms, isoforms and/or domains of an enzyme. Protein-based

probes are typically conjugated or otherwise linked to oligonucleotide encoding agents. The oligonucleotide encoding agents in this case would also include a nucleotide sequence component that allows for identification of the protein probe.

(43) In certain aspects, the present invention provides assays for evaluating differences in the amount and/or activity of biological targets between different locations in a sample and/or between samples. The method includes determining a plurality of encoded results from the biological sample and evaluating the differences in quantity of the biological targets at each location in the biological sample.

Combinatorial Embodiments

(44) To maximize the efficiency of encoding, a combinatorial approach using pairs of coding tags in the encoding oligonucleotides can be used. By de-coupling the target-specific information and the coding tags, the number of oligonucleotides required is dramatically reduced, with a concomitant decrease in cost.

(45) FIG. **4** illustrates a general mechanism for one embodiment of a combinatorial encoding scheme of the assay systems of the invention, where nucleic acids in a representative tissue section (shown at **416**) are assayed. FIG. **4** at A shows two target-specific/encoding oligonucleotide constructs **420** and **422** (e.g., formed between steps **302** and **304** of FIG. **3**) specifically bound to a target nucleic acid **402** of interest, The first encoded probe **420** comprises coding tag **408**, associated with, e.g., a universal priming site for amplification of the assay products or an adapter to enable identification of the coding identifiers using sequencing technologies **404**. The second encoded probe **422** comprises coding tag **406**, associated with, e.g., a universal priming site for amplification of the assay products or an adapter to enable identification of the coding identifiers using sequencing technologies **410**.

(46) FIG. **4** at B shows the spatial pattern that may be used for twenty different coding tags, a1 through a10 (coding tag **406** on encoded probe **420**) and b1 through b10 (coding tag **408** encoded probe **422**). Coding tag al., for example, is deposited on the biological sample in ten discrete areas or spots (shown as the first horizontal line of spots in **412**). Coding tag a2 is deposited on the biological sample in ten spots on the second horizontal line in **412**. Coding tag a3 is deposited on the biological sample in ten spots on the third horizontal line in **412**, and so on. Whereas the “a” tags are deposited in ten horizontal rows, the “b” tags are deposited in ten vertical rows as shown in **414**. For example, coding tag b1 is deposited on the biological sample in ten discrete spots in the first vertical row of **414**, coding tag b2 is deposited on the biological sample in ten discrete spots in the second vertical row of **414**, and so on. Using such a configuration allows for twenty coding tags to uniquely define 100 different locations on the biological sample.

(47) FIG. **4** at C shows a representative tissue section **416** coincident with coding tag grid **418**. The arrows show how the “a” coding tags and the “b” coding tags are deposited on grid **418** that is coincident with tissue section **416**. If, once sequenced, coding tags a1 and b4, e.g., are associated with a target nucleic acid sequence, then that target nucleic acid sequence (i.e., biological target) was present in the tissue section at location a1, b4.

(48) FIG. **5** provides a simplified, specific example of the encoding scheme of the assay systems of the invention. FIG. **5** shows encoding oligonucleotides **510**, comprising a1, a2, a3, a4 and b1, b3, b3 and b4. Target-specific oligonucleotides (TSOs) (probes) 1 and 2 are shown at **520**. A deposit or dispensing scheme is shown at **530**. Like the grid exemplified in FIG. **4**, encoding oligonucleotides a1 through a4 are deposited in spots in a pattern (here, in a vertical pattern), and encoding oligonucleotides b1 through b4 are deposited in spots in a pattern (here, a horizontal pattern). The grid though shown as a square with spots is actually a deposition pattern on a biological sample (not shown) such as tissue section **416** shown in FIG. **4**.

(49) The target-specific oligonucleotides are delivered to the biological sample, where the target-specific oligonucleotides hybridize to target nucleic acids in the biological sample if target nucleic acids are present. Unhybridized target-specific oligonucleotides are then removed, e.g., by washing. The encoding oligonucleotides are then delivered to the biological sample according to the spatial pattern shown at **530**. The encoding oligonucleotides are ligated (or, e.g., extended and ligated) to any target-specific oligonucleotides that hybridized to the target nucleic acid in the biological sample, the ligated constructs are then eluted from the biological sample, pooled, and sequencing adapters are added through, e.g., PCR or ligation, if the sequences were not previously included in the encoding oligonucleotides. The ligated constructs are sequenced by, e.g., high throughput or “next generation” sequencing.

(50) The pool of resulting sequences is shown at **540**. A sequence readout was obtained for target-specific oligonucleotide 1 only at a4b1, a4b2, a1b3, a2b3, a3b3, a4b3 and a4b4 (positions shown with horizontal lines). A sequence readout was obtained for target-specific oligonucleotide 2 only at a1b1 (position shown with vertical lines). A sequence readout was obtained for both target-specific oligonucleotides 1 and 2 at positions a2b1, a3b1, a1b2, a2b2, and a3b2 (positions shown with cross-hatching). No sequence readout was obtained for either target-specific oligonucleotides at a1b4, a2b4 or a3b4 (positions shown without shading). Thus, in the biological sample on which the assay took place the first target nucleic acid was detected in a large portion of the left side and at the bottom of the biological sample, the second target nucleic acid was detected only in the upper left portion of the biological sample, and neither target nucleic acid was detected in the upper right portion of the biological sample. The differential expression of the two target nucleic acids now can be mapped back to the biological sample and to the biological structures or cell types in these locations in the biological sample, as shown in **550**.

(51) In addition to location information, information relating to relative abundance of the encoded tags can be obtained. For example, if it is found that there are ten times as many a4T1b1 sequences occurring in the data set as compared to a4T1b2 sequences, this would indicate that target nucleic acid sequence 1 is ten times more abundant at the a4T1b1 location than at the a4T1b2 location.

(52) In the case of nucleotide analysis as shown in FIG. **3**, by ligating the coding tags directly to target-specific oligonucleotides, only 2n target-specific oligonucleotides are needed for n targets. For example, using the combinatorial approach outlined in FIG. **2**, assaying 100 different targets at 10,000 spatial locations would require 2×100 target-specific oligonucleotides and 2×100 encoding oligonucleotides. The total count of assay oligonucleotides would be only 400 (200 target-specific and 200 encoding), not counting universal primers. In contrast, if the coding oligonucleotides were not decoupled from the target-specific oligonucleotides, (n×X positional codes)+(n×Y positional codes) would be needed, or in the above example, 20,000 oligonucleotides, not counting universal primer sequences. Moreover, though the embodiments shown in FIGS. **2-5** depict a combinatorial scheme using two encoding agents (coding tags), three, four or more encoding agents and coding tags may be used, and attached to the probe or one another by varying means and in varying combinations of steps.

(53) Due to the spatial encoding aspect of the assay system of the invention, a large amount of information can be generated with even a modest number of assays. For example, five or more biological targets assayed at five or more positions in the sample generates 25 or more combinations. Using digital sequencing as a readout, the optimum number of sequence reads per combination depends on the sensitivity and dynamic range required, and can be adjusted, For example, if for each combination on average 100 reads are sampled, the total for 25 combination is 25,000 reads. If 1,000 targets are assayed at 1,000 locations with an average sampling depth of 1,000, then 10.sup.9 reads are required. These numbers, although large, are within the capacity of intrinsically parallel digital sequencing methods, which can generate datasets of billions or even trillions of reads in a reasonable timeframe and at a very low cost per read. Therefore, by varying the numbers of positions interrogated or biological targets assayed, or both, and using digital sequencing, large amounts of information can be obtained. In specific aspects, multiple locations are interrogated for two or more biological molecules.

Reagent Delivery Systems

(54) The reagent delivery system of the invention includes instrumentation that allows the delivery of reagents to discrete portions of the biological sample, maintaining the integrity of the spatial patterns of the encoding scheme. Reagent delivery systems of the assay systems of the invention comprise optional imaging means, reagent delivery hardware and control software. Reagent delivery can be achieved in a number of different ways. It should be noted that reagent delivery may be to many different biological samples at one time. A single tissue section has been exemplified herein; however, multiple biological samples may be affixed and analyzed simultaneously. For example, pions of a tissue sample can be analyzed in parallel

and the data combined to build a 3D map.
(55) Integral to the assay system of the invention is instrumentation that allows for spatial patterning of reagents onto the biological sample. Technologies for formulating and delivering both biological molecules (e.g. oligonucleotides or antibodies) and chemical reagents (e.g., small molecules or dNTPs) are known in the art, and uses of these instrument systems are known to one skilled in the art and easily adaptable to the assay systems of the invention. One example of a suitable reagent delivery system is the Labcyte™ Echo acoustic liquid handier, which can he used to deliver nanoliter scale droplets containing biological molecules with high precision and reproducibility. One skilled in the art could incorporate this reagent delivery device into the overall system, using software to specify the locations to which reagents should be delivered.
(56) Other instruments that can be used for the deposition of agents and/or coding identifiers onto biological samples include, but are not limited to, ink jet spotting; mechanical spotting by means of pin, pen or capillary; micro contact printing; photochemical or photolithographic methods; and the like. For several applications, it may be preferred to segment or sequester certain areas of the biological samples into one or more assay areas for different reagent distributions and/or biological target determination. The assay areas may be physically separated using barriers or channels.
(57) In one exemplary aspect, the reagent delivery system may be a flow-based system. The flow-based systems for reagent delivery in the present invention can include instrumentation such as one or more pumps, valves, fluid reservoirs, channels, and/or reagent storage cells. Reagent delivery systems are configured to move fluid to contact a discrete section of the biological sample. Movement of the reagents can be driven by a pump disposed, for example, downstream of the fluid reagents. The pump can drive each fluid reagent to (and past) the reaction compartment. Alternatively, reagents may be driven through the fluid by gravity. US Pub. Nos. 20070166725 and 20050239192 disclose certain general-purpose fluidics tools that can be used with the assay systems of the invention, allowing for the precise manipulation of gases, liquids and solids to accomplish very complex analytical manipulations with relatively simple hardware.
(58) In a more specific example, one or more flow-cells can be attached to the substrate-affixed biological sample from above. The flow-cell can include inlet and outlet tubes connected thereto and optionally an external pump is used to deliver reagents to the flow-cell and across the biological sample. The flow cells are configured to deliver reagents only to certain portions of the biological sample, restricting the amount and type of reagent delivered to any specific section of the biological sample.
(59) In another aspect, a microfluidic system can be integrated into the substrate upon which the biological sample is disposed or externally attached on top of the substrate. Microfluidic passages for holding and carrying fluid may be formed on and/or above the planar substrate by a fluidics layer abutted to the substrate. Fluid reagents can be selected and delivered according to selective opening and closing of valves disposed between reagent reservoirs.
(60) Pumps generally include any mechanism for moving fluid and/or reagents disposed in fluid. In some examples, the pump can be configured to move fluid and/or reagents through passages with small volumes (i.e., microfluidic structures). The pump can operate mechanically by exerting a positive or negative pressure on fluid and/or on a structure carrying fluid, electrically by appropriate application of an electric field(s), or both, among other means. Exemplary mechanical pumps may include syringe pumps, peristaltic pumps, rotary pumps, pressurized gas, pipettors, etc. Mechanical pumps may be micromachined, molded, etc. Exemplary electrical pumps may include electrodes and may operate by electrophoresis, electroendoosmosis, electrocapillarity, dielectrophoresis (including traveling wave forms thereof), and/or the like.
(61) Valves generally include any mechanism for regulating the passage of fluid through a channel. Valves can include, for example, deformable members that can be selectively deformed to partially or completely close a channel, a movable projection that can be selectively extended into a channel to partially or completely block a channel, an electrocapillary structure, and/or the like.
(62) An open gasket can be attached to the top of the biological sample and the sample and reagents can be injected into the gasket. Suitable gasket materials include, but are not limited to, neoprene, nitrile, and silicone rubber. Alternatively, a watertight reaction chamber may be formed by a gasket sandwiched between the biological sample on the substrate and a chemically inert, water resistant material such as, but not limited to, black-anodized aluminum, thermoplastics (e.g., polystyrene, polycarbonate, etc), glass, etc.
(63) In an optional embodiment, the assay system comprises imaging means to determine features and organization of the biological sample of interest. The images obtained, e.g., may be used to design the deposition pattern of the reagents, Imaging means are optional, as an individual can instead view the biological sample using, e.g., a microscope, analyze the organization of the biological sample, and specify a spatial pattern for delivery assay reagents. If included, the delivery system can comprise a microcircuit arrangement including an imager, such as a CCD or IGFET-based (e.g., CMOS-based) imager and an ultrasonic sprayer for reagent delivery such as described in US Pub. No. 20090197326, which is incorporated herein by reference. Also, it should be noted that although FIGS. **4** and **5** illustrate using a x,y grid configuration, other configurations can be used, such as, e.g., following the topology of a tissue sample; targeting certain groups of cells, cell layers and/or cell types in a tissue, and the like.
(64) In yet another alternative, the reagent delivery system controls the delivery of reagents to specific patterns on a biological sample surface using semiconductor techniques such as masking and spraying. Specific areas of a biological sample can be protected from exposure to reagents through use of a mask to protect specific areas from exposure. The reagents may be introduced to the biological sample using conventional techniques such as spraying or fluid flow. The use of masked delivery results in a patterned delivery scheme on the substrate surface.
(65) In a preferred aspect of the invention, the reagent delivery instrumentation is based on inkjet printing technology. There are a variety of different ink-jetting mechanisms (e.g., thermal, piezoelectric) and compatibility has been shown with aqueous and organic ink formulations. Sets of independently actuated nozzles can be used to deliver multiple reagents at the same time, and very high resolutions are be achieved.
(66) In order to target specific sites of interest, an informative image of the biological sample to be assayed may be used to assist in the reagent delivery methods and associated encoding scheme. Sample regions of the biological sample can be identified using image processing (e.g., images of cell types differentiated by immunohistochemistry or other staining chemistries) integrated with other features of the assay system. In some aspects, software is used to automatically translate image information into a reagent delivery pattern. A mechanism to register and align very precisely the biological sample for reagent delivery is thus an important component of the assay systems of the invention. Mechanisms such as the use of fiducial markers on slides and/or other very accurate physical positioning systems can be adapted to this purpose.
(67) The invention preferably comprises a complete suite of software tailored to the assay system. Optionally, oligonucleotide design software is used to design the encoding nucleotides (and in embodiments where nucleic acids are assayed, the target-specific oligonucleotides) for the specific assay to be run, and may be integrated as a part of the system. Also optionally, algorithms and software for reagent delivery and data analysis (i.e., sequence analysis) may be integrated to determine assay results. Integrated data analysis is particularly useful, as the type of dataset that is generated may be massive as a consequence of scale. Algorithms and software tools that are specifically designed for analysis of the spatially-associated data generated by the assay systems, including pattern-analysis software and visualization tools, enhance the value of the data generated by the assay systems.
(68) In certain aspects, the assay system comprises processes for making and carrying out the quality control of reagents, e.g., the integrity and sequence fidelity of oligonucleotide pools. In particular, reagents are formulated according to factors such as volatility, stability at key temperatures, and chemical compatibility for compatibility with the reagent delivery instrumentation and may be analyzed by instrumentation integrated within the assay system.
Sequencing
(69) Numerous methods can be used to identify the coding tags and probe sequences in the encoded probes of the assay systems of the invention. The coding tags can be detected using techniques such as mass spectroscopy (e.g., Maldi-T of, LC-MS/MS), nuclear magnetic resonance imaging, or, preferably, nucleic acid sequencing. Examples of techniques for decoding the coding tags of the present invention can be found, for example, in US

Pub. No. 20080220434, which is incorporated herein by reference. For example, the coding tags may be oligonucleotide mass tags (OMTs or massTags). Such tags are described, e.g., in US Pub. No. 20090305237, which is incorporated by reference in its entirety. In yet another alternative, the encoded probes can be amplified and hybridized to a microarray. This would require separate amplification reactions to be carried out, in which each amplification is specific to a particular spatial code or subset of codes, accomplished by using code-specific primers. Each amplification would also incorporate a different resolvable label (e.g. fluorophor). Following hybridization, the relative amounts of a particular target mapping to different spatial locations in the sample can he determined by the relative abundances of the resolvable labels.

(70) In one particularly preferred aspect, the resulting coding tags according to the assay system are substrates for high-throughput, next-generation sequencing, and highly parallel next-generation sequencing methods are used to confirm the sequence of the coding tags, for example, with SOLID™ technology (Life Technologies, Inc.) or Genome Ananlyzer (Illumina, Inc.). Such next-generation sequencing methods can be carried out, for example, using a one pass sequencing method or using paired-end sequencing. Next generation sequencing methods include, but are not limited to, hybridization-based methods, such as disclosed in e.g., Drmanac, U.S. Pat. Nos. 6,864,052; 6,309,824; and 6,401,267; and Drmanac et al, U.S. patent publication 2005/0191656; sequencing-by-synthesis methods, e.g., U.S. Pat Nos. 6,210,891; 6,828,100; 6,969,488; 6,897,023; 6,833,246; 6,911,345; 6,787,308; 7,297,518; 7,462,449 and 7,501,245; US Publication application Ser. Nos. 20/110,059436; 20040106110; 20030064398; and 20030022207; Ronaghi, et al, Science, 281:363-365 (1998); and Li, et al, Proc. Natl. Acad. Sci., 100:414-419 (2003); ligation-based methods, e.g., U.S. Pat. Nos. 5,912,148 and 6,130,073; and U.S. Pat. Appln Nos. 20100105052, 20070207482 and 20090018024; nanopore sequencing e.g., U.S. Pat. Appln Nos. 20070036511; 20080032301; 20080128627; 20090082212; and Soni and Meller, Clin Chem 53:1996-2001 (2007)), as well as other methods, e.g., U.S. Pat. Appln Nos. 20110033854; 20090264299; 20090155781; and 20090005252; also, see, McKernan, et al., Genome Res., 19:1527-41 (2009) and Bentley, et al., Nature 456:53-59 (2008), all of which are incorporated herein in their entirety for all purposes.

Applications of Assay System

(71) It will be apparent to one skilled in the art upon reading the present disclosure that there are numerous important areas of biological research, diagnostics, and drug development that will benefit from a high throughput multiplexed assay system that can measure simultaneously the amount and spatial location of a biological target in a biological sample. For example, combining the ability to estimate the relative abundance of different RNA transcripts with the ability to reconstruct an image of spatial patterns of abundance across many locations, which may be as small as or even smaller than individual cells, in a tissue enables many different areas of basic research. The following are exemplary uses and are by no means meant to be limiting in scope.

(72) In one example, 3-dimensional patterns of gene expression are determined by analyzing a series of tissue sections, in a manner analogous to image reconstruction in CT scanning, Such a method can be used to measure changes in gene expression in disease pathology, e.g., in cancerous tissue and/or a tissue upon injury, inflammation or infection. With the assay systems of the invention, more detailed information on gene expression and protein localization in complex tissues is obtained, leading to new insights into the function and regulation both in normal and diseased states, and provides new hypotheses that can be tested. For example, an assay system of the invention may enable some of the insights gained from many individual studies and larger programs like ENCODE (Birney, et al., Nature, 447:799-816 (2007)) and modENCODE to be integrated at the tissue level. The assay systems also aid computational efforts to model interacting networks of gene expression in the field of systems biology.

(73) The assay systems also provide a novel approach to analysis of somatic variation, e.g., somatic mutations in cancer or variability in response to infectious organisms. For example, tumors are typically highly heterogeneous, containing cancer cells as well as genetically normal cells in an abnormal local environment. Cancer cells undergo mutation and selection, and in this process it is not unusual for local clones to develop. Identifying relatively rare somatic mutations in the context of tumors may enable the study of the role of key mutations in the selection of clonal variants. Transcriptional patterns associated with angiogenesis, inflammation, or other cancer-related processes in both cancer and genetically normal cells can be analyzed for insights into cancer biology and assist in the development of new therapeutic agents for the treatment of cancers. In another example, individuals have varying susceptibility to infectious organisms, and the assay systems of the invention can be used to study the interaction between microbes and tissues or the various cell types within the tissue.

(74) Importantly, in addition to providing spatially-associated information, the invention allows a great increase in the sensitivity of detecting rare mutations, as signal to noise can he dramatically increased since only a small location is assayed in any given reaction. In a typical assay for rare mutations in a mixed sample, the sample is treated in bulk, i.e., nucleic acids are extracted from many cells into a single pool. Thus, if a mutation is present in one cell in 10,000, it must be detected against a background of normal DNA from ˜10,000 cells. In contrast, with the assay systems of the invention many cells can be analyzed, but individual cells or small groups of cells would be identified by the spatial coding system. Therefore, in the assay systems of the present invention, background is reduced by orders of magnitude, greatly increasing sensitivity. Furthermore, the spatial organization of mutant cells can be observed, which may be particularly important in detecting key mutations in tissue sections in cancer. Already molecular histological analyses are yielding insights into cancer biology and may have potential for use in diagnostics. The technology of the invention promises to greatly increase the power of such approaches.

(75) The present invention provides assays, assay systems, and methods of using such assays in spatially encoded biological assays. The invention provides an assay system comprising one or more agents provided in defined spatial patterns on a substrate surface, and a detection system for identifying the presence or absence, relative amount, and location of a biological molecule. Such biological molecules include, but are not limited to, nucleic acids, peptides, carbohydrates, cellular components, and the like. The assay system is a novel multiplexing approach, as it allows multiple molecules and their respective multiple locations to be identified in a single system using a unique encoding scheme. This encoding scheme uses both molecule-specific binding agents and coding identifiers to provide a practical and cost-effective determination of information on multiple biological molecules, including specific positional information of such molecules in a biological sample, e.g., a tissue section. The single molecule detection analysis using the encoding system also allows relative amounts of biological molecules to be detected, thus providing information on expression levels, sequestering in specific locales, and the like.

(76) The assay systems detect the presence or absence, and relative amount, of a biological molecule at more than one spatial location in a sample. In addition, the assays provide methods for doing this for multiple biological molecules simultaneously. The assay systems utilize one or more binding agents that specifically bind to the biological molecule of interest and unique coding identifiers associated with specific binding agents. The detection system utilizes a method for identifying the presence and spatial address of the agent binding based on the positive and/or negative results that are obtained using detection of the agent and identifier and the encoding scheme of the spatial patterns on the substrate surface. In a specific aspect, the encoding scheme employs limited reagent delivery to the spatial patterns on the substrate surface, and access of the coding identifiers and/or binding agents to portions of the sample is controlled through such limited delivery.

(77) In one aspect, the assay system detects the presence or absence and spatial location of a biological molecule based on the positive and/or negative results that are obtained using limited reagent delivery and the encoding scheme of the spatial patterns on the substrate surface.

(78) The assay system and methods of the invention are based on relational, solid-state substrates with positions that represent specific spatial locations within a biological sample, e.g., a cell, organelle or tissue. The ability to use encoding features to represent locations allows high-throughput analysis of the presence or absence, and relative amount, of a biological molecule at more than one spatial location in a sample. The encoding features also allow provide assaying of multiple biological molecules at these multiple locations simultaneously.

(79) A primary feature of the invention is the preservation of the spatial organization of elements in a sample of interest through the use of an encoding scheme. For example, the assay may be designed to preserve the relative position of cells in a tissue, and the assay may interrogate the individual cells for genomic DNA variation (including epigenetic modifications), and RNA and protein expression.

(80) In one specific aspect, the encoding scheme of the assay system comprises the use of two or more coding patterns, each comprising regions

defined by spatial patterns on the substrate surface. For example, the assay system can utilize an encoding scheme that comprises a 2-dimensional grid format based on the discrete positioning of the binding agents in the substrate surfaces. In another example, the spatial patterns may be based on more randomized cell locations, e.g., the patterns on the substrate surface follow an underlying biological structure rather than a strict, x,y grid pattern. This aspect includes systems with two or more substantially identical spatial patterns using different binding agents and/or coding identifiers, as well as systems having different patterns for different agents and/or coding identifiers. The encoding scheme of the systems can be controlled by delivery of different reagents to discrete regions on the substrate surfaces, which allows different reactions to take place on substantially similar agents of known location on the substrate surfaces.

(81) In one specific aspect, the invention provides high resolution, high-throughput analysis of nucleic acids and/or expression levels that provides both detection and spatial identification of large numbers of nucleic acids, e.g., DNA or RNA.

(82) In another specific aspect, the invention provides high resolution, high-throughput analysis of proteins that provides both detection and spatial identification of large numbers of such proteins, e.g., kinases or proteases.

(83) Numerous reagent delivery systems can be used with the assay system of the invention. The primary criteria of such reagent delivery systems is the ability to direct delivery of specific agents based on spatial patterns on the substrate surface.

(84) In one preferred aspect, the encoding scheme utilizes a reagent delivery system based on printing and informatics technologies to implement the spatial patterns used for identification and localization of the biological materials. For example, the patterns found in the encoding scheme may be created using ink jet printing technology to provide reagents at specific locations on one or more substrate surfaces. The desired patterns are set out in specific coding patterns on the substrate surface.

(85) In certain aspects of the invention, the binding agents are immobilized directly to the substrate surface, and the location of the binding agents is known or determined prior to use of the substrate surface in the assay system. In another aspect, the binding agents are immobilized onto beads or other separate structural elements that are then provided in known locations on the substrate surface. In yet another aspect, the binding agents may be provided in or on features of the substrate surface, e.g., provided in wells or channels.

(86) In specific aspects of the invention, the binding agents are nucleic acids immobilized directly or indirectly to the substrate surface, e.g., directly through the use of amino groups on the substrate surface or indirectly through the use of a linker. The location of the nucleic acid sequences is known or determined prior to use of the substrate surface in the assay system. In another specific aspect, the nucleic acids may be immobilized directly or indirectly onto beads that are then provided in known locations on the substrate surface. In yet another aspect, the nucleic acids may be provided in or on features of the substrate surface, e.g., provided in wells.

(87) In these aspects involving nucleic acid agents, any methods of sequence determination can be used, e.g., sequencing, hybridization and the like. In a preferred aspect, nucleic acid sequencing, and preferably next-generation sequencing, is used to decode the spatial encoding scheme in the assay system of the invention. This provides a very wide dynamic range for very large numbers of assays, allowing for efficient multiplexing.

(88) In some aspects, the assay utilizes two or more oligonucleotides, the oligonucleotides comprising a universal primer region and a region that correlates specifically to a single spatial pattern within the spatial encoding scheme. In a specific aspect, the assay comprises two allele specific oligonucleotides and one locus specific oligonucleotides. These oligonucleotides allow the identification of specific SNPs, indels or mutations within an allele. This is useful in the identification of genetic changes in somatic cells, genotyping of tissues, and the like.

(89) In other specific aspects of the invention, the binding agents are peptides. In one aspect, these peptides are associated directly or indirectly to known locations on a substrate surface, e.g., using binding protein pairs or through oligonucleotide linkers complementary to oligonucleotides on the substrate surface. In another aspect, the binding agents are peptides are immobilized directly or indirectly onto beads or other separate structural elements that are then provided in known locations on the substrate surface. In yet another aspect, the peptides may be provided in or on features of the substrate surface, e.g., provided in wells.

(90) In yet other specific aspects of the invention, the binding agents are chemical entities (e.g., small molecules) that are coded, e.g. using sequence tags or mass spectroscopy tags as coding identifiers. In one aspect, these chemical entities can be are immobilized directly to the substrate surface. In another aspect, the binding agents are immobilized onto beads or other separate structural elements that are then provided in known locations on the substrate surface. In yet another aspect, the binding agents may be provided in or on features of the substrate surface, e.g., provided in wells.

(91) The assay system of the invention can utilize various detection mechanisms, based on the molecules to be detected and the reagents needed for such detection system. Exemplary methods that can be used with the assay systems of the invention are described in more detail below.

The Invention in General

(92) The assay system and methods of the invention are based on relational methods that allow extraction of data to detect the presence or absence and relative amount of a biological molecule, and the location of this molecule in a sample having a distinct structure, e.g., a tissue section or other biological structure with distinct locations of specific biological molecules. The encoding scheme used in these systems corresponds to the structural elements of the sample, and the information obtained using a two-dimensional coding system is indicative of the spatial addresses of these molecules in a sample of interest.

(93) Integral to the assay system of the invention is a method for spatial patterning of reagents. Technologies for formulating and delivering both biological molecules (e.g. DNA or antibodies) and chemical reagents (e.g., small molecules or dNTPs) have already been demonstrated, and use of these systems will be available to one skilled in the art and easily adaptable upon reading this specification.

(94) The assay design of the invention provides an accurate and easily scalable spatial encoding system. The ability to deliver reagents in a spatially defined pattern together with software, reagents and protocols comprises a novel and highly innovative assay system for spatial analysis of various biological molecules and activities. This allows the assays to measure numerous biological functions in a meaningful spatial environment, including functions such as gene expression and peptide localization. The systems provide the potential to open a new analytical window into the complex spatial patterns of cellular function and regulation in biological systems.

(95) The biological molecules to be detected can be any biological molecules such as proteins, nucleic acids, lipids, carbohydrates, ions, or multicomponent complexes containing any of the above. Further examples of subcellular objects include organelles, e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplast, endocytic vesicle, exocytic vesicles, vacuole, lysosome, etc.

(96) FIG. **4** illustrates such a target-specific assay system for identification of nucleic acid sequences in a sample. In this system, two reagents **420**, **422** that specifically bind to a biological molecule of interest are associated with coding identifiers **406**, **408** that encode for a spatial location in the sample. These coding identifiers **406**, **408** are optionally associated with sites that assist in their identification in the assay format, e.g., universal priming sites **404**, **410** for amplification of the assay products or adapters to enable identification of the coding identifiers and the binding agents using sequencing technologies. The sample that is tested, here shown as a tissue section **416** is encoded using the combination of the patterns **412**, **414** created using the separate coding identifiers **406**, **408** which provide a two dimensional code **418** that shows the location of any positive detection of the biological molecule **402** as well as quantifying the biological molecule **402** at each location assayed in the tissue.

(97) The assay systems of the invention are particularly advantageous in that they are compatible with numerous samples types, such as fresh samples, such as primary tissue sections, and preserved samples including but not limited to frozen samples and paraformalin-fixed, paraffin-embedded (FFPE) samples. An important aspect of the assay systems of the invention is that the binding agents are immobilized on a substrate surface in discrete, independently measureable areas. These discrete areas can be formed by spatially selective deposition of the binding agents on the substrate surface. Numerous methods can be used for the deposition of the agent and the coding identifiers associates with the agent. For example, the coding identifiers can be delivered together or separately from the agent. If delivered together they can be attached (e.g., synthesized as a single molecule or attached through ligation or a chemical coupling mechanism) or simply mixed together to be attached after delivery to the

substrate. In a preferred aspect, the agent and the coding identifier are made separately, mixed together for attachment, and delivered either attached or as a mixture to be attached on the surface. In a specific aspect the binding agents are delivered generally over the substrate surface and the coding identifiers are delivered in a pattern-specific manner.

(98) Examples of methods that can be used for deposition of agents and/or coding identifiers onto the substrate surface include, but are not limited to, ink jet spotting, mechanical spotting by means of pin, pen or capillary, micro contact printing, fluidically contacting the measurement areas with the biological or biochemical or synthetic recognition elements upon their supply in parallel or crossed micro channels, upon exposure to pressure differences or to electric or electromagnetic potentials, and photochemical or photolithographic immobilization methods.

(99) For several applications, it may be preferred to arrange the substrates into segments of one or more measurement areas for reagent distribution and agent determination. These regions may be physically separated using barriers or channels. They may still comprise several additional discrete measurement areas with agents that are different or in different combination from each other.

(100) In certain aspects, the present invention provides a method, e.g., a machine-based method, for evaluating changes in the presence and/or location of a biological molecule over time. The method includes providing a plurality of encoded array results representative of the biological molecule over time and evaluating the differences in detection and/or localization of the biological molecules.

Nucleic Acid Detection and Localization

(101) In a particular aspect, the assay system is used to analyze nucleic acids, e.g genotyping, gene expression analysis, localization of particular transcripts within samples, and the like.

(102) Genotyping may be performed using any technique known to those of skill in the art. Preferred techniques permit rapid, accurate determination of multiple variations with a minimum of sample handling. Some examples of suitable techniques involve but are not limited to direct DNA sequencing, capillary electrophoresis, hybridization, allele-specific probes or primers, single-strand conformation polymorphism analysis, nucleic acid arrays, bead arrays, restriction fragment length polymorphism analysis, cleavage fragment length polymorphism analysis, random amplified polymorphic DNA, ligase detection reaction, heteroduplex or fragment analysis, differential sequencing with mass spectrometry, atomic force microscopy, pyrosequencing, FRET (e.g., TaqMan (Applied Biosystems, Inc., Foster City, Calif.) and Molecular Beacon (Stratagene, La Jolla, Calif.) assays), and other related techniques. Several methods for DNA sequencing are well known and generally available in the art. See, for example, Sambrook, et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, New York) (2001); Ausubel, et al., Current Protocols in Molecular Biology (John Wiley and Sons, New York) (1997), Twyman, et al. (2003) “Techniques Patents for SNP Genotyping”, Pharmacogenomics 4 (1): 67-79; and Kristensen, et al. (2001) “High-Throughput Methods for Detection of Genetic Variation”, BioTechniques 30 (2): 318-332. For details on the use of nucleic acid arrays (DNA chips) for the detection of, for example, SNPs, see U.S. Pat. No. 6,300,063 issued to Lipshultz, et al., and U.S. Pat. No. 5,837,832 to Chee, et al., HuSNP Mapping Assay, reagent kit and user manual, Affymetrix Part No. 90094 (Affymetrix, Santa Clara, Calif.). The molecular inversion probe (MIP) assay format (Hardenbol et al., 2003) is another example of a highly multiplexable assay that may be used with the assay systems of the invention.

(103) In one exemplary and preferred method for analyzing nucleic acids using the assay system of the invention, the detection of nucleic acids uses two allele-specific oligonucleotides and a locus specific oligonucleotide. The assay methods are carried out according to the strategy outlined in FIG. **2** using next-generation sequencing or another highly parallel nucleic acid assay technology. In this assay, a set of two oligonucleotides is designed to hybridize to each target sequence, with a common oligonucleotide and two unique coding identifiers. The allele can be determined, e.g., by primer extension of the locus specific oligonucleotide. Following primer extension and ligation, an amplifiable template is formed with universal primer sequences at either end. Assay oligonucleotides are annealed to a template and enzymatic reactions are used to join the two oligonucleotides only when both are correctly annealed. The detection techniques and read out parameters used in this system of the invention include a much shorter tag than the oligonucleotides used in the assays that are based on capture by hybridization. These shorter tags are designed to be read out by sequencing or, preferably, used to ligate codes onto both ends of the fragment as illustrated in FIG. **2**.

(104) In FIG. **3**, two target-specific assay oligonucleotides are ligated together **302** following in situ hybridization to target sequences. At the same time, encoding oligonucleotides containing tag sequence sets X and Y are ligated **304** to the target specific oligonucleotides. Oligonucleotides containing X ligate specifically to one side of the targeting construct and oligonucleotides containing Y ligate to the other. The oligonucleotides contain universal primer sites P1 and P2. Following ligation, the constructs are eluted and, optionally, sequencing adapters can be attached **306**, e.g., via PCR.

(105) In one preferred aspect, the final construct created from the assay method is a substrate for next-generation sequencing, and highly parallel next-generation sequencing methods are used to confirm the sequence of constructs. Such sequencing methods can be carried out, for example, using a one pass sequencing method or using paired-end sequencing. Next generation sequencing methods include, but are not limited to, hybridization-based methods, such as disclosed in Drmanac, U.S. Pat. Nos. 6,864,052; 6,309,824; and 6,401,267; and Drmanac et al, U.S. patent publication 2005/0191656, and sequencing by synthesis methods, e.g., Nyren et al, U.S. Pat. No. 6,210,891; Ronaghi, U.S. Pat. No. 6,828,100; Ronaghi et al (1998), Science, 281:363-365; Balasubramanian, U.S. Pat. No. 6,833,246; Quake, U.S. Pat. No. 6,911,345; Li et al, Proc. Natl. Acad. Sci., 100:414-419 (2003); Smith et al, PCT publication WO 2006/074351; use of reversible extension terminators, e.g., Turner, U.S. Pat. No. 6,833,246 and Turner, U.S. Pat. No. 6,833,246 and ligation-based methods, e.g., Shendure et al (2005), Science, 309:1728-1739, Macevicz, U.S. Pat. No. 6,306,597; which references are incorporated by reference. Soddart et al., PNAS USA. 2009 Apr. 20; Xiao et al., Nat Methods. 2009 March; 6(3):199-201. Epub 2009 Feb. 8.

(106) To maximize the efficiency of encoding, a combinatorial approach using pairs of oligonucleotides can be used. For example, with only two sets of 100 codes, a substrate can theoretically encode up to 10,000 locations. The number of assay oligonucleotides required is dramatically reduced, the cost decreased, and the robustness of the approach increased by decoupling the coding sequences from the genome-specific sequences. Alternative assay formats can also be used (e.g. ligation or primer extension followed by ligation).

(107) By ligating the codes on separately, only 2n target-specific assay oligonucleotides are needed for n targets. For example, assaying 100 different targets at 10,000 spatial locations would require 2×100 targeting oligonucleotides and 2×100 encoding oligonucleotides, using a combinatorial approach outlined in FIG. **2**. The total count of assay oligonucleotides would be only 400 (200 target-specific and 200 encoding), not counting universal primers. In contrast, if the coding oligonucleotides were not decoupled, (n×X positional codes)+(n×Y positional codes) would be needed, or in the above example, 20,000 oligonucleotides, not counting universal primer sequences.

(108) Due to the matrix system of the invention, a large amount of information can be obtained even using five or more positions interrogated for five or more biological molecules. By varying one or the other of these, large amounts of information can be obtained, both in terms of locations and/or specific biological In specific aspects, multiple locations are interrogated for two or more biological molecules. As an example, for each datapoint ˜1,000 reads may be sampled, for a total of −10E9 reads for 10E6 datapoints.

Peptide Detection Systems

(109) The assay system of the invention can be used to analyze biological molecules using peptide agents that are associated with the substrate surface in a spatial pattern. Such peptides may comprise an active region of an enzyme, a binding domain of an immunoglobulin, defined domains of proteins, whole proteins, synthetic peptides, peptides with introduced mutations, etc.

(110) The assay system of the invention allows the identification and spatial location of various forms of peptides, including isoforms and peptides that have undergone posttranslational modification. Importantly, certain aspects of the invention allow the identification of active versus non-active forms of such peptides in a sample. This allows the identification of the presence or absence of specific peptide isoforms, and also acts as a proxy for identification of peptide activity in a sample.

(111) In certain aspects of the invention, the binding agents associated with the substrate surfaces of the assay system include substrates for enzymes or proenzymes, e.g., a kinase, a phosphatase, a zymogen, a protease, or a fragment thereof. In certain aspects, the binding agents associated with the substrate surfaces are phosphorylation substrates used to detect proteins involved with one or more signal transduction pathways, e.g., a kinase or a phosphatase. In another specific aspect of the invention, the binding agents are specific protease substrates that associate only with individual or classes of proteases. In other aspects, the binding agents on the substrate surface are different processed forms, isoforms and/or domains of an enzyme.

Reagent Delivery

(112) The reagent delivery system of the invention can be any system that allows the delivery of reagents to discrete portions of the array in order to keep the integrity of the defined spatial patterns of the encoding scheme. Such discrete delivery can be achieved in a number of different ways.

(113) In one exemplary aspect, the reagent delivery system can be a flow-based system. The flow-based systems for reagent delivery in the present invention can include one or more pumps, valves, fluid reservoirs, channels, and/or reagent storage cells. Such a reagent delivery system is configured to move fluid in contact with a discrete section of the substrate surface. Movement of the reagents can be driven through a fluid by a pump disposed, for example, downstream of the fluid reagents. The pump can drive each fluid reagent to (and past) the reaction compartment. Alternatively, the reagents may be driven through the fluid by gravity.

(114) US Appln Nos. 20070166725 and 20050239192 disclose certain general-purpose fluidics tools that can be used with the assay systems of the invention. These allow the precise manipulation of gases, liquids and solids to accomplish very complex analytical manipulations with relatively simple hardware.

(115) In a more specific example, one or more flow-cells can be attached to the substrate from above. The flow-cell can include inlet and outlet tubes connected thereto and optionally an external pump can be used to deliver the sample or reagents to the flow-cell and across the substrate. The flow cell is configured to deliver reagents only to certain portions of the array, restricting the amount and type of reagent delivered to any specific section of the array.

(116) In another aspect, a microfluidic system can be integrated into the substrate or externally attached on top of the substrate. Microfluidic passages for holding and carrying fluid can be formed on and/or above the planar substrate by a fluidics layer abutted to the substrate. Fluid reagents can be selected according to selective opening and closing of valves disposed between reagent reservoirs.

(117) Pumps generally include any mechanism for moving fluid and/or reagents disposed in fluid. In some examples, the pump can be configured to move fluid and/or reagents through passages with small volumes (i.e., microfluidic structures). The pump can operate mechanically by exerting a positive or negative pressure on fluid and/or on a structure carrying fluid, electrically by appropriate application of an electric field(s), or both, among others. Exemplary mechanical pumps may include syringe pumps, peristaltic pumps, rotary pumps, pressurized gas, pipettors, etc. The mechanical pumps may be micromachined, molded, etc. Exemplary electrical pumps can include electrodes and may operate by electrophoresis, electroendoosmosis, electrocapillarity, dielectrophoresis (including traveling wave forms thereof), and/or the like.

(118) Valves generally include any mechanism for regulating the passage of fluid through a channel. The valves can include, for example, deformable members that can be selectively deformed to partially or completely close a channel, a movable projection that can be selectively extended into the channel to partially or completely block the channel, an electrocapillary structure, and/or the like.

(119) In yet another aspect, an open gasket can be attached to the top of the substrate and the sample and reagents can be injected into the gasket. Suitable gasket materials include, but are not limited to, neoprene, nitrile, and silicone rubber. Alternatively, a watertight reaction chamber formed by a gasket sandwiched between the substrate and a chemically inert, water resistant material such as, but not limited to, black-anodized aluminum, thermoplastics (e.g., polystyrene, polycarbonate, etc), glass, etc.

(120) In a specific aspect of the present invention, the delivery system can compose a microcircuit arrangement including an imager, such as a CCD or IGFET-based (e.g., CMOS-based) imager and an ultrasonic sprayer for reagent delivery such as described in US Appln No. 20090197326, which is incorporated herein by reference.

(121) In yet another aspect of the invention, the reagent delivery system controls the delivery of reagents to specific patterns on a substrate surface using semiconductor techniques such as masking and spraying. Specific areas of a substrate surface can be protected from exposure to reagents through use of a mask to protect specific areas from exposure. The reagents may be introduced to the substrate using conventional techniques such as spraying or fluid flow. The use of the masked substrate delivery results in a patterned delivery scheme on the substrate surface.

(122) In a preferred aspect of the invention, the reagent delivery instrumentation is based on inkjet printing technology. There are a variety of different ink-jetting mechanisms (e.g., thermal, piezoelectric) and compatibility has been shown with aqueous and organic ink formulations. Sets of independently actuated nozzles can be used to deliver multiple reagents at the same time, and very high resolutions can be achieved.

Software for Use in the Assay System

(123) In order to target specific sites of interest, an informative image of the biological section to be analyzed can be used to assist in the reagent delivery methods and associated encoding scheme. Sample regions can be identified using image processing (e.g., images of cell types differentiated by immunohistochemistry or other staining chemistries) integrated with the other features of the assay system. In some aspects, software is used to automatically translate this information into a reagent delivery pattern. A mechanism to register and align very precisely the biological sample in a targeting system is thus a preferred component of the assay systems of the invention. Mechanisms such as the use of fiducial markers on slides and other very accurate physical positioning systems can be adapted to this purpose.

(124) Additional software components will also be key components that will be part of a complete assay system. The invention thus preferably comprises a complete suite of software tailored to the assay system. Optionally, oligonucleotide design software will be customized for the specific assay to be run, and may be integrated as a part of the system. Also optionally, algorithms and software for data analysis may be integrated to assist in determination of results of the assays. This can be especially useful, as the type of dataset that will be generated will be novel, particularly as a consequence of scale. The ability to provide algorithms and software tools that are specifically designed for analysis of spatially-associated data for significant patterns, including pattern-analysis software and visualization tools, is a novel feature that will enhance the value of the data generated by the assay systems.

(125) In certain aspects, the assay system will comprise processes for making and carrying out quality control of reagents, e.g., the integrity and sequence fidelity of oligonucleotide pools. In particular, reagents will need to be formulated for compatibility with the reagent delivery instrumentation. Factors such as volatility, stability at key temperatures, and chemical compatibility can be optimized by those skilled in the art upon reading the present disclosure.

Applications of Assay System

(126) It will be apparent to one skilled in the art upon reading the present disclosure that there are numerous very important areas of biological research, diagnostics, and drug development that will benefit from a high throughput means to simultaneously measure the presence or absence and spatial location of a biological molecule in a sample. For example, this technology combining the ability to analyze semi-quantitatively the expression of many different genes with the ability to image the spatial organization of expression across many cells in a tissue is enabling for many different areas of basic research. The following are exemplary uses and are by no means meant to be limiting in scope.

(127) In one example, 3-dimensional patterns of expression can be determined by analyzing a series of tissue sections, in a manner analogous to image reconstruction in CT scanning. This can be used to measure changes in gene expression in disease pathology, e.g., in cancerous tissue and/or a tissue upon injury, inflammation or infection. With the assay systems of the invention, more detailed information on gene expression and protein localization in complex tissues can be obtained. This may lead to new insights into the function and regulation both in normal and diseased states,

and is likely to provide new hypotheses that can be tested. For example, a system of the invention may enable some of the insights gained from many individual studies and larger programs like ENCODE (Birney et al., 2007) and modENCODE to be integrated at the tissue level. The assay systems will also aid in computational efforts to model interacting networks of gene expression in the field of systems biology.

(128) The assay systems also provide a novel approach that enables the analysis of somatic variation, e.g., somatic mutations in cancer or variability in response to infectious organisms. For example, tumors are typically highly heterogeneous, containing cancer cells as well as genetically normal cells in an abnormal local environment. Cancer cells undergo mutation and selection, and in this process it is not unusual for local clones to develop. Identifying relatively rare somatic mutations in the context of tumors may enable the study of the role of key mutations in the selection of clonal variants. Transcriptional patterns associated with angiogenesis, inflammation, or other cancer related processes in both cancer and genetically normal cells can be analyzed for insights into cancer biology and assist in the development of new therapeutic agents for the treatment of cancers.

(129) In another example, different people have varying susceptibility to infectious organisms, and much of this may be to underlying genetic differences in individuals and/or populations. Identifying these differences will aid in an understanding of the underlying disease pathologies and assist in the development of vaccines or therapeutics to prevent or ameliorate these disease states.

(130) Importantly, in addition to providing spatially associated information, the technology of the invention will allow a great increase in the sensitivity of detecting rare mutations. The reason is that signal to noise can be dramatically increased because the approach of the invention assays a small location in any given reaction. In a typical assay for rare mutations in a mixed sample, the sample is treated in bulk, i.e. nucleic acids are extracted from many cells into a single pool. Thus, if a mutation is present in 1 cell in 10,000, it must be detected against a background of normal DNA from ˜10,000 cells. In contrast, with the systems of the invention many cells can be analyzed, but individual cells or small groups of cells would be identified by the spatial coding system. Therefore, the background can be reduced by orders of magnitude, greatly increasing sensitivity. Furthermore, the spatial organization of mutant cells can be observed. This may be particularly important in detecting key mutations in tissue sections in cancer. Already, molecular histological analyses are yielding insights into cancer biology and may have potential for use in diagnostics (Choe et al., 2003). The technology of the invention promises to greatly increase the power of such approaches.

EXAMPLES

(131) The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventor regards as his invention, nor are they intended to represent or imply that the experiments below are all of or the only experiments performed. It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

(132) Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees centigrade, and pressure is at or near atmospheric.

Example 1: Initial Proof of Concept of Encoding Scheme

(133) As an initial proof of concept, a model system is developed using a microarray to demonstrate a working single-plex assay. The basic design validates the concept of the assay, and establishes a working assay prior to addressing issues related to the analysis of a more complicated biological sample. Conventional sequencing is used as a readout for this proof of concept.

(134) A microarray is used as a proxy for a tissue section. The target sequences of the microarray are fully specified, so that the composition of the targets are known and can be varied systematically. Synthetic oligonucleotide templates are attached to a glass slide via a 5′ amino modification. Each slide has a single oligonucleotide template sequence, and the assays that are carried out may employ either ligation, or extension followed by ligation as this may be useful in determining certain polymorphisms.

(135) Once the in situ part of the assay is complete, the reaction products are eluted and analyzed by qPCR to determined presence or absence of a product and estimate yield, and by conventional sequencing to determine the structure of the assay products. The single plex assays that are tested include appropriate positive and negative controls, and a single nucleotide variant (SNV) to check ability to discriminate single base variants.

Example 2: Scalability

(136) The complexity of the assay system is increased to establish scalability of the assay for use in high throughput studies. Scalability of both the spatial encoding and assay systems is demonstrated by carrying out a 24-plex×24-site assay using a microarray model system.

(137) The amount of biological target, here a DNA target sequence, at each assay location is systematically varied on microarray substrate. For example, in a microarray with 50 micron spot size (center to center), a 1 mm.sup.2 area contains ˜400 spots. The region around each site is optionally occupied by a region that is devoid of these spots to allow individual resolvability of the target sequences. Alternatively, the spots may be clustered, with two or more directly adjacent spots surrounded by or adjacent to a region that is devoid of target sequences.

(138) In order to demonstrate that spatial encoding is accurate, the sites comprise different target compositions to show that the assay readout matches the expected composition of each site. With 24 target sequences, a simple digital pattern is made with each site having a different set of 12 targets present and 12 targets absent, to make a binary code (0=absent, 1=present). The assay readout is then determined to show that the detected regions match the expected signal after spatial decoding. In this particular example, the code space is large enough (2.sup.24) so that even a few errors would not result in different codes being mixed up. Moreover, this design allows identification of errors and allows an estimation not only of accuracy of spatial encoding but also of accuracy calling the presence or absence of target sequences.

(139) In an exemplary aspect, a 4×4 arrangement of 16 sequences is used for the array configuration. A white square indicates that the sequence is absent and a black square that it is present, i.e. 8 of the 16 possible sequences are present in this sample. In a different sample, a different pattern of absent and present sequences can be constructed. In this way, unique patterns are associated with spatial locations so that the accuracy of spatial encoding can be measured.

(140) The ability to detect quantitative differences is evaluated by generating dose-response curves for each of the 24 assays that are carried out at each site in a 24-site assay. This allows estimation of the limit of detection, dynamic range, and power to detect a given fold-change across the range.

(141) In one aspect, a latin square design is used to represent individual targets at different ratios by varying the number of features for each target. In other words, with multiple spots in a site, the number of spots allocated to each of the 24 target sequences can be varied and each of the 24 sites can have a different composition. A 1×3 inch microarray is sufficiently large to permit multiple replicates. This larger set of 24 sequences will require deconvolution, and this is accomplished using high throughput techniques such as next-generation sequencing technologies (e.g., SOLiD™ technology (Life Technologies, Inc., Carlsbad, CA) or Genome Analyzer (Illumina, Inc., San Diego, CA)). The use of the 24-plex assay demonstrates both the accuracy of spatial encoding and decoding, and the quantitative response of the assay system.

Example 3: Adaptation of the Assay to Preserved Samples

(142) Genomic DNA is assayed as a proof of concept for assaying RNA, as it provides a way to establish a single-copy reference signal. Once a working assay is developed for FFPE samples, it is adapted to an RNA assay. To this end, assay oligonucleotide concentrations are assayed to ensure compatibility with high multiplexing. Assuming a cell diameter of 10 microns, and delivery of a 10 micron diameter reagent droplet to an individual cell, the volume of the droplet will be ˜500 μl and can contain ˜3×10.sup.11 molecules at a 1 μM concentration. To assay 1,000 target sequences in 10,000 cells, ˜2,000 targeting oligonucleotides would be required in a droplet. Therefore, each droplet could contain ˜160 million copies of each assay oligo, a vast excess over the few thousand target sequences in a cell.

(143) The handling of small absolute numbers of product molecules generated from very small or compromised samples are enhanced to counter the issue of low recovery efficiency; that is, elution is efficient and losses resulting from adsorption of molecules to surfaces are prevented. An approach

to addressing the latter issue is to include a carrier material, such as glycogen or carrier nucleic acids.
Example 4: Adapting the Assay to a Biological Sample
(144) A control RNA template is immobilized to a solid support in order to create an artificial system. The assay is performed using T4 DNA ligase, which can repair nicks in DNA/RNA hybrids. Assays are carried out on matched slides, or different sections of the same slide, where in one case gDNA is assayed and in the other RNA is assayed. When assaying gDNA the slide can be pretreated with RNase, and when assaying RNA the slide is pretreated with DNase. Results of the assay are confirmed by extracting gDNA or RNA and quantitating the relative amounts by qPCR or RT-qPCR respectively.
(145) In order make the tissue section RNA assays as informative as possible, pre-existing information on expression levels in specific tissues to target transcripts across a range of abundances are used in the assay design. Both high abundance transcripts, as well as some medium and low abundance transcripts, are targeted to enable an initial assessment of the quantitative performance characteristics of the assay.
(146) The preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims. In the claims that follow, unless the term “means” is used, none of the features or elements recited therein should be construed as means-plus-function limitations pursuant to 35 U.S.C. § 112, ¶6.

Claims

1. A method comprising: (a) providing a substrate comprising a plurality of nucleic acid molecules each having (i) a first sequence configured to bind a target biological molecule in a tissue section, and (ii) a second sequence corresponding to a location on the substrate; (b) contacting the tissue section with the substrate; (c) capturing the target biological molecule from the tissue section onto a nucleic acid molecule of the plurality of nucleic acid molecules using the first sequence; and (d) generating a nucleic acid molecule comprising (i) a sequence of the captured target biological molecule, or a complement thereof, and (ii) the second sequence corresponding to the location on the substrate, or a complement thereof.
2. The method of claim 1, wherein the tissue section is a fresh-frozen or formalin-fixed paraffin-embedded tissue sample.
3. The method of claim 1, wherein the target biological molecule is an RNA molecule.
4. The method of claim 3, wherein the RNA molecule is an mRNA molecule.
5. The method of claim 1, wherein the target biological molecule is a DNA molecule.
6. The method of claim 1, wherein (c) comprises hybridizing the target biological molecule to the first sequence of the nucleic acid molecule.
7. The method of claim 1, wherein (c) comprises coupling the target biological molecule to the nucleic acid molecule.
8. The method of claim 7, wherein the coupling comprises ligation.
9. The method of claim 8, wherein the ligation comprises enzymatic ligation.
10. The method of claim 1, wherein (d) comprises extending the nucleic acid molecule using the target biological molecule as a template.
11. The method of claim 10, wherein the extending is performed by a polymerase.
12. The method of claim 1, wherein the substrate is a flow cell.
13. The method of claim 1, wherein the plurality of nucleic acid molecules further comprises a universal priming site.
14. The method of claim 1, further comprising staining the tissue section.
15. The method of claim 14, wherein the staining is selected from immunohistochemistry or hematoxylin and eosin staining.
16. The method of claim 14, further comprising obtaining an image of the stained tissue section.
17. The method of claim 1, further comprising amplifying the generated nucleic acid molecule.
18. The method of claim 17, further comprising sequencing all or a portion of the amplified, generated nucleic acid molecule.
19. The method of claim 1, further comprising determining the location on the substrate where the target biological molecule was captured.
20. The method of claim 19, wherein the method further comprises mapping the location of the target biological molecule to a location in the tissue section.